

CURRICULUM VITAE FOR ACADEMIC PROMOTION
The Johns Hopkins University School of Medicine

Michelle Petri

Michelle Petri, MD MPH

November 16, 2024

DEMOGRAPHIC AND PERSONAL INFORMATION

Current Appointments

University

2001-present Professor, Division of Rheumatology, Department of Medicine
Johns Hopkins University School of Medicine and Johns Hopkins Hospital

Hospital

1986-present Attending Physician, Johns Hopkins Hospital

Other

n/a

Personal Data

Business Address 1830 E. Monument Street, Suite 7500
Division of Rheumatology
Department of Medicine
Building and room 1830 Building, Room 7507
Tel (410) 955-3823
Fax (410) 614-0498
E-mail mpetri@jhmi.edu

Education and Training

Undergraduate

1976 BA, Biology, Harvard-Radcliffe College, Boston, MA

Doctoral/Graduate

1980 MD, Harvard Medical School, Boston, MA

1990 MPH, Epidemiology, Johns Hopkins Univ. School of Hygiene and Public Health, Baltimore, MD

Postdoctoral

1980-1983 Internship and Residency, Internal Medicine, Massachusetts General Hospital, Boston, MA

1983-1985 Fellowship, Allergy and Immunology, University of California, San Francisco, CA

1983-1986 Fellowship, Rheumatology, University of California, San Francisco, CA

Professional Experience

Dates	Positions	Institutions
7/1/85 - 6/30/86	Instructor, Medicine, Division of Rheumatology,	University of California, San Francisco, CA
7/1/86 - 12/31/91	Assistant Professor, Medicine, Division of Rheumatology,	Johns Hopkins University School of Medicine
1/1/92 - 4/30/2001	Associate Professor, Medicine, Division of Rheumatology,	Johns Hopkins University School of Medicine
5/1/2001- present	Professor, Medicine, Division of Rheumatology,	Johns Hopkins University School of Medicine

PUBLICATIONS

Original Research [OR]

1. Manschreck, T and **Petri, M.** The atypical psychoses. *Culture, Medicine and Psychiatry* 2: 233, 1978.
2. Manschreck, T and **Petri, M.** The paranoid syndrome. *Lancet* II: 251, 1978.
3. **Petri, M** and Fye, K. Digital necrosis: a paraneoplastic syndrome. *J Rheumatol* 12: 800, 1985.
4. Scharre, D, **Petri, M,** Engman, E and DeArmond, S. Large cell arteritis with giant cells in systemic lupus erythematosus. *Ann Intern Med* 104: 661, 1986.
5. Steinbach, L, Hellmann, D, **Petri, M,** Gillespy, T and Genant, H. Magnetic resonance imaging: a review of rheumatologic applications. *Sem. Arthritis and Rheumatism* 16:79, 1986.
6. **Petri, M,** Rheinschmidt, M, Whiting-O'Keefe, Q, Hellmann, D, Corash, L. The Frequency of Lupus Anticoagulant in Systemic Lupus Erythematosus: A Study of 60 Consecutive Patients by Activated Partial Thromboplastin Time, Russell Viper Venom Time, and Anticardiolipin Antibody. *Ann Intern Med* 106:524-531, 1987.
7. **Petri, M,** Golbus, M, Anderson, R, Whiting-O'Keefe, Q, Corash, L, and Hellmann, D. Antinuclear Antibodies, Lupus Anticoagulant, and Anticardiolipin Antibody in Idiopathic Habitual Abortion: A Controlled Prospective Study of 44 Women. *Arthritis Rheum* 30:601-606, 1987.
8. **Petri, M,** Dobrow, R, Neiman, R, Whiting-O'Keefe, Q, Seaman, W. Randomized double-blind placebo-controlled study of the treatment of the painful shoulder. *Arthritis Rheum* 30:1040-1045, 1987.
9. Hellmann, DB, **Petri, M,** Whiting-O'Keefe, Q. Fatal infections in systemic lupus erythematosus: the role of opportunistic organisms. *Medicine* 66:341-348, 1987.
10. Hellmann, DB, Laing, TJ, **Petri, M,** Whiting-O'Keefe, Q, Parry, GJ. Mononeuritis Multiplex: the yield of evaluations for occult rheumatic diseases. *Medicine* 67:145-153, 1988.
11. Roubenoff, R, Hoyt, M, **Petri, M,** Hochberg, M, Hellmann, D. Effects of anti-inflammatory and immunosuppressive drugs on pregnancy and fertility. *Sem Arthritis Rheum*, 18:88-110, 1988.
12. Kirsch, CM, Payan, DG, Wong, MYS, Dohlman, JG, Blake, VA, **Petri, MA,** Offenberger, J, Goetzl, EJ, Gold, WM. The effect of eicosapentaenoic acid in asthma. *Clin Allergy*, 18:177-187, 1988.
13. **Petri, M,** Bockenstedt, L, Colman, J, Whiting-O'Keefe, Q, Fitz, G, Sebastian, A, Hellmann, D. Serial assessment of glomerular filtration rate in lupus nephropathy. *Kidney Int*, 34:832-839, 1988.
14. Simonson, JS, Schiller NB, **Petri M,** Hellmann, DB. Pulmonary hypertension in systemic lupus erythematosus. *J Rheumatol*, 16:918-925, 1989.
15. Ratain, J, **Petri, M,** Hochberg, M, Hellmann, D. Accuracy of creatinine clearance in patients with systemic lupus erythematosus without clinical evidence of renal disease. *Arthritis and Rheumatism* 33:277-280, 1990.
16. Roubenoff, R, Drew, H, Moyer, M, **Petri, M,** Whiting-O'Keefe, Q, Hellmann, DB. Oral cimetidine improves the accuracy and precision of creatinine clearance in lupus nephritis. *Annals Internal Medicine* 113:501-506, 1990.
17. **Petri, M,** Genovese, M, Engle, E, Hochberg, M. Definition, Incidence and Clinical Description of Flare in Systemic Lupus Erythematosus: A Prospective Cohort Study. *Arthritis Rheum* 34:937-944, 1991.
18. Perez-Gutthann S, **Petri M,** Hochberg, MC. Comparison of two methods of classifying patients with systemic lupus erythematosus. *J Rheumatol* 18:1176-1179, 1991.
19. **Petri, M,** Karlson, EW, Cooper, DS, Ladenson, PW. Auto-antibody tests in autoimmune thyroid disease: a case-control study. *J Rheumatol* 18:1529-1531, 1991.
20. Repke, J, **Petri, M.** Management of the pregnant lupus patient. *Maryland Medical Journal* 40:917-921, 1991.
21. **Petri, M,** Perez-Gutthann, S, Longenecker, JC, Hochberg, MC. Morbidity of systemic lupus erythematosus: role of race and socioeconomic status. *Amer J Med* 91:345-353, 1991.
22. **Petri, M,** Howard, D, Repke, J. Frequency of lupus flare in pregnancy: the Hopkins Lupus Pregnancy Center experience. *Arthritis Rheum* 34:1538-1545, 1991.
23. **Petri, M,** Nelson, L, Weimer, F, Anderson, D, Darlington, T, Corash, L. The automated Russell viper venom test for the lupus anticoagulant. *J Rheumatol* 18:1823-1825 1991.
24. **Petri, M,** Hellmann, D., Hochberg, M. Validity and Reliability of Lupus Activity Measures in the Routine Clinic Setting. *J Rheumatol* 19:53-59, 1992.
25. **Petri, M,** Allbritton, J. Antibiotic allergy in systemic lupus erythematosus. *J Rheumatol* 19:265-269, 1992.

Michelle Petri, M.D., M.P.H.

26. Watson, R, Scheel, JN, **Petri, M**, Lee, LA, Bias, WB, McLean, R. Neonatal lupus erythematosus syndrome: analysis of C4 isotypes and C4 genes in neonatal lupus mothers and their offspring and their potential role in the pathogenesis of this disease. *Medicine* 71:84-95, 1992.
27. **Petri, M**. Pancreatitis: a rare manifestation of systemic lupus erythematosus. *Rheumatol Rev* 1:75-79, 1992
28. **Petri, M**, Allbritton, J. Hair product use in systemic lupus erythematosus: a case-control study. *Arthritis Rheum* 35:625-629, 1992.
29. **Petri, M**, Genovese, M. Incidence of and risk factors for hospitalizations in systemic lupus erythematosus: a prospective study of the Hopkins Lupus Cohort. *J Rheumatol* 19:1559-1565, 1992.
30. **Petri, M**, Spence, D, Bone, LR, Hochberg, MC. Coronary artery disease risk factors in the Hopkins Lupus Cohort: prevalence, patient recognition, and preventive practices. *Medicine* 71:291-302, 1992.
31. **Petri, M**, Perez-Gutthann, S, Spence, D, Hochberg, MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. *Am J Med* 93:513-519, 1992.
32. Gladman, D, Ginzler, E, Goldsmith, C, Fortin, P, Liang, M, Urowitz, M, Bacon, P, Bombardieri, S, Hanly, J, Hay, E, Isenberg, D, Jones, JV, Nived, O, **Petri, M**, Richter, M, Sanchez-Guerrero, J, Snaith, M, Sturfelt, G, Symmons, D. Workshop Report. Systemic Lupus International Collaborative Clinics (SLICC): development of a damage index in SLE. *J Rheumatol* 19:1820-1821, 1992.
33. **Petri, M**, Howard, D, Repke, J, Goldman, DW. The Hopkins Lupus Pregnancy Center: 1987–1991 Update. *Amer J Reprod Immunol* 28:188-191, 1992.
34. **Petri, M**, Allbritton, J. Fetal outcome of lupus pregnancy: a retrospective case-control study of the Hopkins Lupus Cohort. *J Rheumatol* 20:650-656, 1993.
35. **Petri, M**, Watson, R, Winkelstein, JA, McLean, RH. Clinical expression of systemic lupus erythematosus in patients with C4a deficiency. *Medicine* 72:236-244, 1993
36. **Petri M**, Lakatta C, Magder L, Goldman DW. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. *Am J Med* 96:254-259 1994.
37. Sullivan KE, **Petri M**, Schmeckpeper BJ, McLean RH, Winkelstein JA. Prevalence of a mutation causing C2 deficiency in SLE. *J Rheumatol* 21:1128-1133, 1994.
38. Watson, RM, Scheel, JN, **Petri, M**, Kan, JS, Provost, TT, Rattie III, H, Callan, NA. Neonatal lupus erythematosus: report of serologic and immunogenetic studies in twins discordant for congenital heart block. *Br J Dermatol* 130:342-348, 1994.
39. Bermas, B, **Petri, M**, Goldman, D, Mittleman, B, Miller, MW, Stocks, NI, Via, CS, Shearer, GM. T-helper cell dysfunction in systemic lupus erythematosus (SLE): relation to disease activity. *J Clin Immunol* 14:169-177, 1994.
40. Bermas BL, **Petri M**, Berzofsky JA, Waisman A, Shearer GM, Mozes E. Binding of glycoprotein 120 and peptides from the HIV-1 envelope by autoantibodies in mice with experimentally induced systemic lupus erythematosus and in patients with the disease. *AIDS Res Hum Retroviruses*. 10:1071-1077, 1994.
41. Utset, TO, Golden, M, Siberry, G, Kiri, N, Crum, RM, **Petri, M**. Depressive symptoms in patients with SLE: association with CNS lupus and SS. *J Rheumatol* 21:2039-2045, 1994.
42. Hsu, C-D, Chan, DW, Iriye, B, Johnson, TRB, Hong, S-F, **Petri, M**. Plasma thrombomodulin levels in systemic lupus erythematosus. *Am J Perinatol* 12:27-29, 1995.
43. Hellmann DB, Kirsch CM, Whiting-O'Keefe Q, Simonson J, Schiller NB, **Petri M**, Gamsu G, Gold W. Dyspnea in ambulatory patients with SLE: prevalence, severity and correlation with incremental exercise testing. *J Rheumatol* 22:455-461, 1995.
44. Simmons-O'Brien E, Chen S, Watson R, Antoni C, **Petri M**, Hochberg M, Stevens MS, Provost TT. 100 anti-Ro (SS-A) antibody positive patients: a ten year follow-up. *Medicine* 74:109-130, 1995.
45. **Petri M**, Ho AC, Patel J, Demers D, Joseph JM, Goldman D. Elevation of maternal alpha-fetoprotein in systemic lupus erythematosus: a controlled study. *J Rheumatol* 22:1365-1368, 1995.
46. **Petri M**. Musculoskeletal Complications of Systemic Lupus Erythematosus in the Hopkins Lupus Cohort: An Update. *Arthritis Care and Research* 8:137-145, 1995.
47. Buyon JP, Kalunian KC, Skovron ML, **Petri M**, Lahita R, Merrill J, Sammaritano L, Yung C, Licciardi F, Belmont HM, Hahn BH. Can women with systemic lupus erythematosus safely use exogenous estrogens? *J Clin Rheumatol* 1:205-212, 1995.

Michelle Petri, M.D., M.P.H.

48. Bluemke, DA, **Petri, M**, Zerhouni EA. Femoral head perfusion and composition: MRI imaging and spectroscopic evaluation of patients with systemic lupus erythematosus and at risk for avascular necrosis. *Radiology*, 197:433-438, 1995.
49. Johnson, MJ, **Petri, M**, Witter, FR, Repke, JT. Evaluation of preterm delivery in a systemic lupus erythematosus pregnancy clinic. *Obstet Gynecol* 86:396-399, 1995.
50. Casciola-Rosen L, Rosen A, **Petri M**, Schlissel M. Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus. *Proc Natl Acad Sci, US* 93:1624-1629, 1996.
51. Dunn JP, Noorily SW, **Petri M**, Finkelstein D, Rosenbaum JT, Jabs DA. Antiphospholipid antibodies and retinal vascular disease. *Lupus* 5:313-322, 1996.
52. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, Bacon P, Bombardieri S, Hanly JG, Hay E, Isenberg D, Jones J, Nived O, **Petri M**, Richter M, Sanchez-Guerrero J, Snaith M, Sturfelt G, Symmons D. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College Rheumatology damage index for systemic lupus erythematosus. *Arthritis Rheum*, 39:363-369, 1996.
53. Gladman D, Urowitz M, Fortin P, Isenberg D, Goldsmith C, Gordon C, **Petri M**, Systemic Lupus International Collaborating Clinics Group. Systemic Lupus International Collaborating Clinics Conference on Assessment of Lupus Flare and Quality of Life Measures in SLE. *J Rheumatol*, 23:1953-1955, 1996.
54. Sullivan KE, Wisniewski J, Winkelstein JA, Louie J, Sachs E, Choi R, Veksler E, Goldman D, **Petri M**. Serum complement determinations in patients with quiescent SLE. *J Rheumatol* 23:2063-2067, 1996.
55. Sullivan KE, Wooten C, Goldman D, **Petri M**. Mannose-binding protein genetic polymorphisms in black patients with systemic lupus erythematosus. *Arthritis Rheum* 39:2046-2051, 1996.
56. **Petri M**, Roubenoff R, Nadeau MR, Selhub J, Rosenberg IH. Plasma homocysteine is a risk factor for atherothrombotic events in systemic lupus erythematosus. *Lancet* 348:1120-1124, 1996.
57. Mont MA, Glueck CJ, Pacheco I, Wang P, Hungerford DS, **Petri M**. Risk factors for osteonecrosis in systemic lupus erythematosus. *J Rheumatol* 24:654-662, 1997.
58. Gladman D, Urowitz, MB, Goldsmith CH, Fortin P, Ginzler E, Gordon C, Hanly J, Isenberg D, Kalunian K, Nived O, **Petri M**, Sanchez-Guerrero J, Snaith M, Sturfelt G. Reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. *Arthritis Rheum* 40:809-813, 1997.
59. Sasso EH, Suzuki LA, Thompson AR, **Petri MA**. Hereditary resistance to activated protein C: an uncommon risk factor for thromboembolic disease in lupus patients with antiphospholipid antibodies. *Arthritis Rheum* 40:1720-1721, 1997.
60. Mont MA, Fairbank AC, **Petri M**, Hungerford DS. Core decompression for osteonecrosis of the femoral head in systemic lupus erythematosus. *Clin Orthop Jan* (334):91-97, 1997.
61. Sullivan KE, Wooten C, Schmeckpeper BJ, Goldman D, **Petri MA**. A promotor polymorphism of tumor necrosis factor α associated with systemic lupus erythematosus in African Americans. *Arthritis Rheum* 40:2207-2211, 1997.
62. Mathis JM, **Petri M**, Naff N. Percutaneous vertebroplasty treatment of steroid induced osteoporotic compression fractures. *Arthritis Rheum* 41: 171-175, 1998.
63. **Petri M**. Hopkins Lupus Cohort: The effect of race on incidence and clinical course in systemic lupus erythematosus: the Hopkins Lupus Cohort. *J Am Med Women's Assoc* 53:9-12, 1998.
64. Sullivan KE, Mannery T, **Petri MA**. The polymorphic CYP17 allele is not found with increased frequency in systemic lupus erythematosus. *Arthritis Rheum* 41:940-941, 1998.
65. Koene HR, Kleijer M, Swaak AJG, Sullivan KE, Biji M, **Petri MA**, Kallenberg CGM, Roos D, von dem Borne AEG, de Haas M. The Fc γ RIIIA-158F allele is a risk factor for systemic lupus erythematosus. *Arthritis Rheum* 41:1813-1818, 1998.
66. Brodsky RA, **Petri M**, Smith BD, Seifter EJ, Spivak JL, Styler M, Dang CV, Brodsky I, Jones RJ. Immunoablative high-dose cyclophosphamide without stem cell rescue for refractory, severe autoimmune disease. *Ann Int Med* 129:1031-1035, 1998.
67. Nousari HC, Lynch W, Anhalt GJ, **Petri M**. The effectiveness of mycophenolate mofetil in refractory pyoderma gangrenosum. *Arch Dermatol* 134:1509-1511, 1998.

Michelle Petri, M.D., M.P.H.

68. Moser KL, Neas BR, Salmon JE, Yu H, Gray-McGuire C, Asundi N, Bruner GR, Fox J, Kelly J, Henshall S, Bacino D, Dietz M, Hogue R, Koelsch G, Nightingale L, Shaver T, Abdou NI, Albert DA, Carson C, **Petri M**, Treadwell EL, James JA, Harley JB. Genome scan of human systemic lupus erythematosus: evidence for linkage on chromosome 1q in African-American pedigrees. *Proc. Natl. Acad. Sci. USA* 95:14869-14874, 1998.
69. Gilkeson G, Cannon C, Oates J, Reilly C, Goldman D, **Petri M**. Correlation of serum measures of nitric oxide production with lupus disease activity. *J Rheum* 26:318-324, 1999.
70. Clarke AE, **Petri MA**, Manzi S, Isenberg DA, Gordon C, Senecal J-L, Goulet JR, Choquette D, Sutcliffe N, Grodzicky T, Fortin PR, Joseph L, Danoff DS, Ho V, Esdaile JM for the TRINATION Study Group. An international perspective on the well being and health care costs for patients with SLE. *J Rheumatol* 26:1500-1511, 1999.
71. Oh M, **Petri MA**, Kim NA, Sullivan KE. Frequency of the FcγRIIIA-158F allele in African American patients with SLE. *J Rheumatol* 26:1486-1489, 1999.
72. Rzyany B, Coresh J, Whelton PK, **Petri M**. Risk factors for hypercreatinemia in patients with systemic lupus erythematosus. *Lupus* 8:532-540, 1999.
73. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. Guidelines for referral and management of systemic lupus erythematosus in adults. *Arthritis Rheum* 42:1785-1796, 1999.
74. Sullivan KE, Kim NA, Goldman D, **Petri MA**. C4a deficiency due to a 2bp insertion is increased in patients with systemic lupus erythematosus. *J Rheumatol* 26:2144-2147, 1999.
75. Barr S, Zonana-Nacach A, Magder L, **Petri M**. Patterns of disease activity in systemic lupus erythematosus. *Arthritis Rheum* 42:2682-2688, 1999.
76. The Collaborative Osteonecrosis Group. Symptomatic multifocal osteonecrosis – a multicenter study. *Clinical Orthop* (369):312-326, 1999.
77. Smolen JS, Strand V, Cardiel M, Edworthy S, Furst D, Gladman D, Gordon C, Isenberg DA, Klippel JH, **Petri M**, Simon L, Tugwell P, Wolfe F. Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: consensus on a preliminary core set of outcome domains. *J Rheumatol* 26:504-507, 1999.
78. Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Fortin P, Ginzler E, Gordon C, Hanly JG, Isenberg DA, **Petri M**, Nived O, Snaith M, Sturfelt G, for the Systemic Lupus International Collaborating Clinics. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. *J Rheumatol* 27:373-376, 2000.
79. Sullivan KE, Piliero LM, Goldman D, **Petri MA**. A TNFR2 3' flanking region polymorphism in systemic lupus erythematosus. *Genes Immunity* 1:225-227, 2000.
80. Akkasilpa S, Minor M, Goldman D, Magder LS, **Petri M**. Association of coping responses with fibromyalgia tender points in patients with SLE. *J Rheumatol* 27:671-674, 2000.
81. Stewart M, **Petri M**. Lupus nephritis outcomes: health maintenance organizations compared to non-health maintenance organizations. *J Rheumatol* 27:900-902, 2000.
82. Strand V (for the OMERACT SLE Steering Committee), Gladman D, Isenberg D, **Petri M**, Smolen J, Tugwell P. Endpoints: consensus recommendations from OMERACT IV. *Lupus* 9:322-327, 2000.
83. Mont MA, Payman RK, Laporte DM, **Petri M**, Jones LC, Hungerford DS. Atraumatic osteonecrosis of the humeral head. *J Rheumatol* 27:1766-1773, 2000.
84. Zonana-Nacach A, Barr SG, Magder LS, **Petri M**. Damage in systemic lupus erythematosus and its association with corticosteroids. *Arthritis Rheum* 43:1801-1808, 2000.
85. **Petri M**. Epidemiology of the anti-phospholipid antibody syndrome. *J Autoimmunity* 15:145-151, 2000.
86. Moore AD, **Petri MA**, Manzi S, Isenberg DA, Gordon C, Senecal J-L, St. Pierre Y, Joseph L, Penrod J., Fortin PR, Sutcliffe N, Goulet JR, Choquette D, Grodzicky T, Esdaile JM, Clarke AE for the TRINATION Study Group. The use of alternative medical therapies in patients with systemic lupus erythematosus (SLE). *Arthritis Rheum* 43:1410-1418, 2000.
87. Sullivan KE, Piliero LM, Dharia T, Goldman D, **Petri MA**. 3' polymorphisms of ETS1 are associated with different clinical phenotypes in SLE. *Hum Mutat* 16:49-53, 2000.
88. Clarke AE, Penrod J, St. Pierre Y, **Petri MA**, Manzi S, Isenberg DA, Gordon C, Senecal J-L, Fortin PR, Sutcliffe N, Goulet JR, Choquette D, Grodzicky T, Esdaile JM. Underestimating the value of women: assessing the indirect costs of women with systemic lupus erythematosus. *J Rheumatol* 27:2597-2604, 2000.

Michelle Petri, M.D., M.P.H.

89. Segal J, Kickler T, **Petri M**. Tissue Factor activity in patients with SLE: association with disease activity. *J Rheumatol* 27:2827-2832, 2000.
90. Witter FR, **Petri M**. Antenatal detection of intrauterine growth restriction in patients with systemic lupus erythematosus. *Int J Gyn Ob* 71:67-68, 2000.
91. Casciola-Rosen LA, Pluta AF, Plotz PH, Cox AE, Morris S, Wigley FM, **Petri M**, Gelber AC, Rosen A. The DNA mismatch repair enzyme PMS1 is a myositis-specific autoantigen. *Arthritis Rheum* 44:389-396, 2001.
92. **Petri M**. Exogenous estrogen in systemic lupus erythematosus: oral contraceptives and hormone replacement therapy. *Lupus* 10:222-226, 2001.
93. Verthelyi D, **Petri M**, Ylamus M, Klinman DM. Disassociation of sex hormone levels and cytokine production in SLE patients. *Lupus* 10:352-358, 2001.
94. Ho A, Barr SG, Magder LS, **Petri M**. A decrease in complement is associated with increased renal and hematologic flares in patients with systemic lupus erythematosus. *Arthritis Rheum* 44:2350-2357, 2001.
95. Ho A, Magder LS, Barr SG, **Petri M**. Decreases in anti-double stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. *Arthritis Rheum* 44:2342-2349, 2001.
96. Asherson RA, Cervera R, Piette J-C, Shoenfeld Y, Espinosa G, **Petri MA**, Lim E, Lau C, Gurjal A, Jedryka-Goral A, Chwalinska-Sadowska H, Dibner RJ, Rojas-Rodriguez J, Garcia-Carrasco M, Grandone JT, Parke AL, Barbosa P, Vasconcelos C, Ramos-Casals M, Font J, Ingelmo M. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. *Medicine* 80:355-377, 2001.
97. Leritz E, Brandt J, Minor M, Reis-Jensen F, **Petri M**. "Subcortical" cognitive impairment in patients with systemic lupus erythematosus. *J Inter Neuropsych Soc* 6:821-825, 2001.
98. Alarcon GS, McGwin Jr G, **Petri M**, Reveille JD, Ramsey-Goldman R, Kimberly RP for the PROFILE Study Group. Baseline characteristics of a multiethnic lupus cohort: profile. *Lupus* 11:95-101, 2002.
99. Maddison P, Farewell V, Isenberg D, Arano C, Bae S-C, Barr S, Buyon J, Fortin P, Ginzler E, Gladman D, Hanly J, Manzi S, Nived O, **Petri M**, Ramsey-Goldman R, Sturfelt G for the Systemic Lupus International Collaborating Clinics. The rate and pattern of organ damage in late onset systemic lupus erythematosus. *J Rheumatol* 29:913-917, 2002.
100. **Petri MA**, Lahita RG, van Vollenhoven RF, Merrill JT, Schiff M, Ginzler EM, Strand V, Kunz A, Gorelick KJ, Schwartz KE for the GL701 Lupus Study Group. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus. *Arthritis Rheum* 46:1820-1829, 2002.
101. Forton AC, **Petri MA**, Goldman D, Sullivan KE. An osteopontin (SPP1) polymorphism is associated with systemic lupus erythematosus. *Hum Mutat* 19:459, 2002.
102. Leritz E, Brandt J, Minor M, Reis-Jensen F, **Petri M**. Neuropsychological functioning and its relationship to antiphospholipid antibodies in patients with systemic lupus erythematosus. *J. Clin Exper Neuropsychol* 24:527-533, 2002.
103. Segal J, Lehman H., **Petri M**, Kickler TS. Testing strategies for diagnosing lupus anticoagulant: a cost-effectiveness analysis. *Am J Hematology* 70:195-205, 2002.
104. Somers E, Magder LS, **Petri M**. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with SLE. *J Rheumatol* 29:2531-2536, 2002.
105. **Petri, M**. Epidemiology of systemic lupus erythematosus. *Best Practice Res Clin Rheumatol*, 16:847-858, 2002.
106. **Petri M**, Jones RJ, Brodsky RA. High dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. *Arthritis Rheum* 48:166-173, 2003.
107. **Petri M**. Systemic lupus erythematosus: pathogenesis, diagnosis, and treatment. *The Female Patient* 28(February):1-5, 2003.
108. Sullivan KE, Jawad AF, Piliero L, Kim N, Luan X, Goldman D, **Petri M**. Analysis of polymorphisms affecting immune complex handling in systemic lupus erythematosus. *Rheumatology* 42:446-452, 2003.
109. **Petri M**. Systemic Lupus Erythematosus. *The Female Patient* 28(March):24-28, 2003.
110. **Petri M**. Pregnancy in the lupus patient. *The Female Patient* 28(April):12-15, 2003.
111. Jones LC, Mont MA, Le TB, **Petri M**, Hungerford DS, Wang P, Glueck CJ. Procoagulants and osteonecrosis. *J Rheumatol* 30:783-791, 2003.
112. Lockshin M, Tenedios F, **Petri M**, McCarty G, Forastiero R, Krilis S, Tincani A, Erkan D, Khamashta MA, Shoenfeld Y. Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report. *Lupus* 12:518-523, 2003.

Michelle Petri, M.D., M.P.H.

113. **Petri M.** Evidence-based management of thrombosis in the antiphospholipid antibody syndrome. *Curr Rheumatol Reports* 5:370-373, 2003.
114. Costenbader KH, Kim DJ, Peerzada J, Lockman S, Nobles-Knight D, **Petri M**, Karlson EW. Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis. *Arthritis Rheum* 50:849-837, 2004.
115. **Petri M.** Cyclophosphamide: new approaches for systemic lupus erythematosus. *Lupus* 13:366-371, 2004.
116. Clarke AE, **Petri M**, Manzi S, Isenberg DA, Gordon C, Senecal J-L, Penrod J, Joseph L, St. Pierre Y, Fortin PR, Sutcliffe N, Goulet J-R, Choquette D, Grodzicky T, Esdaile J. The systemic lupus erythematosus tri-nation study: absence of a link between health resource use and health outcome. *Rheumatology* 43:1016-24, 2004.
117. Tang S, Calkins H, **Petri M.** Neurally mediated hypotension in systemic lupus erythematosus patients with fibromyalgia. *Rheumatology* 43:609-614, 2004.
118. Christopher-Stine L, **Petri M**, Astor BC, Fine D. Urine protein-to-creatinine ratio is a reliable measure of proteinuria in lupus nephritis. *J Rheumatol* 31:1557-1559, 2004.
119. **Petri M**, Hufman SL, Waser G, Cui H, Snabes MC, Verberg KM. Celecoxib Effectively Treats Patients with Acute Shoulder Tendinitis/Bursitis. *J Rheumatol* 31:1614-1620, 2004.
120. Kyogoku C, Langefeld CD, Ortmann WA, Lee A, Selby S, Carlton VEH, Chang M, Ramos P, Baechler EC, Batliwalla FM, Novitzke J, Williams AH, Gillett C, Rodine P, Graham RR, Gaffney PM, Moser KL, **Petri M**, Begovich AB, Gregersen PK, Behrens TW. Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. *Am J Hum Genet* 75:504-507, 2004.
121. Wollaston SJ, Farewell VT, Isenberg DA, Gordon C, Merrill JT, **Petri MA**, Kalunian KC for the Systemic Lupus International Collaborating Clinics (SLICC). Defining response in systemic lupus erythematosus: a study by the Systemic Lupus International Collaborating Clinics Group. *J. Rheumatol.* 31:2390-2394, 2004.
122. **Petri MA**, Measse PJ, Merrill JT, Lahita RG, Iannini MJ, Yocum DE, Ginzler EM, Katz RS, Gluck OS, Genovese MC, Van Vollenhoven R, Kalunian KC, Manzi S, Greenwald MW, Buyon JP, Olsen NJ, Schiff MH, Kavanaugh AF, Caldwell JR, Ramsey-Goldman R, St. Clair EW, Goldman AL, Egan RM, Polisson RP, Moder KG, Rothfield NF, Spencer RT, Hobbs K, Fessler BJ, Calabrese LH, Moreland LW, Cohen SB, Quarles BJ, Strand V, Gurwith M, Schwartz KE. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus: results of a multicenter randomized, double-blind, placebo-controlled trial. *Arthritis Rheum* 50:2858-2868, 2004.
123. ACR Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology Response Criteria for Systemic Lupus Erythematosus Clinical Trials: Measures of Overall Disease Activity. *Arthritis Rheum* 50:3418-3426, 2004.
124. ACR Ad Hoc Working Group Committee on Steroid-Sparing Criteria in Lupus. Criteria for Steroid-Sparing ability of interventions in Systemic Lupus Erythematosus: Report of a Consensus Meeting. *Arthritis Rheum.* 50:3427-3431, 2004.
125. Akkasilpa S, Goldman D, Magder LS, **Petri M.** Number of fibromyalgia tender points is associated with health status in patients with systemic lupus erythematosus. *J Rheumatol* 32:48-50, 2005.
126. Clowse MEB, Magder L, Witter F, **Petri M.** The impact of increased lupus activity on obstetric outcomes. *Arthritis Rheum* 52:514-521, 2005.
127. Bernatsky S, Boivin JF, Joseph L, Rajan R, Zoma A, Manzi S, Ginzler E, Urowitz M, Gladman D, Fortin PR, **Petri M**, Edworthy S, Barr S, Gordon C, Bae SC, Sibley J, Isenberg D, Rahman A, Aranow C, Dooley MA, Steinsson K, Nived O, Sturfelt G, Alarcon G, Senecal JL, Zummer M, Hanly J, Ensworth S, Pope J, El-Gabalawy H, McCarthy T, St. Pierre Y., Ramsey-Goldman R, Clarke A. An international cohort study of cancer in systemic lupus erythematosus. *Arthritis Rheum* 52:1481-1490, 2005.
128. Buyon J, **Petri MA**, Kim MY, Kalunian KC, Grossman J, Hahn BH, Merrill JT, Sammaritano L, Lockshin M, Alarcon GS, Manzi S, Belmont HM, Askanase AD, Sigler L, Dooley MA, Von Feldt J, McCune WJ, Friedman A, Wachs J, Cronin M, Hearsh-Holmes M, Tan M, Licciardi F. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. *Ann Intern Med* 142:953-962, 2005.
129. Merkel PA, Lo GH, Holbrook J, Tibbs A, Allen N, Davis JC Jr, Hoffman GS, McCune WJ, St Clair EW, Specks U, Spiera R, **Petri M**, Stone JH, Wegener's Granulomatosis Etanercept Trial Research Group.. High Incidence of Venous Thrombotic Events among Patients with Wegener Granulomatosis: The Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study. *Ann Intern Med* 142: 620-626, 2005.
130. Clowse MEB, Magder L, **Petri M.** Cyclophosphamide for lupus during pregnancy. *Lupus* 14:593-597, 2005.

Michelle Petri, M.D., M.P.H.

131. Mok CC, Tang SSK, To CH, **Petri M**. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. *Arthritis Rheum* 52:2774-2782, 2005.
132. Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Urowitz M, Gladman D, Fortin P, Gordon C, Barr S, Edworthy S, Bae SC, **Petri M**, Sibley J, Isenberg D, Rahman A, Steinsson K, Aranow C, Dooley MA, Alarcon GS, Hanly J, Sturfelt G, Nived O, Pope J, Ensworth S, Rajan R, El-Gabalawy H, McCarthy T, St. Pierre Y, Clarke A, Ramsey-Goldman R. Race/Ethnicity and cancer occurrence in systemic lupus erythematosus. *Arthritis Rheum* 53:781-784, 2005.
133. To CH, **Petri M**. Is Antibody Clustering Predictive of Clinical Subsets and Damage in Systemic Lupus Erythematosus? *Arthritis Rheum* 52:4003-4010, 2005.
134. **Petri M**, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, Lockshin M, Merrill JT, Belmont HM, Askanase AD, McCune WJ, Heath-Holmes M, Dooley MA, Von Feldt J, Friedman A, Tan M, Davis J, Cronin M, Diamond B, Mackay M, Sigler L, Fillius M, Rupel A, Licciardi F, Buyon JP, OC-SELENA Trial. Combined oral contraceptives in women with systemic lupus erythematosus. *N Engl J Med* 353:2550-2558, 2005.
135. Panopalis P, **Petri M**, Manzi S, Isenberg DA, Gordon C, Senecal J, Penrod J, Joseph L, St. Pierre Y, Pineau C, Fortin PR, Sutcliffe N, Goulet J-R, Choquette D, Grodzicky T, Esdaile JM, Clarke AE. The systemic lupus erythematosus Tri-Nation study: longitudinal changes in physical and mental well-being. *Rheumatol* 44:751-755, 2005.
136. Ginzler EM, Dooley MA, Aranow C, Kim M, Buyon J, Merrill JT, **Petri M**, Gilkeson G, Wallace DJ, Weisman MH, Appel G. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. *N Engl J Med* 353:2219-2228, 2005.
137. Childers MK, Borenstein D, Brown RL, Gershon S, Hale ME, **Petri M**, Wan GJ, Laudadio C, Harrison DD. Low-dose cyclobenzaprine versus combination therapy for ibuprofen for acute neck or back pain with muscle spasm: a randomized trial. *Curr Med Res Opin* 21:1485-1493, 2005.
138. Clowse M, Magder L, Witter F, **Petri M**. Early risk factors for pregnancy loss in lupus. *Obstet Gynecol*. 107:293-299, 2006.
139. Kasitanon N, Fine DM, Haas M, Magder LS, **Petri M**. Hydroxychloroquine use predicts complete renal remission within 12-months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. *Lupus* 15:366-370, 2006.
140. Oestensen M, Khamashta M, Lockshin M, Parke A, Brucato A, Carp H, Doria A, Rai R, Meroni P, Cetin I, Derkesn R, Branch W, Motta M, Gordon C, Ruiz-Irastorza G, Spinillo A, Friedman D, Cimaz R, Czeizel A, Piette JC, Cervera R, Levy RA, Clementi M, De Carolis S, **Petri M**, Shoenfeld Y, Faden D, Valesini G, Tincani A. Anti-inflammatory and immunosuppressive drugs and reproduction. *Arthritis Research & Therapy* 8:209-227, 2006.
141. Kasitanon N, Magder LS, **Petri M**. Predictors of survival in systemic lupus erythematosus. *Medicine* 85:147-156, 2006.
142. Bernatsky S., Boivin J-F., Joseph L., Manzi S., Ginzler E., Gladman D. D., Urowitz M., Fortin P. R., **Petri, M.** Barr S., Gordon C., Bae S-C., Isenberg D., Zoma A., Aranow C., Dooley M-A., Nived O., Sturfelt G., Steinsson K., Alarcón G., Senécal J-L., Zummer M., Hanly J., Ensworth S., Pope J., Edworthy S., Rahman A., Sibley J., El-Gabalawy H., McCarthy T., St. Pierre Y., A. Clarke, Ramsey-Goldman R.. Mortality in systemic lupus erythematosus. *Arthritis Rheum* 54:2550-2557, 2006.
143. **Petri M**, Qazi U. Management of antiphospholipid syndrome in pregnancy. *Rheum Dis Clin NA* 32:591-607, 2006.
144. Vasilu IM, **Petri MA**, Baer AN. Therapy with granulocyte colony-stimulating factor in systemic lupus erythematosus may be associated with severe flares. *J Rheumatol* 33:1878-1880, 2006.
145. Clowse M, Magder L, Witter F, **Petri M**. Hydroxychloroquine in lupus pregnancy. *Arthritis Rheum* 54:3640-3647, 2006.
146. **Petri M**, Brodsky R. High-dose cyclophosphamide and stem cell transplantation for refractory systemic lupus erythematosus. *JAMA* 295:559-560, 2006.

Michelle Petri, M.D., M.P.H.

147. Graham RR, SV Kozyrev, EC Baechler, MVPL Reddy, RM Plenge, JW Bauer, WA Ortmann, T Koeuth, MFG Escribano, the Argentine and Spanish Collaborative groups, B Pons-Estel, **M Petri**, M Daly, PK Gregersen, J Martín, D Altshuler, TW Behrens, and ME Alarcón-Riquelme. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk for systemic lupus erythematosus. *Nature Genetics* 38:550-555, 2006.
148. Danowski A, Magder L, **Petri M**. Flares in lupus: outcome assessment trial (FLOAT), a comparison between oral methylprednisolone and intramuscular triamcinolone. *J Rheumatol* 33:57-60, 2006.
149. Kiani AN, Fishman EK, **Petri M**. Aortic valve calcification in systemic lupus erythematosus. *Lupus* 15:873-876, 2006.
150. Sule S, **Petri M**. Socioeconomic status in systemic lupus erythematosus. *Lupus* 15:720-723, 2006.
151. Maksimowicz-McKinnon K, Magder LS, **Petri M**. Predictors of carotid atherosclerosis in SLE. *J Rheumatol* 33:2458-2463, 2006.
152. Danowski A, Kickler TS, **Petri M**. Anti-beta2 glycoprotein I: prevalence, clinical correlations and importance of persistent positivity in patients with antiphospholipid syndrome and systemic lupus erythematosus. *J Rheumatol*. 33:1775-1779, 2006.
153. Alarcón GS, McGwin Jr G, **Petri M**, Ramsey-Goldman R, Vilá LM, Fessler BJ, Edberg J, Reveille JD, Kimberly RP. Time to renal disease and end-stage renal disease in PROFILE, a multiethnic lupus cohort. *PLoS Med*. 2006 Oct;3(10):e396.
154. Bauer JW, Baechler EC, **Petri M**, Batliwalla FM, Crawford D, Ortmann WA, Espe KJ, Li W, Patel DD, Gregersen PK, Behrens TW. Elevated Serum Levels of Interferon-Regulated Chemokines Are Biomarkers for Active Human Systemic Lupus Erythematosus. *PLoS Med*. 2006 Dec;3(12):e491.
155. Hanly JG, Urowitz MB, Sanchez-Guerrero J, Bae SC, Gordon C, Wallace DJ, Isenberg D, Alarcon G, Clarke A, Bernatsky S, Merrill JT, **Petri M**, Dooley MA, Gladman D, Fortin P, Steinsson K, Bruce I, Manzi S, Khamashta M, Zoma A, Aranow C, Ginzler E, Van Vollenhoven R, Font J, Sturfelt G, Nived O, Ramsey-Goldman R, Kalunian K, Douglas J, Thompson K, Farewell V for the Systemic Lupus International Collaborating Clinics (SLICC). Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. *Arthritis Rheum* 56:265-273, 2007.
156. Christopher-Stine L, Siedner M, Lin J, Haas M, Parekh H, **Petri M**, Fine D. Renal biopsy in lupus patients with low levels of proteinuria. *J Rheumatol* 34:332-325, 2007.
157. Sullivan KE, Suriano A, Dietzmann K, Lin J, Goldman D, **Petri MA**. The TNFalpha locus is altered in monocytes from patients with systemic lupus erythematosus. *Clin Immunol* 123:74-81, 2007.
158. Panopalis P, **Petri M**, Manzi S, Isenberg DA, Gordon C, Senécal J-L, Penrod J, Joseph L, St. Pierre Y, Pineau C, Fortin PR, Sutcliffe N, Goulet J-R, Choquette D, Grodzicky T, Esdaile J, Clarke AE for the Tri-Nation Study Group. The Systemic lupus erythematosus Tri-Nation Study: cumulative indirect costs. *Arthritis Care Res* 57:64-71, 2007.
159. Graham RR, Kyogoku C, Sigurdsson S, Vlasova IA, Davies LRL, Baechler EC, Plenge RM, Koeuth T, Ortmann WA, Hom G, Bauer JW, Gillett C, Burt N, Graham DSC, Onofrio R, **Petri M**, Gunnarsson I, Svenungsson E, Roonblom L, Nordmark G, Gregersen PK, Moser KL, Gaffney PM, Criswell L, Vyse TJ, Syvanen A-C, Bohjanen PR, Daly M, Behrens TW, Altshuler D. Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. *Proc Natl Acad Sci US*104:6758-6763, 2007.
160. Bin J, Bernatsky S, Gordon C, Boivin J-F, Ginzler E, Gladman D, Fortin PR, Urowitz M, Manzi S, Isenberg D, Rahman A, **Petri M**, Nived O, Sturfelt G, Ramsey-Goldman R, Clarke AE. Lung cancer in systemic lupus erythematosus. *Lung Cancer* 56:303-306, 2007.
161. Kiani A, Mahoney JA, **Petri M**. sCD154 is not associated with atherosclerosis in systemic lupus erythematosus. *J Rheumatol* 34:969-972, 2007.
162. Kiani AB, Mahoney JA, **Petri M**. Asymmetric dimethylarginine is a marker of poor prognosis and coronary calcium in systemic lupus erythematosus. *J Rheumatol* 34:1502-1505, 2007.
163. M. B. Urowitz, D. Gladman, D. Ibañez, P. Fortin, J. Sanchez-Guerrero, S. Bae, A. Clarke, S. Bernatsky, C. Gordon, J. Hanly, D. Wallace, D. Isenberg, E. Ginzler, J. Merrill, G. Alarcon, K. Steinsson, M. **Petri**, M. A. Dooley, I. Bruce, S. Manzi, M. Khamashta, R Ramsey-Goldman, A. Zoma, G. Sturfelt, O. Nived, P. Maddison, J. Font, R. van Vollenhoven, C. Aranow, K. Kalunian, T. Stoll, J. Buyon. Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort. *Lupus* 16:731-735, 2007.

164. Erkan D, Harrison MJ, Levy R, Peterson M, **Petri M**, Sammaritano L, Unalp-Arida A, Vilela V, Yazici Y, Lockshin MD. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. *Arthritis Rheum.* 56:2382-2391, 2007.
165. Kasitanon N, **Petri M**. Estimating renal function in lupus nephritis: comparison of the modification of diet in renal disease and Cockcroft Gault equations. *Lupus* 16:887-895, 2007.
166. Bernatsky S, Joseph L, Boivin JF, Gordon C, Urowitz M, Gladman D, Fortin P, Ginzler E, Bae SC, Barr S, Edworthy S, Isenberg D, Rahman A, **Petri M**, Alarcon G, Aranow C, Dooley MA, Rajan R, Senecal JL, Zummer M, Manzi S, Ramsey-Goldman R, Clarke AE. The relationship between cancer and medication exposures in systemic lupus erythematosus: a case-cohort study. *Ann Rheum Dis* 67:74-79, 2008.
167. Edberg JC, Wu J, Langefeld CD, Brown EE, Marion MC, McGwin Jr G, **Petri M**, Ramsey-Goldman R, Vila LM, Reveille JD, Frank SG, Kaufman KM, Harley JB, Alarcon GS, Kimberly RP. Genetic variation in the CRP promoter: association with systemic lupus erythematosus. *Hum Molec Genetics* 17:1-9, 2008.
168. Kasitanon N, **Petri M**, Haas M, Magder LS, Fine DM. Mycophenolate mofetil as the primary treatment of membranous lupus nephritis with and without concurrent proliferative disease: a retrospective study of 29 cases. *Lupus* 17(1):40-5, 2008.
169. Siedner MJ, Gelber AC, Rovin BH, McKinley AM, Christopher-Stine L, Astor B, **Petri M**, Fine DM. Diagnostic Accuracy Study of Urine Dipstick in Relation to 24-Hour Measurement as a Screening Tool for Proteinuria in Lupus Nephritis. *J Rheumatol* 35(1):84-90, 2008.
170. Urowitz MB, Gladman D, Ibañez D, Fortin P, Sanchez-Guerrero J., Bae S., Clarke A., Bernatsky S., Gordon C., Hanly J., Wallace D., Isenberg D., Ginzler E., Merrill J., Alarcon G., Steinsson K., **Petri, M.** Dooley M. A., Bruce I., Manzi S., Khamashta M., Ramsey-Goldman R, Zoma, A. Sturfelt G., Nived O., Maddison P., Font J., van Vollenhoven R., Aranow C., Kalunian K., Stoll T., Buyon J.. Accumulation of coronary artery disease risk factors over three years: data from an international inception cohort. *Arthritis Care Res* 59:176-180, 2008.
171. Clarke AE, Panopalis P, **Petri M**, Manzi S, Isenberg DA, Gordon C, Senecal J-L, Joseph L, St. Pierre Y, Li T. Systemic lupus erythematosus patients with renal damage incur higher health care costs. *Rheumatol* 47:329-333, 2008.
172. Hom G, Graham RR, Modrek B, Taylor KE, Ortmann W, Garnier S, Lee AT, Chung SA, Ferreira RC, Pant K, Ballinger DG, Kosoy R, Demirci FY, Kamboh MI, Kao AH, Tian C, Gunnarsson I, Bengtsson AA, Rantapaa-Dahlqvist S, **Petri M**, Manzi S, Seldin MF, Ronnblom L, Syvanen AC, Criswell LA, Gregersen, PK, Behrens TW. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. *N Engl J Med.* 358:900-909, 2008.
173. Lee S-S, Singh S, Magder LS, **Petri M**. Predictors of high sensitivity C-reactive protein levels in patients with systemic lupus erythematosus. *Lupus* 17:114-123, 2008.
174. Hanly JG, Urowitz MB, Siannis F, Farewell V, Gordon C, Bae SC, Isenberg D, Dooley MA, Clarke A, Bernatsky S, Gladman D, Fortin PR, Manzi S, Steinsson K, Bruce IN, Ginzler E, Aranow C, Wallace DJ, Ramsey-Goldman R, Van Vollenhover R, Sturfelt G, Nived O, Sanchez-Guerrero J, Alarcon GS, **Petri M**, Khamashta M, Zoma A, Font J, Kalunian K, Douglas J, Qi Q, Thompson K, Merrill JT for the Systemic Lupus International Collaborating Clinics. Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis. *Arthritis Rheum* 58:843-853, 2008.
175. Ramsey-Goldman R, Alarcón GS, McGwin Jr G, **Petri M**, Vilá LM, Edberg JC, Reveille JD, Kimberly RP, for the PROFILE Study Group. Time to seizure occurrence and damage in PROFILE, a multiethnic SLE cohort. *Lupus* 17:177-184, 2008.
176. Qazi U, Lam C, Karumanchi SA, **Petri M**. Soluble Fms-like tyrosine kinase associated with preeclampsia in pregnancy in SLE. *J Rheumatol* 35:631-634, 2008.
177. Hanly JG, Urowitz MB, Su L, Sanchez-Guerrero J, Bae SC, Gordon C, Wallace DJ, Isenberg D, Alarcon GS, Merrill JT, Clarke A, Bernatsky S, Dooley MA, Fortin PR, Gladman D, Steinsson K, **Petri M**, Bruce I, Manzi S, Khamashta M, Zoma A, Font J, Van Vollenhover R, Aranow C, Ginzler E, Nived O, Sturfelt G, Ramsey-Goldman R, Kalunian K, Douglas J, Qi KQ, Farewell V. Short-term outcome of neuropsychiatric events in systemic lupus erythematosus upon enrollment in a cohort. *Arthritis Care Res* 59:721-729, 2008.
178. Lee S-S, Singh S, Link K, **Petri M**. High-Sensitivity C-reactive Protein as an Associate of Clinical Subsets and Organ Damage in Systemic Lupus Erythematosus. *Semin Arthritis Rheum* 38:41-54, 2008.

Michelle Petri, M.D., M.P.H.

179. Sanchez-Guerrero J, Fragoso-Loyo HE, Neuwelt CM, Wallace D, Ginzler E, Sherrer YRS, McIlwain HH, Freeman PG, Aranow CB, **Petri MA**, Deodhar AA, Blanton E, Manzi S, Kavanaugh A, Lisse JR, Ramsey-Goldman R, McKay JD, Kivitz AJ, Mease PJ, Winkler AE, Kahl LE, Lee AH, Furie RA, Strand V, Lou L, Ahmed M, Quarles B, Schwartz KE. Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy. *J Rheumatol* 35:1567-75, 2008.
180. Singh V, Mahoney JA, **Petri M**. Erythrocyte C4d and complement receptor 1 in SLE. *J Rheumatol* 35:1989-1993, 2008.
181. Taylor KE, Remmers EF, Lee AT, Ortmann WA, Plenge RM, Tian C, Chung SA, Nititham J, Hom G, Kao AH, Demirci FY, Kamboh MI, **Petri M**, Manzi S, Kastner DL, Seldin MF, Gregersen PK, Behrens TW, Criswell LA. Specificity of the STAT4 Genetic Association for Severe Disease Manifestations of Systemic Lupus Erythematosus. *PLoS Genet* 2008 30;4:e1000084, 2008. [doi: 10.1371/journal.pgen.1000084].
182. **Petri M**, Naqibuddin M, Carson KA, Sampedro M, Wallace DJ, Weisman MH, Holliday SL, Padilla PA, Brey RL. Cognitive function in systemic lupus erythematosus inception cohort. *J Rheumatol* 35:1776-1781, 2008.
183. Kelly JA, Kelley JM, Kaufman KM, Kilpatrick J, Bruner GR, Merrill JT, James JA, Frank SG, Reams E, Brown EE, Gibson AW, Marion MC, Langefeld CD, Zhen-Li Q, Karp DR, Wakeland EK, **Petri M**, Ramsey-Goldman R, Reveille JD, Vila LM, Alarcon GS, Kimberly RP, Harley JB, Edberg JC. Interferon regulatory factor 5 (IRF5) is genetically associated with systemic lupus erythematosus in African-Americans. *Genes Immun* 9:187-194, 2008.
184. Scofield H, Namjou B, Kimberly R, Bruner G, Alarcon G, Kelly J, Harley J, Reveille J, Vila L, **Petri M**, Ramsey-Goldman R, Li S. Klinefelter's syndrome, 47,XXY, in male systemic lupus erythematosus: support for the notion of a gene-dose effect from the X chromosome. *Arthritis Rheum* 58:2511-2517, 2008.
185. Musone SL, Taylor KE, Lu TT, Nititham J, Ferreira RC, Ortmann W, Shifrin N, **Petri MA**, Kamboh MI, Manzi S, Seldin MF, Gregersen PK, Behrens TW, Ma A, Kwok PY, Criswell LA. Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. *Nat Genet* 40:1062-1064, 2008
186. **Petri M**, Kasitanon N, Lee SS, Link K, Magder L, Bae SC, et al. Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response index. *Arthritis Rheum* 58:1784-8, 2008.
187. **Petri M**, Kasitanon N, Singh S, Link K, Magder L, Bae SC, et al. Systemic lupus international collaborating clinics renal activity/response exercise: comparison of agreement in rating renal response. *Arthritis Rheum* 58:1789-95, 2008.
188. Kiani AN, Magder L, **Petri M**. Coronary calcium in systemic lupus erythematosus is associated with traditional cardiovascular risk factors, but not with disease activity. *J Rheumatol* 35:1300-6, 2008.
189. **Petri M**, Naqibuddin M, Carson KA, Wallace DJ, Weisman MH, Holliday SL, Sampedro M, Narayana S, Fox PT, Franklin C, Padilla PA, Brey RL. Brain MRI in newly diagnosed SLE. *J Rheumatol* 35:2348-2354, 2008.
190. **Petri M**, Buyon JP. Oral contraceptives in systemic lupus erythematosus: the case for (and against). *Lupus* 17:708-710, 2008.
191. Dussan KB, Magder L, Brodsky RA, Jones RJ, **Petri M**. High dose cyclophosphamide performs better than monthly dose cyclophosphamide in quality of life measures. *Lupus* 17:1079-1085, 2008.
192. **Petri M**, Stohl W, Chatham W, McCune WJ, Chevrier M, Ryel J, Recta V, Zhong J, Freimuth W. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. *Arthritis Rheum* 58:2453-2459, 2008.
193. Wolfe F, **Petri M**, Alarcon GS, Goldman J, Chakravarty EF, Katz RS, Karlson EW. Fibromyalgia, systemic lupus erythematosus (SLE), and evaluation of SLE activity. *J Rheumatol* 36:82-88, 2009.
194. Thamer M, Hernan MA, Zhang Y, Cotter D, **Petri M**. Prednisone, lupus activity, and permanent organ damage. *J Rheumatol* 36:560-564, 2009.
195. Webb R, Wren JD, Jeffries M, Kelly JA, Kaufman KM, Tang Y, Frank MB, Merrill J, Kimberly RP, Edberg JC, Ramsey-Goldman R, **Petri M**, Reveille JD, Alarcón GS, Vilá LM, Alarcón-Riquelme ME, James JA, Vyse TJ, Moser KL, Gaffney PM, Gilkeson GS, Harley JB, Sawalha AH. Variants within MEC2, a key transcription regulator, are associated with increased susceptibility to lupus and differential gene expression in patients with systemic lupus erythematosus. *Arthritis Rheum* 60:1076-1084, 2009.

196. Namjou B, Sestak AL, Armstrong DL, Zidovetzki R, Kelly JA, Jacob N, Ciobanu V, Kaufman KM, Ojwang JO, Ziegler J, Quismorio FP Jr, Reiff A, Myones BL, Guthridge JM, Nath SK, Bruner GR, Mehrian-Shai R, Silverman E, Klein-Gitelman M, McCurdy D, Wagner-Weiner L, Nocton JJ, Putterman C, Bae SC, Kim YJ, **Petri M**, Reveille JD, Vyse TJ, Gilkeson GS, Kamen DL, Alarcón-Riquelme ME, Gaffney PM, Moser KL, Merrill JT, Scofield RH, James JA, Langefeld CD, Harley JB, Jacob CO. High-density genotyping of STAT4 reveals multiple haplotypic associations with systemic lupus erythematosus in different racial groups. *Arthritis Rheum* 60:1085-1095, 2009.
197. Webb R, Merrill JT, Kelly JA, Sestak A, Kaufman KM, Langefeld CD, Ziegler J, Kimberly RP, Edberg JC, Ramsey-Goldman R, **Petri M**, Reveille JD, Alarcón GS, Vilá LM, Alarcón-Riquelme ME, James JA, Gilkeson GS, Jacob CO, Moser KL, Gaffney PM, Vyse TJ, Nath SK, Lipsky P, Harley JB, Sawalha AH. A polymorphism within IL21R confers risk for systemic lupus erythematosus. *Arthritis Rheum* 60:2401-2407, 2009.
198. Chung SA, Tian C, Taylor KE, Lee AT, Ortmann WA, Hom G, Graham RR, Nititham J, Kelly JA, Morrisey J, Wu H, Yin H, Alarcón-Riquelme ME, Tsao BP, Harley JB, Gaffney PM, Moser KL, Manzi S, **Petri M**, Gregersen PK, Langefeld CD, Behrens TW, Seldin MF, Criswell LA. European population substructure is associated with mucocutaneous manifestations and autoantibody production in systemic lupus erythematosus. *Arthritis Rheum* 60:2448-2346, 2009.
199. Douglas KB, Windels DC, Zhao J, Gadeliya AV, Wu H, Kaufman KM, Harley JB, Merrill J, Kimberly RP, Alarcón GS, Brown EE, Edberg JC, Ramsey-Goldman R, **Petri M**, Reveille JD, Vilá LM, Gaffney PM, James JA, Moser KL, Alarcón-Riquelme ME, Vyse TJ, Gilkeson GE, Jacob CO, Ziegler JT, Langefeld CD, Ulgiati D, Tsao BP, Boackle SP. Complement receptor 2 polymorphisms associated with systemic lupus erythematosus modulate alternative splicing. *Genes Immun* 10:457-69, 2009.
200. Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, **Petri MA**, Ginzler EM, Chatham WW, McCune WJ, Fernandez V, Chevrier MR, Zhong ZJ, Freimuth WW. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of Belimumab in patients with active systemic lupus erythematosus. *Arthritis Rheum* 61:1168-1178, 2009.
201. Furie RA, **Petri MA**, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, Chatham WW, Strand V, Weinstein A, Chevrier MR, Zhong ZJ, Freimuth WW. Novel evidence-based systemic lupus erythematosus responder index. *Arthritis Rheum* 61:1143-1151, 2009.
202. Danowski A, de Azevedo MNL, de Souza Papi, JA, **Petri M**. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. *J Rheumatol* 36:1195-1199, 2009.
203. Bauer JW, **Petri M**, Batliwalla FM, Koeuth T, Wilson J, Slattery C, Panoskaltis-Mortari A, Gregersen PK, Behrens TW, Baechler EC. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: A validation study. *Arthritis Rheum* 60:3098-3107, 2009.
204. Kiani AN, Johnson K, Chen C, Diehl E, Hu H, Vasudevan G, Singh S, Magder LS, Knechtle SJ, **Petri M**. Urine osteoprotegerin (OPG) and monocyte chemoattractant protein-1 (MCP-1) in lupus nephritis. *J Rheumatol*, 36:2224-2230, 2009.
205. Bertoli AM, Vila LM, Alarcon GS, McGwin Jr G, Edberg JC, **Petri M**, Ramsey-Goldman R, Reveille JD, Kimberly RP for the PROFILE Study Group. Factors associated with arterial vascular events in PROFILE: a multiethnic lupus cohort. *Lupus*, 18:958-965, 2009.
206. **Petri M**, Singh S, Tesfayone H, Dedrick R, Fry K, Lal P, Williams G, Bauer JW, Gregersen PK, Behrens TW, Baechler EC. Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus. *Lupus* 18:980-989, 2009.
207. Gateva V, Sandling Jk, Hom G, Taylor KE, Chung SA, Sun X, Ortmann W, Kosoy R, Ferreira RC, Nordmark G, Gunnarsson I, Svenungsson E, Padyukov L, Sturfelt G, Jonsen A, Bengtsson A, Rantapaa-Dahlqvist S, Baechler EC, Brown EE, Alarcon GS, Edberg JC, Ramsey-Goldman R, McGwin Jr G, Reveille JD, Vila LM, Kimberly RP, Manzi S, **Petri MA**, Lee A, Gregersen PK, Seldin MF, Ronnblom L, Criswell LA, Syvanen A-C, Behrens TW, Graham RR. A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1, and IL10 as risk loci for systemic lupus erythematosus. *Nat Genet* 41:1228-33, 2009.

208. Guo L, Deshmukh H, Lu R, Vidal GS, Kelly JA, Kaufman KM, Dominguez N, Klein W, Kim-Howard X, Bruner GR, Scofield RH, Moser KL, Gaffney PM, Dozmorov IM, Gilkeson GS, Wakeland EK, Li Q-Z, Langefeld CD, Marion MC, Williams AH, Divers J, Alarcón GS, Brown EE, Kimberly RP, Edberg JC, Ramsey-Goldman R, Reveille JD, McGwin Jr. G, Vilá LM, **Petri M**, Vyse TJ, Merrill JT, James JA, Nath SK, Harley JB, Guthridge JM. Replication of the BANK1 genetic association with systemic lupus erythematosus in a European-derived population. *Genes Immun* 10:531-8, 2009.
209. Lu R, Vidal GS, Kelly JA, Delgado-Vega AM, Howard XK, Macwana SR, Dominguez N, Klein W, Burrell C, Harley IT, Kaufman KM, Bruner GR, Moser KL, Gaffney PM, Gilkeson GS, Wakeland EK, Li Q-Z, Langefeld CD, Marion MC, Divers J, Alarcón GS, Brown EE, Kimberly RP, Edberg JC, Ramsey-Goldman R, Reveille JD, McGwin Jr. G, Vilá LM, **Petri MA**, Bae S-C, Cho S-K, Bang S-Y, Kim I, Choi C-B, Martin J, Vyse TJ, Merrill JT, Harley JB, Alarcón-Riquelme ME for the BIOLUPUS and GENLES Multicenter Collaborations, Nath SK, James JA, Guthridge JM. Genetic Associations of LYN with systemic lupus erythematosus. *Genes Immun* 10:397-403, 2009.
210. Giles JT, Szklo M, Post W, **Petri M**, Blumenthal RS, Lam G, et al. Coronary arterial calcification in rheumatoid arthritis: comparison with the Multi-Ethnic Study of Atherosclerosis. *Arthritis research & therapy*. 11:R36, 2009.
211. **Petri M**, Singh S, Tesfayone H, Malik A. Prevalence of flare and influence of demographic and serologic factors on flare risk in SLE: A prospective study. *J Rheumatol* 36:2476-2480, 2009.
212. J G Hanly, M B Urowitz, L Su, S C Bae, C Gordon, D J Wallace, A Clarke, S Bernatsky, D Isenberg, A Anisur, G S Alarcon, D D Gladman, P R Fortin, J Sanchez-Guerrero, J Romero-Diaz, J T Merrill, E Ginzler, I N Bruce, K Steinsson, M Khamashta, **M Petri**, S Manzi, MA Dooley, R Ramsey-Goldman, R van Vollenhoven, O Nived, G Sturfelt, C Aranow, K Kalunian, M Ramos-Casals, A Zoma, J Douglas, K Thompson, V Farewell. Prospective analysis of neuropsychiatric events in an international disease inception cohort of SLE patients. *Ann Rheum Dis* 69:529-535, 2010. Published Online First, April 8, 2009.
213. Fine DM, Ziegenbein M, **Petri M**, Han EC, McKinley AM, Chellini JW, et al. A prospective study of protein excretion using short-interval timed urine collections in patients with lupus nephritis. *Kidney Int.* 76:1284-1288. 2009.
214. Birnbaum J, **Petri M**, Thompson R, Izbudak I, Kerr D. Distinct subtypes of myelitis in systemic lupus erythematosus. *Arthritis Rheum.* 60:3378-87, 2009.
215. Makol A, **Petri M**. Pancreatitis in systemic lupus erythematosus: frequency and associated factors – a review of the Hopkins Lupus Cohort. *J Rheumatol* 37:341-345, 2010 (Epub ahead of print December 23, 2009).
216. Zhang Z, Song L, Maurer K, **Petri MA**, Sullivan KE. Global H4 acetylation analysis by ChIP-chip in systemic lupus erythematosus monocytes. *Genes Immun* 11:124-133, 2010 (Epub ahead of print August 27, 2009).
217. Costenbader KH, Khamashta M, Ruiz-Garcia S, Perez-Rodriguez MT, **Petri M**, Elliott J, Manzi S, Karlson EW, Turner-Stokes T, Bermas B, Coblyn J, Massarotti E, Schur P, Fraser P, Navarro I, Hanly JG, Shaver TS, Katz RS, Chakravarty E, Fortin PR, Sanchez ML, Liu J, Michaud K, Alarcón GS, Wolfe F. Development and initial validation of a self-assessed lupus organ damage instrument. *Arthritis Care Res* 62:559-568, 2010.
218. Richman IB, Chung SA, Taylor KE, Kosoy R, Tian C, Ortmann WA, Nititham J, Lee AT, Rutman S, **Petri M**, Manzi SM, Behrens TW, Gregersen PK, Seldin MF, Criswell LA. European population substructure correlates with systemic lupus erythematosus endophenotypes in North Americans of European descent. *Genes Immun* (Epub ahead of print, October 22, 2009).
219. Kim-Howard X, Maiti AK, Anaya JM, Bruner GR, Brown E, Merrill JT, Edberg JC, **Petri MA**, Reveille JD, Ramsey-Goldman R, Alarcon GS, Vyse TJ, Gilkeson G, Kimberly RP, James JA, Guthridge JM, Harley JB, Nath SK. ITGAM coding variant (rs1143679) influences the risk of renal disease, discoid rash, and immunologic manifestations in lupus patients with European ancestry. *Ann Rheum Dis* (Epub ahead of print November 5, 2009).
220. Mehta BM, Kiani AN, Chen C, Jani J, Kickler TS, **Petri M**. Endogenous thrombin potential in the assessment of hypercoagulability in systemic lupus erythematosus. *Am J Hematol.* 85:83-85, 2010.
221. Kiani AN, Vogel-Claussen J, Magder LS, **Petri M**. Noncalcified coronary plaque in SLE. *J Rheumatol* 37:579-584, 2010.
222. Kobayashi H, Giles JT, Polak JF, Blumenthal RS, Leffell MS, Szklo M, **Petri M**, Gelber AC, Post W, Bathon JM. Increased Prevalence of Carotid Artery Atherosclerosis in Rheumatoid Arthritis is Artery Specific. *J Rheumatol* 37:730-739, 2010.

223. **Petri M**, Brodsky RA, Jones RJ, Gladstone D, Fillius M, Magder LS. High Dose Cyclophosphamide versus Monthly Intravenous Cyclophosphamide for Systemic Lupus Erythematosus: A Prospective Randomized Trial. *Arthritis Rheum* 62:1487-93, 2010.
224. Urowitz MB, Gladman D, Ibanez D, Bae S-C, Sanchez-Guerrero J, Gordon C, Clarke A, Bernatsky S, Fortin P, Hanly J, Wallace D, Isenberg D, Rahman A, Alarcón G, Merrill JT, Ginzler E, Khamashta M, Nived O, Sturfelt G, Bruce I, Steinsson K, Manzi S, Ramsey-Goldman R, Dooley MA, Zoma A, Kalunian K, van Vollenhoven R, Aranow C, Stoll T, **Petri M**, Maddison P. Atherosclerotic events in a multinational inception cohort of systemic lupus erythematosus (SLE). *Arthritis Care Res* 62:881-887, 2010.
225. Harley ITW, Niewold TB, Stormont RM, Kaufman KM, Glenn SB, Franek BS, Kelly JA, Kilpatrick JR, Hutchings D, Divers J, Bruner GR, Edberg JC, McGwin Jr G, **Petri MA**, Ramsey-Goldman R, Reveille JD. The role of genetic variation near interferon- κ in systemic lupus erythematosus. *J Biomedicine Biotechnol* vol. 2010, Article ID 706825, 11 pages, 2010.
226. Mosca M, Tani C, Aringer M, Bombardieri S, Boumpas D, Brey R, Cervera R, Doria A, Jayne D, Khamashta MA, Kuhn A, Gordon C, **Petri M**, Rekvig OP, Schneider M, Sherer Y, Shoenfeld Y, Smolen JS, Talarico R, Tincani A, van Vollenhoven RF, Ward MM, Werth VP, Carmona L. European League against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. *Ann Rheum Dis* 69:1269-1274, 2010.
227. **Petri M**, Naqibuddin M, Carson KA, Wallace DJ, Weisman MH, Holliday SL, Sampedro M, Padilla PA, Brey RL. Depression and cognitive impairment in newly diagnosed systemic lupus erythematosus. *J Rheumatol* 37:2032-2038, 2010.
228. Rasmussen A, Sevier S, Kelly JA, Glenn SB, Aberle T, Cooney CM, Grether A, James E, Ning J, Tesiram J, Morrisey J, Powe T, Drexel M, Daniel W, Namjou B, Ojwang JO, Nguyen KL, Cavett JW, Te JL, James JA, Scofield RH, Moser K, Gilkeson GS, Kamen DL, Carson CW, Quintero-Del-Rio AI, Ballesteros MD, Punaro MG, Karp DR, Wallace DJ, Weisman M, Merrill JT, Rivera R, **Petri MA**, Albert DA, Espinoza LR, Utset TO, Shaver TS, Arthur E, Anaya JM, Bruner GR, Harley JB. The Lupus Family Registry and Repository. *Rheumatology (Oxford)*. 50:47-59, 2011 [Epub ahead of print Sep 23 2010.]
229. Lessard CJ, Adrianto I, Kelly JA, Kaufman KM, Grundahl KM, Adler A, Williams AH, Gallant C, Alarcón-Riquelme ME for the BIOLUPUS and GENLES Networks, Anaya J-M, Bae SC, Boackle SA, Brown EE, Chang D-M, Criswell LA, Edberg JC, Freedman BI, Gregersen PK, Gilkeson GS, Jacob CO, James JA, Kamen DL, Kimberly RP, Martin J, Merrill JT, Niewold TB, Park S-Y, **Petri MA**, Pons-Estel BA, Ramsey-Goldman R, Reveille JD, Song YW, Stevens AM, Tsao BP, Vila LM, Vyse TJ, Yu S-Y, Guthridge JM, Bruner GR, Langefeld CD, Montgomery C, Harley JB, Scofield RH, Gaffney PM, Moser KL. Identification of a systemic lupus erythematosus susceptibility locus at 11p13 between PDHX and CD44 in a multi-ethnic study. *Am J Hum Gen* 88:83-91, 2011.
230. Giles JT, Allison M, Blumenthal RS, Post W, Gelber AC, **Petri M**, Tracy R, Szklo M, Bathon JM. Abdominal adiposity in rheumatoid arthritis: association with cardiometabolic risk factors and disease characteristics. *Arthritis Rheum* 62:3137-3182, 2010.
231. Freedman BI, Edberg JC, Comeau ME, Murea M, Bowden DW, Divers J, Alarcón GS, Brown EE, McGwin G Jr, Kopp JB, Winkler CA, Nelson GW, Illei G, **Petri M**, Ramsey-Goldman R, Reveille JD, Vilá LM, Langefeld CD, Kimberly RP; PROFILE Study Group. The non-muscle Myosin heavy chain 9 gene (MYH9) is not associated with lupus nephritis in African Americans. *Am J Nephrol* 32:66-72, 2010.
232. Golding, A., Rosen, A., **Petri, M.**, Akhter, E., Andrade, F. Interferon-alpha regulates the dynamic balance between human activated regulatory and effector T cells—Implications for anti-viral and autoimmune responses. *Immunology* 131:107-117, 2010.
233. **Petri M**, Kiani AN, Post W, Christopher-Stine L, Magder LS. Lupus Atherosclerosis Prevention Study (LAPS). *Ann Rheum Dis* 70:760-5, 2011. [Epub ahead of print Dec 10, 2010].
234. Bertolaccini ML, Amengual O, Atsumi T, Binder WL, de Laat B, Forastiero R, Kutteh WH, Lambert M, Matsubayashi H, Murthy V, Petri M, Rand JH, Sanmarco M, Tebo AE, Pierangeli SS. Non-criteria aPL tests: report of a task force and perconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010. *Lupus* 20:191-205, 2011.
235. Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EK-M, Thomas M, Kim H-Y, León MG, Tanasescu C, Nasonov E, Lan J-L, Pinela L, Zhong ZJ, Freimuth W, **Petri MA**, for the BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. *Lancet* 377:721-731, 2011.

236. Chung, SA, Taylor KE, Graham RR, Nititham J, Lee AT, Ortmann WA, Jacob CO, Alarcón-Riquelme ME, Tsao BP, Harley JB, Gaffney PM, Moser KL, SLEGEN, **Petri M**, Demirci FY, Kamboh MI, Manzi S, Gregersen PK, Langefeld CD, Behrens TW, Criswell, LA. Differential genetic associations for systemic lupus erythematosus based on anti-dsDNA autoantibody production. *PLoS Genet* 7(3): e1001323. doi:10.1371/journal.pgen.1001323, 2011.
237. Adrianto I, Wen F, Templeton A, Wiley G, King JB, Lessard CJ, Bates JS, Hu Y, Kelly JA, Kaufman KM, Guthridge JM, Alarcón-Riquelme ME, Anaya J-M, Bae S-C, Bang S-Y, Boackle SA, Brown EE, **Petri MA**, Gallant C, Ramsey-Goldman R, Reveille JD, Vila LM, Criswell LA, Edberg JC, Freedman BI, Gregersen PK, Gilkeson GS, Jacob CO, James JA, Kamen DL, Kimberly RP, Martin J, Merrill JT, Niewold TB, Park S-Y, Pons-Estel BA, Scofield RH, Stevens AM, Tsao BP, Vyse TJ, Langefeld CD, Harley JB, Moser KL, Webb CF, Humphrey MB, Montgomery CG, Gaffney PM. Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus. *Nature Genetics* March, 253 – 258, 2011.
238. Isenberg DA, Allen E, Farewell V, D’Cruz D, Alarcón GS, Aranow C, Bruce IN, Dooley MA, Fortin PR, Ginzler EM, Gladman DD, Hanly JG, Inanc M, Kalunian K, Khamashta M, Merrill JT, Nived O, **Petri M**, Ramsey-Goldman R, Sturfelt G, Urowitz M, Wallace DJ, Gordon C, Rahman A. An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA. *Ann Rheum Dis* 70:54-59, 2011.
239. Mehrani T, **Petri M**. Association of IgA anti- β_2 glycoprotein I with clinical and laboratory manifestations of systemic lupus erythematosus. *J Rheumatol* 38:64-68, 2011.
240. Mehrani T, **Petri M**. IgM anti- β_2 glycoprotein I is protective against lupus nephritis and renal damage in systemic lupus erythematosus. *J Rheumatol* 38:450-453, 2011.
241. DeZern AE, **Petri M**, Drachman DB, Kerr D, Hammond ER, Kowalski J, Tsai H-L, Loeb DM, Anhalt G, Wigley F, Jones RJ, Brodsky RA. High dose cyclophosphamide without stem cell rescue in 207 patients with aplastic anemia and other autoimmune diseases. *Medicine* 90:89-98, 2010.
242. Baer AN, Maynard JW, Shaikh F, Magder LS, **Petri M**. Secondary Sjogren's syndrome in systemic lupus erythematosus defines a distinct disease subset. *J Rheumatol* 37:1143-1149, 2010.
243. Ippolito A, Wallace DJ, Gladman D, Fortin PR, Urowitz M, Werth V, Costner M, Gordon C, Alarcón GS, Ramsey-Goldman R, Maddison P, Clarke A, Bernatsky S, Manzi S, Bae S-C, Merrill JT, Ginzler E, Hanly JG, Nived O, Sturfelt G, Sanchez-Guerrero J, Bruce I, Aranow C, Isenberg D, Zoma A, Magder SL, Buyon J, Kalunian K, Dooley MA, Steinsson K, van Vollenhoven RF, Stoll T, Weisman M, **Petri M**. Autoantibodies in systemic lupus erythematosus: comparison of historical and current assessment of seropositivity. *Lupus* 20:250-5, 2011.
244. Sule S, Rosen A, **Petri M**, Akhter E, Andrade F. Abnormal production of pro- and anti-inflammatory cytokines by lupus monocytes in response to apoptotic cells. *PLoS ONE* 6: e17495, 2011.
245. Clowse MEB, Madger L, **Petri M**. Clinical utility of measuring complement and anti-dsDNA antibodies in systemic lupus erythematosus pregnancies. *J Rheumatol* 38:1012-16, 2011. [Mar 16, Epub ahead of print].
246. Hanly JG, Urowitz MB, Jackson D, Bae SC, Gordon C, Wallace DJ, Clarke A, Bernatsky S, Vasudevan A, Isenberg D, Rahman A, Sanchez-Guerrero J, Romero-Diaz J, Merrill JT, Fortin PR, Gladman DD, I. Bruce N, Steinsson K, Khamashta M, Alarcón GS, Fessler B, **Petri M**, Manzi S, Nived O, Sturfelt G, Ramsey-Goldman R, Dooley MA, Aranow C, Van Vollenhoven R, Ramos-Casals M, Zoma A, Kalunian K, Farewell V for the Systemic Lupus International Collaborating Clinics (SLICC). SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus. *Ann Rheum Dis*, 2011. [Feb 21, Epub ahead of print].
247. Mosca M, Tani C, Aringer M, Bombardieri S, Boumpas D, Cervera R, Doria A, Jayne D, Khamashta MA, Kuhn A, Gordon C, **Petri M**, Schneider M, Shoenfeld Y, Smolen JS, Talarico R, Tincani A, Ward MM, Werth VP, Carmona L. Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practice. *Autoimmun Rev* 10:383-388, 2011. [Jan 9, Epub ahead of print; doi: 10.1016/j.autrev.2010.12.008].
248. Hughes T, Kim-Howard X, Kelly JA, Kaufman KM, Langefeld CD, Ziegler J, Sanchez E, Kimberly RP, Edberg JC, Ramsey-Goldman R, **Petri M**, Reveille JD, Martin J, Brown EE, Vilá LM, Alarcón GS, James JA, Gilkeson GS, Moser KL, Gaffney PM, Merrill JT, Vyse TJ, Alarcón-Riquelme ME on behalf of the BIOLUPUS Network, Nath SK, Harley JB, Sawalha AH. Fine mapping and trans-ethnic genotyping establish IL2/IL21 genetic association with lupus and localize this genetic effect to IL21. *Arthritis Rheum* 63:1689-97, 2011. [Mar 18, Epub ahead of print].

249. Namjou B, Kothari PH, Kelly J, Glenn S., Ojwang JO, Adler A, Alarcón-Riquelme ME, Boackle S, Criswell L, Kimberly R, Brown E, Edberg J, Stevens AM, Jacob C, Tsao BP, Gilkeson GS, Kamen DL, Merrill JT, **Petri M**, Ramsey Goldman R, Vila L, Anaya J-M, Niewold T, Martin J, Pons-Estel BA, Gallant CJ, Vyse TJ, Bae S-C, Scofield RH, Moser K, Gaffney P, James JA, Langefeld CD, Kaufman KM, Harley JB, Atkinson JP. Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort. *Genes Immunity*, 2011 Jan 27. [Jan 27, Epub ahead of print].
250. Ramos PS, Williams AH, Ziegler JT, Comeau ME, Guy RT, Lessard CJ, Edberg JC, Zidovetzki R, Criswell LA, Gaffney PM, Graham DC, Graham RR, Kelly JA, Kaufman KM, Brown EE, Alarcón GS, **Petri MA**, Reveille JD, Vilá LM, Ramsey-Goldman R, Jacob CO, Vyse TJ, Tsao BP, Harley JB, Kimberly RP, Alarcón-Riquelme ME, Langefeld CD, Moser KL. Genetic analyses of interferon pathway-related genes reveals multiple new loci associated with systemic lupus erythematosus. *Arthritis Rheum* 63:2049-2057, 2011. [Mar 24, Epub ahead of print].
251. Stagnaro-Green A, Akhter E, Yim C, Davies TF, Magder LS, **Petri M**. Thyroid disease in pregnant women with systemic lupus erythematosus: increased preterm delivery. *Lupus* 20:690-699, 2011. [Mar 24, Epub ahead of print].
252. Taylor KE, Chung SA, Graham RR, Ortmann WA, Lee AT, Langefeld CD, Jacob CO, Kamboh MI, Alarcon-Riquelme ME, Tsao BP, Moser KL, Gaffney PM, Harley JB, **Petri M**, Manzi S, Gregersen PK, Behrens TW, Criswell LA. Risk alleles for systemic lupus erythematosus in a large case-control collection and associations with clinical subphenotypes. *PLoS Genet.* 7:e1001311, 2011.
253. Vinet E, Clarke AE, Gordon C, Urowitz MB, Hanly J, Pineau CA, St-Pierre Y, Isenberg D, Rahman A, Wallace D, Alarcon G, Bruce I, **Petri M**, Dooley MA, Kalunian K, Maddison P, Aranow C, van Vollenhoven R, Bernatsky S. Decreased live births in women with systemic lupus erythematosus. *Arthritis Care Res* 63:1068-1072, 2011. [Mar 18, Epub ahead of print].
254. Merrill JT, Wallace DJ, **Petri M**, Kirou KA, Yao Y, White WI, Robbie G, Levin R, Berney SM, Chindalore V, Olsen N, Richman L, Le C, Jallal B, White B for the Lupus Interferon Skin Activity (LISA) Study Investigators. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. *Ann Rheum Dis* 2011;70:1905-1913.
255. Hanly JG, Urowitz MB, Su L, Bae SC, Gordon C, Sanchez-Guerrero J, Clarke A, Bernatsky S, Vasudevan A, Isenberg D, Rahman A, Wallace DJ, Fortin PR, Gladman DD, Dooley MA, Bruce N, Steinsson K, Khamashta M, Manzi S, Ramsey-Goldman R, Sturfelt G, Nived O, Van Vollenhoven R, Ramos-Casals M, Aranow C, Mackay M, Kalunian K, Alarcón GS, Fessler B, Ruiz-Irastorza G, **Petri M**, Lim S, Kamen D, Peschken C, Farewell V, Thompson K, Theriault C, Merrill JT. Autoantibodies as Biomarkers for the Prediction of Neuropsychiatric Events in Systemic Lupus Erythematosus. *Ann Rheum Dis* 70:1726-1732, 2011.
256. Sanchez E, Nadig A, Richardson BC, Freedman BI, Kaufman KM, Kelly JA, Niewold TM, Kamen DL, Gilkeson GS, Ziegler JT, Langefeld CD, Edberg JC, Ramsey-Goldman R, **Petri M**, Brown EE, Kimberly RP, Reveille JD, Vilá LM, Merrill JT, Anaya J-M, James JA, Pons-Estel BA, Martin J, Bae S-C, Moser KL, Vyse TJ, Criswell LA, Gaffney PM, Tsao BP, Jacob CO, Harley JB, Alarcón-Riquelme ME, on behalf of BIOLUPUS and GENLES, Sawalha AH. Phenotypic associations of genetic susceptibility loci in systemic lupus erythematosus. *Ann Rheum Dis* 70:1752-1757, 2011.
257. **Petri M**, Naqibuddin M, Sampedro M, Omdal R, Carson KA. Memantine in systemic lupus erythematosus: A randomized, double-blind placebo-controlled trial. *Semin Arthritis Rheum* 41:194-202, 2011. [Mar Epub ahead of print].
258. Kiani AN, Post W, Magder LS, **Petri M**. Predictors of progression in atherosclerosis over 2 years in systemic lupus erythematosus. *Rheumatology*, 2011, doi: 10.1093/rheumatology/ker285 [August, Epub ahead of print].
259. Ramage AE, Fox PT, Brey RL, Narayana S, Cykowski MD, Naqibuddin M, Sampedro M, Holliday SL, Franklin C, Wallace DJ, Weisman MH, **Petri M**. Neuroimaging evidence of white matter inflammation in newly diagnosed systemic lupus erythematosus. *Arthritis Rheum* 63:3048-57, 2011.
260. Sanchez E, Comeau ME, Freedman BI, Kelly JA, Kaufman KM, Langefeld CD, Brown EE, Kimberly RP, Alarcón GS, Kimberly RP, Edberg JC, Ramsey-Goldman R, **Petri M**, Reveille JD, Vilá LM, Merrill JT, Tsao BP, Kamen DL, Gilkeson GS, James JA, Vyse TJ on behalf of the International Consortium on the Genetics of Systemic Lupus Erythematosus, Gaffney PM, Jacob CO, Niewold TM, Richardson BC, Harley JB, Alarcón-Riquelme ME, Sawalha AH. Identification of novel genetic susceptibility loci in African American lupus patients in a candidate gene association study. *Arthritis Rheum* 63:3493-3501, 2011.

261. Giles JT, Post WS, Blumenthal RS, Polak J, **Petri M**, Gelber AC, Szklo M, Bathon JM. Longitudinal predictors of progression of carotid atherosclerosis in rheumatoid arthritis. *Arthritis Rheum* 63:3216-3225, 2011.
262. Akhter E, Burlingame RW, Seaman AL, Magder L, Petri M. Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers. *Lupus* 20:1267-74, 2011.
263. Furie RA, **Petri MA**, Zamani O, Cervera R, Wallace DJ, Tegzova D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth WW, van Vollenhoven RF, for the BLISS-76 Study Group. A phase III, randomized, placebo-controlled, study of Belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with active systemic lupus erythematosus. *Arthritis Rheum* 63:3918-3930, 2011.
264. Romick-Rosendale LE, Brunner HI, Bennett MR, Mina R, Nelson S, **Petri M**, Kiani A, Devarajan P, Kennedy MA. Identification of urinary metabolites that distinguish membranous lupus nephritis from proliferative lupus nephritis and focal segmental glomerulosclerosis. *Arthritis Research Therapy* 13(7 December):R199, 2011.
265. Lanata C, Mahmood T, Fine DM, Petri M. Combination therapy of mycophenolate mofetil and tacrolimus in lupus nephritis. *Lupus*, 19: 935-940, 2011.
266. Namjou B, Kothari PH, Kelly J, Glenn S, Ojwang JO, Adler A, Alarcón-Riquelme ME, Boackle S, Criswell L, Kimberly K, Brown E, Edberg J, Stevens AM, Jacob C, Tsao BP, Gilkeson GS, Kamen DL, Merrill JT, **Petri M**, Ramsey Goldman R, Vila L, Anaya J-M, Niewold T, Martin J, Pons-Estel BA, Gallant CJ, Vyse TJ, Bae S-C, Scofield RH, Moser K, Gaffney P, James JA, Langefeld CD, Kaufman KM, Harley JB, Atkinson JP. Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort. *Genes Immun* 12:270-279, 2011.
267. Tan W, Sunahori K, Zhao J, Deng Y, Kaufman KM, Kelly JA, Langefeld CD, Williams AH, Comeau ME, Ziegler JT, Marion MC, Bae S-C, Lee JH, Lee J-S, Chang D-M, Song YW, Yu C-Y, Kimberly RP, Edberg JC, Brown EE, **Petri MA**, Ramsey-GoldmanR, Vila LM, Reveille JD, Alarcón-Riquelme ME on behalf of the BIOLUPUS and GENLES networks, Harley JB, Boackle SA, Stevens AM, Scofield RH, Merrill JT, Freedman BI, Anaya J-M, Criswell LA, Jacob CO, Vyse TJ, Niewold TB, Gaffney PM, Moser KL, Gilkeson GS, Kamen DL, James JA, Grossman JM, Hahn BH, Tsokos GC, Tsao BP. Association of *PPP2CA* polymorphisms with systemic lupus erythematosus susceptibility in multiple ethnic groups. *Arthritis Rheum* 63:2755-2763, 2011.
268. Zhao J, Wu H, Khosravi M, Cui H, Qian X, Kelly JA, Kaufman KM, Langefeld CD, Williams AH, Comeau ME, Ziegler JT, Marion MC, Adler A, Glenn SB, Alarcón-Riquelme ME on behalf of the BIOLUPUS and GENLES networks, Harley JB, Bae S-C, Lee JH, Lee J-S, Jacob CO, Vyse TJ, Niewold TB, Gaffney PM, Moser KL, Kimberly RP, Edberg JC, Brown EE, **Petri MA**, Ramsey-GoldmanR, Vila LM, Reveille JD, James JA, Gilkeson GS, Kamen DL, Freedman BI, Anaya J-M, Merrill JT, Criswell LA, Scofield RH, Stevens AM, Boackle SA, Guthridge JM, Chang D-M, Song YW, Grossman JM, Hahn BH, Goodship THJ, Cantor RM, Yu C-Y, Shen N, Tsao BP. Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility. *PLoS Genetics* 7:e1002079, 2011.
269. Adrianto I, Wen F, Templeton A, Wiley G, King JB, Lessard CJ, Bates JS, Hu Y, Kelly JA, Kaufman KM, Guthridge JM, Alarcón-Riquelme ME; BIOLUPUS and GENLES Networks, Anaya JM, Bae SC, Bang SY, Boackle SA, Brown EE, **Petri MA**, Gallant C, Ramsey-Goldman R, Reveille JD, Vila LM, Criswell LA, Edberg JC, Freedman BI, Gregersen PK, Gilkeson GS, Jacob CO, James JA, Kamen DL, Kimberly RP, Martin J, Merrill JT, Niewold TB, Park SY, Pons-Estel BA, Scofield RH, Stevens AM, Tsao BP, Vyse TJ, Langefeld CD, Harley JB, Moser KL, Webb CF, Humphrey MB, Montgomery CG, Gaffney PM. Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus. *Nat Genet.* 43(3):253-8, 2011.
270. Kiani AN, Magder LS, **Petri M**. Mycophenolate mofetil (MMF) does not slow the progression of subclinical atherosclerosis in SLE over 2 years. *Rheumatol Int*, 2011. [July Epub ahead of print].
271. Niewold TB, Kelly JA, Kariuki SN, Franek BS, Kumar AA, Kaufman KM, Thomas K, Walker D, Kamp S, Frost JM, Wong AK, Merrill JT, Alarcón-Riquelme ME, Tikly M, Ramsey-Goldman R, Reveille JD, **Petri MA**, Edberg JC, Kimberly RP, Alarcón GS, Kamen DL, Gilkeson GS, Vyse TJ, James JA, Gaffney PM, Moser KL, Crow MK, Harley JB. IRF5 Haplotypes Demonstrate Diverse Serologic Associations which Predict Serum Interferon Alpha Activity and Explain the Majority of the Genetic Association with Systemic Lupus Erythematosus. *Ann Rheum Dis*, 2011. [Nov Epub ahead of print].
272. Vinet E, Clarke AE, Gordon C, Urowitz MB, Hanly JG, Pineau CA, St-Pierre Y, Isenberg D, Rahman A, Wallace D, Alarcón GS, Bruce I, **Petri M**, Dooley MA, Kalunian K, Maddison P, Aranow C, van Vollenhoven R, Bernatsky S. Decreased live births in women with systemic lupus erythematosus. *Arthritis Care Res* 63:1068-1072, 2011.

273. Urowitz MB, Gladman DD, Ibanez D, Fortin PR, Bae SC, Gordon C, Clarke A, Bernatsky S, Hanly JG, Isenberg D, Rahman A, Sanchez-Guerrero J, Wallace DJ, Ginzler E, Alarcón GS, Merrill JT, Bruce IN, Sturfelt G, Nived O, Steinsson K, Khamashta M, **Petri M**, Manzi S, Ramsey-Goldman R, Dooley MA, van Vollenhoven RF, Ramos M, Stoll T, Zoma A, Kalunian K, Aranow C. Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. *Arthritis Care Res* 64:132-137, 2012.
274. Hughes T, Adler A, Kelly JA, Kaufman KM, Williams AH, Langefeld CD, Brown EE, Alarcón GS, Kimberly RP, Edberg JC, Ramsey-Goldman R, **Petri MA**, Boackle SA, Stevens AM, Reveille JD, Sanchez E, Martin J, Niewold TB, Vila LM, Scofield RH, Gilkeson GS, Gaffney PM, Criswell LA, Moser KL, Merrill JT, Jacob CO, Tsao BP, James JA, Vyse TJ, Alarcón-Riquelme ME on behalf of the BIOLUPUS network, Harley JB, Richardson BC, Sawalha AH. Evidence for gene-gene epistatic interactions among susceptibility loci for systemic lupus erythematosus. *Arthritis Rheum* 64:485-492, 2012.
275. Tan TC, Fang H, Magder LS, **Petri MA**. Differences between male and female systemic lupus erythematosus in a multiethnic population. *J Rheumatol* 39:759-769, 2012.
276. Maynard JW, Fang H, **Petri M**. Low Socioeconomic Status is Associated with Cardiovascular Risk Factors and Outcomes in Systemic Lupus Erythematosus. *J Rheumatol* 39:777-783, 2012.
277. Hughes T, Adler A, Merrill JT, Kelly JA, Kaufman KM, Williams AH, Langefeld CD, Gilkeson GS, Sanchez E, Martin J, Boackle SA, Stevens AM, Alarcón GS, Niewold TB, Brown EE, Kimberly RP, Edberg JC, Ramsey-Goldman R, **Petri MA**, Reveille JD, Criswell LA, Vila LM, Jacob CO, Gaffney PM, Moser KL, Vyse TJ, Alarcón-Riquelme ME, BIOLUPUS network, James JA, Tsao BP, Scofield RH, Harley JB, Richardson BC, Sawalha AH. Analysis of autosomal genes reveals gene-sex interactions and higher total genetic risk in men with systemic lupus erythematosus. *Ann Rheum Dis* 71:694-699, 2012.
278. Namjou B, Choi C-B, Harley ITW, Alarcón-Riquelme ME, on behalf of the BIOLUPUS network, Kelly JA, Glenn SB, Ojwang JO, Adler A, Kim K, Gallant CJ, Boackle SA, Criswell LA, Kimberly RP, Brown EE, Edberg JC, Alarcón GS, Stevens AM, Jacob CO, Gilkeson GS, Kamen DL, Tsao BP, Anaya J-M, Kim E-M, Park S-Y, Sung Y-K, Guthridge JM, Merrill JT, **Petri MA**, Ramsey-Goldman R, Vila LM, Niewold TB, Martin J, Pons-Estel BA on behalf of the Genoma en Lupus Network, Vyse TJ, Freedman BI, Moser KL, Gaffney PM, Williams AH, Comeau ME, Reveille JD, Kang C, James JA, Scofield RH, Langefeld CD, Kaufman KM, Harley JB, Bae S-C. Evaluation of TRAF6 in a large multiancestral lupus cohort. *Arthritis Rheum* 64:1960-1969, 2012.
279. Kiani AN, Wu T, Fang H, Zhou XJ, Ahn CW, Magder LS, Mohan C, Petri M. Urinary vascular cell adhesion molecule, but not neutrophil gelatinase-associated lipocalin, is associated with lupus nephritis. *J Rheumatol* 39:1231-1237, 2012.
280. Kim K, Brown EE, Choi C-B, Alarcón-Riquelme ME, Kelly JA, Glenn SB, Ojwang JO, Adler A, Lee H-S, Boackle SA, Criswell LA, Alarcón GS, Edberg JC, Stevens AM, Jacob CO, Gilkeson GS, Kamen DL, Tsao BP, Anaya J-M, Guthridge JM, Nath SK, Richardson B, Sawalha AH, Kang YM, Shim SC, Suh C-H, Lee S-K, Kim C-S, Merrill JT, **Petri M**, Ramsey-Goldman R, Vilá LM, Niewold TB, Martin J, Pons-Estel BA, Vyse TJ, Freedman BI, Moser KL, Gaffney PM, Williams A, Comeau M, Reveille JD, James JA, Scofield RH, Langefeld CD, Kaufman KM, Harley JB, Kang C, Kimberly RP, Bae S-C. Variation in the ICAM1-ICAM4-ICAM5 locus is associated with systemic lupus erythematosus susceptibility in multiple ancestries. *Ann Rheum Dis* 71(11):1809-14, 2012. [doi: 10.1136/annrheumdis-2011-201110. Epub 2012 Apr 20].
281. Manzi S, Sanchez-Guerrero J, Merrill J, Furie R, Gladman D, Navarra S, Ginzler E, D'Cruz D, Doria A, Cooper S, Zhong ZJ, Hough D, Freimuth W, **Petri M**. Effects of belimumab, a B-lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. *Ann Rheum Dis*, 2012. [May Epub ahead of print, doi: 10.1136/annrheumdis-2011-200831].
282. Santiago-Casas Y, Vila LM, McGwin G Jr, Cantor RS, **Petri M**, Ramsey-Goldman R, Reveille JD, Kimberly R, Alarcon GS, Brown EE. Association of discoid lupus erythematosus with clinical manifestations and damage accrual in a multiethnic lupus cohort. *Arthritis Care Res* 64:704-712, 2012.
283. Van Vollenhoven RF, **Petri MA**, Cervera R, Roth DA, Ji BN, Kleoudis CS, Zhong ZJ, Freimuth W. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. *Ann Rheum Dis* 71:1343-1349, 2012. [April Epub ahead of print, doi: 10.1136/annrheumdis-2011-200937].

284. Hanly JG, Urowitz MB, Su L, Gordon C, Bae SC, Sanchez-Guerrero J, Romero-Diaz J, Wallace DJ, Clarke AE, Ginzler E, Merrill JT, Isenberg D, Rahman A, **Petri M**, Fortin PR, Gladman DD, Bruce IN, Steinsson K, Dooley MA, Khamashta M, Alarcón GS, Fessler BJ, Ramsey-Goldman R, Manzi S, Zoma AA, Sturfelt G, Nived O, Aranow C, Mackay M, Ramos-Casals M, Van Vollenhoven R, Kalunian K, Ruiz-Irastorza G, Lim S, Kamen DL, Peschken CA, Inanc M, Theriault C, Thompson K, Farewell V. Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. *Ann Rheum Dis* 71:1502-1509, 2012.
285. Brunner HI, Bennett MR, Mina R, Suzuki M, **Petri M**, Kiani A, Pendl J, Witte D, Ying J, Rovin BH, Devarajan P. Association of noninvasively measured renal protein biomarkers with histologic features of lupus nephritis. *Arthritis Rheum* 64:2687-2697, 2012.
286. **Petri M**, Orbai A-M, Alarcón GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg D, Wallace DJ, Nived O, Sturfelt G, Ramsey-Goldman R, Bae SC, Hanly JG, Sanchez-Guerrero J, Clarke A, Aranow C, Manzi S, Urowitz MB, Gladman DD, Kalunian K, Costner M, Werth V, Zoma A, Bernatsky S, Ruiz-Irastorza G, Khamashta M, Jacobsen S, Buyon JP, Maddison P, Dooley MA, Van Vollenhoven R, Ginzler E, Stoll T, Peschken C, Jorizzo JL, Callen JP, Lim S, Fessler BJ, Inanc M, Kamen DL, Rahman A, Steinsson K, Franks Jr. AG, Sigler L, Hameed S, Fang H, Pham N, Brey R, Weisman MH, McGwin Jr. G, Magder LS. Derivation and validation of Systemic Lupus International Collaborating Clinics (SLICC) classification criteria for systemic lupus erythematosus. *Arthritis Rheum* 64:2677-2686, 2012.
287. Kaiser R, Li Y, Chang M, Catanese J, Begovich A, Brown EE, Edberg JC, McGwin G Jr., Alarcón GS, Ramsey-Goldman R, Reveille JD, Vilá LM, **Petri MA**, Kimberly RP, Taylor K, Criswell LA. Genetic risk factors for thrombosis in systemic lupus erythematosus. *J Rheumatol* 39:1603-1610, 2012.
288. Magder LS, **Petri M**. Incidence of and Risk Factors for Adverse Cardiovascular Events Among Patients With Systemic Lupus Erythematosus. *Amer J Epidemiol* 176:708-19, 2012.
289. Richman IB, Taylor KE, Chung SA, Trupin L, **Petri M**, Yelin E, Graham RR, Lee A, Behrens TW, Gregersen PK, Seldin MF, Criswell LA. European genetic ancestry is associated with a decreased risk of lupus nephritis. *Arthritis Rheum* 64(10):3374-3382, 2012.
290. Manzi S, Sánchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, Ginzler EM, D’Cruz DP, Doria A, Cooper S, Zhong ZJ, Hough D, Freimuth W, **Petri MA**, on behalf of the BLISS-52 and BLISS-76 Study Groups. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. *Ann Rheum Dis* 71:1833-1838, 2012.
291. **Petri M**, Purvey S, Fang H, Magder LS. Predictors of Organ damage in systemic lupus erythematosus. *Arthritis Rheum* 64:4021-8, 2012.
292. Kiani AN, Vogel-Claussen J, Arbab-Zadeh A, Magder LS, Lima J, **Petri M**. Semiquantified noncalcified coronary plaque in systemic lupus erythematosus. *J Rheumatol* 39:2286-93, 2012.
293. Adrianto I, Wang S, Wiley GB, Lessard CJ, Kelly JA, Adler AJ, Glenn SB, Williams AH, Ziegler JT, Comeau ME, Marion MC, Wakeland BE, Liang C, Kaufman KM, Guthridge JM, Alarcon-Riquelme ME, Biolupus, Networks G, Alarcon GS, Anaya JM, Bae SC, Kim JH, Joo YB, Boackle SA, Brown EE, **Petri MA**, Ramsey-Goldman R, Reveille JD, Vila LM, Criswell LA, Edberg JC, Freedman BI, Gilkeson GS, Jacob CO, James JA, Kamen DL, Kimberly RP, Martin J, Merrill JT, Niewold TB, Pons-Estel BA, Scofield RH, Stevens AM, Tsao BP, Vyse TJ, Langefeld CD, Harley JB, Wakeland EK, Moser KL, Montgomery CG, Gaffney PM. Association of two independent functional risk haplotypes in TNIP1 with systemic lupus erythematosus. *Arthritis Rheum* 64:3695-705, 2012.
294. Lessard CJ, Adrianto I, Ice JA, Wiley GB, Kelly JA, Glenn SB, Adler AJ, Li H, Rasmussen A, Williams AH, Ziegler J, Comeau ME, Marion M, Wakeland BE, Liang C, Ramos PS, Grundahl KM, Gallant CJ, Alarcón-Riquelme ME, Alarcón GS, Anaya JM, Bae SC, Boackle SA, Brown EE, Chang DM, Cho SK, Criswell LA, Edberg JC, Freedman BI, Gilkeson GS, Jacob CO, James JA, Kamen DL, Kimberly RP, Kim JH, Martin J, Merrill JT, Niewold TB, Park SY, **Petri MA**, Pons-Estel BA, Ramsey-Goldman R, Reveille JD, Scofield RH, Song YW, Stevens AM, Tsao BP, Vila LM, Vyse TJ, Yu CY, Guthridge JM, Kaufman KM, Harley JB, Wakeland EK, Langefeld CD, Gaffney PM, Montgomery CG, Moser KL; BIOLUPUS Network; GENLES Network. Identification of IRF8, TMEM39A, and IKZF3-ZPBP2 as susceptibility loci for systemic lupus erythematosus in a large-scale multiracial replication study. *Am J Hum Genet*. 90(4):648-60, 2012. [doi: 10.1016/j.ajhg.2012.02.023. Epub 2012 Mar 29]

295. Sanchez E, Rasmussen A, Riba L, Acevedo-Vasquez E, Kelly JA, Langefeld CD, Williams AH, Ziegler JT, Comeau ME, Marion MC, Garcia-De La Torre I, Maradiaga-Cecena MA, Cardiel MH, Esquivel-Valerio JA, Rodriguez-Amado J, Moctezuma JF, Miranda P, Perandones CE, Castel C, Laborde HA, Alba P, Musuruana JL, Goecke IA, Anaya JM, Kaufman KM, Adler A, Glenn SB, Brown EE, Alarcon GS, Kimberly RP, Edberg JC, Vila LM, Criswell LA, Gilkeson GS, Niewold TB, Martin J, Vyse TJ, Boackle SA, Ramsey-Goldman R, Scofield RH, **Petri M**, Merrill JT, Reveille JD, Tsao BP, Orozco L, Baca V, Moser KL, Gaffney PM, James JA, Harley JB, Tusie-Luna T, Pons-Estel BA, Jacob CO, Alarcon-Riquelme ME. Impact of genetic ancestry and sociodemographic status on the clinical expression of systemic lupus erythematosus in American Indian-European populations. *Arthritis Rheum.* 64:3687-94, 2012.
296. Lockshin MD, Kim M, Laskin CA, Guerra M, Branch DW, Merrill J, **Petri M**, Porter F, Sammaritano L, Stephenson MD, Buyon J, Salmon JE. Lupus anticoagulant, but not anticardiolipin antibody, predicts adverse pregnancy outcome in patients with antiphospholipid antibodies. *Arthritis Rheum* 64:2311-8, 2012.
297. Duarte-Garcia A, Fang H, To CH, Magder LS, **Petri M**. Seasonal variation in the activity of systemic lupus erythematosus. *J Rheumatol.* 39:1392-8, 2012.
298. Lin CP, Adrianto I, Lessard CJ, Kelly JA, Kaufman KM, Guthridge JM, Freedman BI, Anaya JM, Alarcón-Riquelme ME; BIOLUPUS and GENLES Networks, Pons-Estel BA, Martin J, Glenn S, Adler A, Bae SC, Park SY, Bang SY, Song YW, Boackle SA, Brown EE, Edberg JC, Alarcón GS, **Petri MA**, Criswell LA, Ramsey-Goldman R, Reveille JD, Vila LM, Gilkeson GS, Kamen DL, Ziegler J, Jacob CO, Rasmussen A, James JA, Kimberly RP, Merrill JT, Niewold TB, Scofield RH, Stevens AM, Tsao BP, Vyse TJ, Langefeld CD, Moser KL, Harley JB, Gaffney PM, Montgomery CG. Role of MYH9 and APOL1 in African and non-African populations with lupus nephritis. *Genes Immun.* 13:232-8, 2012. [doi: 10.1038/gene.2011.82. Epub 2011 Dec 22]
299. Grönwall C, Akhter E, Oh C, Burlingame RW, **Petri M**, Silverman GJ. IgM autoantibodies to distinct apoptosis-associated antigens correlate with protection from cardiovascular events and renal disease in patients with SLE. *Clin Immunol.* 142:390-398, 2012.
300. Wang S, Adrianto I, Wiley GB, Lessard CJ, Kelly JA, Adler AJ, Glenn SB, Williams AH, Ziegler JT, Comeau ME, Marion MC, Wakeland BE, Liang C, Kaufman KM, Guthridge JM, Alarcón-Riquelme ME; BIOLUPUS and GENLES Networks, Alarcón GS, Anaya JM, Bae SC, Kim JH, Joo YB, Boackle SA, Brown EE, **Petri MA**, Ramsey-Goldman R, Reveille JD, Vilá LM, Criswell LA, Edberg JC, Freedman BI, Gilkeson GS, Jacob CO, James JA, Kamen DL, Kimberly RP, Martin J, Merrill JT, Niewold TB, Pons-Estel BA, Scofield RH, Stevens AM, Tsao BP, Vyse TJ, Langefeld CD, Harley JB, Wakeland EK, Moser KL, Montgomery CG, Gaffney PM. A functional haplotype of UBE2L3 confers risk for systemic lupus erythematosus. *Genes Immun.* 13:380-7, 2012. [doi: 10.1038/gene.2012.6. Epub 2012 Apr 5]
301. Wallace DJ, Kalunian K, **Petri MA**, Strand V, Houssiau FA, Pike M, Kilgallen B, Bongardt S, Barry A, Kelley L, Gordon C. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. *Ann Rheum Dis* 73:183-190, 2014. [online: January 12, 2013 as 10.1136/annrheumdis-2012-202760]
302. Kaiser R, Taylor KE, Deng Y, Zhao J, Li Y, Nititham J, Chang M, Catanese J, Begovich AB, Brown EE, Edberg JC, McGwin G, Alarcon GS, Ramsey-Goldman R, Reveille JD, Vila LM, **Petri M**, Kimberly RP, Feng X, Sun L, Shen N, Li W, Lu J-X, Wakeland EK, Li Q-Z, Yang W, Lau Y-L, Liu F-L, Chang D-M, Yu C-Y, Song YW, Howe HS, The Tan Tock Seng Hospital Systemic Lupus Erythematosus Study Group, Tsao BP, Criswell LA. SNPs in VKORC1 are risk factors for systemic lupus erythematosus in Asians. *Arthritis Rheum* 65:211-5, 2012.
303. Wallace DJ, Navarra SV, **Petri MA**, Gallacher A, Thomas M, Furie R, Levy RA, van Vollenhoven RF, Cooper S, Zhong ZJ, Freimuth W, Cervera R, for the BLISS-52 and BLISS-76, and LBSL02 Study Groups. Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. *Lupus* 22:144-154, 2013.
304. Akhter E, Shums Z, Normal GL, Binder W, Fang H, **Petri M**. Utility of antiphosphatidylserine/prothrombin and IgA antiphospholipid assays in systemic lupus erythematosus. *J Rheumatol* 40:282-6, 2013.
305. **Petri M**, Wallace DJ, Spindler A, Chindalore V, Kalunian K, Mysler E, Neuwelt CM, Robbie G, White WI, Higgs BW, Yao Y, Wang L, Ethgen D, Greth W. Sifalimumab, a human anti-interferon- α monoclonal antibody, in systemic lupus erythematosus: a Phase I randomized, controlled, dose-escalation study. *Arthritis Rheum* 65:1011-1021, 2013.

306. Bernatsky S, Ramsey-Goldman R, Labrecque J, Joseph L, Boivin JF, **Petri M**, Zoma A, Manzi S, Urowitz MB, Gladman D, Fortin PR, Ginzler E, Yelin E, Bae SC, Wallace DJ, Edworthy S, Jacobsen S, Gordon C, Dooley MA, Peschken CA, Hanly JG, Alarcon GS, Nived O, Ruiz-Irastorza G, Isenberg D, Rahman A, Witte T, Aranow C, Kamen DL, Steinsson K, Askanase A, Barr S, Criswell LA, Sturfelt G, Patel NM, Senecal JL, Zummer M, Pope JE, Ensworth S, El-Gabalawy H, McCarthy T, Dreyer L, Sibley J, St Pierre Y, Clarke AE. Cancer risk in systemic lupus: an updated international multi-centre cohort study. *J Autoimmunity* 42:130-5, 2013.
307. Kiani AN, Strand V, Fang H, Jaranilla J, **Petri M**. Predictors of self-reported health-related quality of life in systemic lupus erythematosus. *Rheumatology* 2013; doi: 10.1093/rheumatology/ket171.
308. Rahimi H, Maurer K, Song L, Akhter E, **Petri M**, Sullivan KE. Aberrant regulation of the integrin very late antigen-4 in systemic lupus erythematosus. *Lupus* 22:297-306, 2013.
309. **Petri M**, Bello KJ, Fang H, Magder LS. Vitamin D in systemic lupus erythematosus: modest association with disease activity and urine protein-to-creatinine ratio. *Arthritis Rheum* 65:1865-71, 2013.
310. Zahr ZA, Fang H, Magder LS, **Petri M**. Predictors of corticosteroid tapering in SLE patients: the Hopkins Lupus Cohort. *Lupus* 22:697-701, 2013.
311. **Petri MA**, van Vollenhoven RF, Buyon J, Levy RA, Navarra SV, Cervera R, Zhong ZJ, Freimuth W, on behalf of the BLISS-52 and BLISS-76 Study Groups. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the Phase III Belimumab trials. *Arthritis Rheum* 65:2143-53, 2013.
312. Stojan G, Fang H, Magder L, **Petri M**. Erythrocyte sedimentation rate is a predictor of renal and overall SLE disease activity. *Lupus* 22:827-834, 2013.
313. Tessier Cloutier B, Clarke AE, Ramsey-Goldman R, Wang Y, Foulkes W, Gordon C, Hansen JE, Yelin E, Urowitz MB, Gladman D, Fortin PR, Wallace DJ, Petri M, Manzi S, Ginzler EM, Labrecque J, Edworthy S, Dooley MA, Senecal JL, Peschken CA, Bae SC, Isenberg D, Rahman A, Ruiz-Irastorza G, Hanly JG, Jacobsen S, Nived O, Witte T, Criswell LA, Barr SG, Dreyer L, Sturfelt G, Bernatsky S, Systemic Lupus International Collaborating Clinics, SLICC. Breast cancer in SLE. *Oncology* 85:117-121, 2013.
314. Parker B, Urowitz MB, Gladman DD, Lunt M, Bae SC, Sanchez-Guerrero J, Romero-Diaz J, Gordon C, Wallace DJ, Clarke AE, Bernatsky S, Ginzler E, Isenberg D, Rahman A, Merrill JT, Alarcón GS, Fessler BJ, Fortin PR, Hanly JG, **Petri M**, Steinsson K, Dooley MA, Manzi S, Khamashta M, Ramsey-Goldman R, Zoma AA, Sturfelt G, Nived O, Aranow C, Mackay M, Ramos-Casals M, Van Vollenhoven R, Kalunian K, Ruiz-Irastorza G, Lim S, Kamen DL, Peschken CA, Inanc M, Bruce IN. Clinical associations of the metabolic syndrome in systemic lupus erythematosus: Data from an international inception cohort. *Ann Rheum Dis* 72:1308-14, 2013.
315. Caster DJ, Korte EA, Nanda SK, McLeish KR, Oliver RK, G'Sell RT, Sheehan RM, Freeman DW, Coventry SC, Kelly JA, Guthridge JM, James JA, Sivils KL, Alarcon-Riquelme ME, Scofield RH, Adrianto I, Gaffney PM, Stevens AM, Freedman BI, Langefeld CD, Tsao BP, Pons-Estel BA, Jacob CO, Kamen DL, Gilkeson GS, Brown EE, Alarcon GS, Edberg JC, Kimberly RP, Martin J, Merrill JT, Harley JB, Kaufman KM, Reveille JD, Anaya J-M, Criswell LA, Vila LM, **Petri M**, Ramsey-Goldman R, Bae S-C, Boackle SA, Vyse TJ, Niewold TB, Cohen P, Powell DW. ABIN1 dysfunction as a genetic basis for lupus nephritis. *J Am Soc Nephrol* 24:1743-54, 2013 [Epub 2013 August 22; doi: 10.1681/ASN.2013020148]
316. Kiani AN, Fang H, Magder LS, **Petri M**. Vitamin D deficiency does not predict progression of coronary artery calcium, carotid intima media thickness or high-sensitivity C-reactive protein in systemic lupus erythematosus. *Rheumatology* 2013;52:2071-2076, August 2013 [Epub August 16, 2013; doi:10.1093/rheumatology/ket271].
317. Bello KJ, Fang H, Fazeli P, Bolad W, Corretti M, Magder LS, **Petri M**, et al. Omega-3 in SLE: A double-blind, placebo-controlled randomized clinical trial of endothelial dysfunction and disease activity in systemic lupus erythematosus. *Rheumatol Int* 33:2789-96, 2013. [July 2, 2013 Epub ahead of print].
318. **Petri M**, Kawata A, Fernandes A, Gajria K, Greth W, Hareendran A, Ethgen D. Impaired health status and the effect of pain and fatigue on functioning in clinical trial patients with systemic lupus erythematosus. *J Rheumatol* 40:1865-74,2013.
319. Sakurai D, Zhao J, Deng Y, Kelly JA, Brown EE, Harley JB, Bae S-C, Alarcón-Riquelme ME on behalf of the BIOLUPUS and GENLES networks, Edberg JC, Kimberly RP, Ramsey-Goldman R, **Petri MA**, Reveille JD, Vilá LM, Alarcón GS, Kaufman KM, Vyse TJ, Jacob CO, Gaffney PM, Sivils KM, James JA, Kamen DL, Gilkeson GS, Niewold TB, Merrill JT, Scofield RH, Criswell LA, Stevens AM, Boackle SA, Kim J-H, Choi J, Pons-Estel BA on behalf of the Argentine Collaborative Group, Freedman BI, Anaya J-M, Martin J, Yu CY, Chang D-M, Song YW, Langefeld CD, Chen W, Grossman JM, Cantor RM, Hahn BH, Tsao BP. Preferential binding to Elk-1 by SLE-associated IL10 risk allele upregulates IL10 expression. *PLoS Genet.* 9:e1003870, 2013. [doi: 10.1371/journal.pgen.1003870. Epub 2013 Oct 10].

320. Tessier Cloutier B, Clarke AE, Ramsey-Goldman R, Wang Y, Foulkes W, Gordon C, Hansen JE, Yelin E, Urowitz MB, Gladman D, Fortin PR, Wallace DJ, **Petri M**, Manzi S, Ginzler EM, Labrecque J, Edworthy S, Dooley MA, Sénécal JL, Peschken CA, Bae SC, Isenberg D, Rahman A, Ruiz-Irastorza G, Hanly JG, Jacobsen S, Nived O, Witte T, Criswell LA, Barr SG, Dreyer L, Sturfelt G, Bernatsky S.. Non-lymphoma hematological malignancies in systemic lupus erythematosus. *Oncology* 85:235-240, 2013.
321. Namjou B, Kim-Howard X, Sun C, Adler A, Chung SA, Kaufman KM, Kelly JA, Glenn SB, Guthridge JM, Scofield RH, Kimberly RP, Brown EE, Alarcón GS, Edberg JC, Kim JH, Choi J, Ramsey-Goldman R, **Petri MA**, Reveille JD, Vilá LM, Boackle SA, Freedman BI, Tsao BP, Langefeld CD, Vyse TJ, Jacob CO, Pons-Estel B; Argentine Collaborative Group, Niewold TB, Moser Sivils KL, Merrill JT, Anaya JM, Gilkeson GS, Gaffney PM, Bae SC, Alarcón-Riquelme ME; BIOLUPUS and GENLES Networks, Harley JB, Criswell LA, James JA, Nath SK. PTPN22 association in systemic lupus erythematosus (SLE) with respect to individual ancestry and clinical sub-phenotypes. *PLoS One*. 8(8):e69404, 2013. [doi: 10.1371/journal.pone.0069404. eCollection 2013]
322. Hanley J, Urowitz MB, O’Keeffe AG, Gordon C, Bae S-C, Sanchez-Guerrero J, Romero-Diaz J, Clarke AE, Bernatsky S, Wallace DJ, Ginzler EM, Isenberg DA, Rahman A, merrill JT, **Petri M**, Fortin PR, Gladman DD, Fessler BJ, Alarcón GS, Bruce IN, Dooley MA, Steinsson K, Khamashta MA, Ramsey-Goldman R, Manzi S, Sturfelt GK, Nived O, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Aranow C, Mackay M, Ruiz-Irastorza G, Kalunian KC, Lim SS, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Theriault C, Thompson K, Farewell V. Headache in systemic lupus erythematosus results from a prospective, international, inception cohort study. *Arthritis Rheum* 65:2887-97, 2013.
323. Murthy V, Willis R, Romay-Penabad Z, Ruiz-Limón P, Martinez-Martinez LA, Jatwani S, Jajoria P, Seif A, Alarcón GS, Papalardo E, liu J, Vilá LM, McGwin Jr G, McNearney TA, Maganti R, Sunkureddi P, Parekh T, Tarantino M, Akhter E, Fang H, Gonzalez EB, Binder WR, Norman GL, Shums Z, Teodorescu M, Reveille JD, **Petri M**, Pierangeli SS. Value of isolated IgA anti- β -glycoprotein I positivity in the diagnosis of the antiphospholipid syndrome. *Arthritis Rheum* 65:3186-3193, 2013.
324. Chung CP, Giles JT, Kronmal R, Post WS, Gelber AC, **Petri M**, Szklo M, Detrano R, Budoff MJ, Blumenthal RS, Ouyang P, Bush D, Bathon JM. Progression of coronary artery atherosclerosis in rheumatoid arthritis: comparison with participants from the multiethnic study of atherosclerosis (MESA). *Arthritis Res Therapy* 15:R134, 2013.
325. Stojan G, Magder LS, **Petri M**. Atherosclerosis in systemic lupus erythematosus. *J Cardiovasc Pharm* 62:255-262, 2013.
326. Li X, Wu J, Ptacek T, Redden DT, Brown EE, Alarcón GS, Ramsey-Goldman R, **Petri MA**, Reveille JD, Kaslow RA, Kimberly RP, Edberg JC. Allelic-dependent expression of an activating Fc receptor on B cells enhances humoral immune responses. *Science Translational Medicine* 5(216):216ra175, 2013.
327. Ramos PS, Oates JC, Kamen DL, Williams AH, Gaffney PM, Kelly JA, Kaufman KM, Kimberly RP, Niewold TB, Jacob CO, Tsao BP, Alarcón GS, Brown EE, Edberg JC, **Petri MA**, Ramsey-Goldman R, Reveille JD, Vilá LM, James JA, Guthridge JM, Merrill JT, Boackle SA, Freedman BI, Scofield RH, Stevens AM, Vyse TJ, Criswell LA, Moser KL, Alarcón-Riquelme ME, Langefeld CD, Harley JB, Gilkeson GS.. Variable association of reactive intermediate genes with systemic lupus erythematosus in populations with different African ancestry. *J Rheumatol* 40:842-849, 2013.
328. Smith LW, Gelber AC, **Petri M**. Diffuse lymphadenopathy as the presenting manifestation of systemic lupus erythematosus. *J Clin Rheumatol* 19:397-399, 2013.
329. Kaufman KM, Kelly JA, Hughes T, Adler A, Sanchez E, Ojwang JO, Langefeld CD, Ziegler JT, Williams AH, Comeau ME, Marion MC, Glenn SB, James JA, Guthridge J, Kimberly RP, Edberg JC, Ramsey-Goldman R, **Petri M**, Reveille JD, Brown EE, Vilá LM, Anaya J-M, Boackle SA, Stevens AM, Freedman BI, Criswell LA, Jacob CO, Scofield RH, Gilkeson GS, Moser KL, Gaffney PM, Merrill JT, Niewold TB, Vyse TJ, Bae S-C, Alarcón-Riquelme ME, on behalf of the BIOLUPUS network, Harley JB, Sawalha AH, Tsao BP. Fine mapping of Xq28: Both MECP2 and IRAK1 contribute to risk for systemic lupus erythematosus in multiple ancestral groups. *Ann Rheum Dis*. 72:437-44, 2013. [doi: 10.1136/annrheumdis-2012-201851. Epub 2012 Aug 17].

330. Molineros JE, Maiti AK, Sun C, Looger LL, Han S, Kim Howard X, Glenn S, Adler A, Kelly JA, Niewold TB, Gilkeson GS, Brown EE, Alarcón GS, Edberg JC, **Petri M**, Ramsey-Goldman R, Reveille JD, Vilá LM, Freedman BI, Tsao BP, Criswell LA, Jacob CO, Moore JH, Vyse TJ, Langefeld CL, Guthridge JM, Gaffney PM, Moser KL, Scofield RH, Alarcón-Riquelme ME, on behalf of the BIOLUPUS Network, Williams SM, Merrill JT, James JA, Kaufman KM, Kimberly RP, Harley JB, Nath SK. Admixture mapping in lupus identifies multiple functional variants within IFIH1 associated with apoptosis, inflammation and autoantibody production. *PLoS Genet.* 9:e1003222. [doi: 10.1371/journal.pgen.1003222. Epub 2013 Feb 18].
331. Deng Y, Zhao J, Sakuai D, Kaufman KM, Edberg JC, Kimberly RP, Kamen DL, Gilkeson GS, Jacob CO, Scofield RH, Langefeld CD, Kelly JA, Ramsey-Goldman R, **Petri M**, Reveille JD, Vilá LM, Vyse TJ, Pons-Estel BA on behalf of the Argentine Collaborative Group, Freedman BL, Gaffney PM, Sivils KM, James JA, Gregersen PK, Anaya J-M, Niewold TB, Merrill JT, Criswell LA, Stevens AM, Boackle SA, Cantor RM, Chen W, Grossman JM, Hahn BH, Harley JB, Alarcón-Riquelme ME, on behalf of the BIOLUPUS and GENLES networks, Brown EE, on behalf of PROFILE and Tsao BP. MicroRNA-3148 Modulates Allelic Expression of Toll-Like Receptor 7 Variant Associated With Systemic Lupus Erythematosus. *PLoS Genet.* 9:e1003336, 2013. [doi: 10.1371/journal.pgen.1003336. Epub 2013 Feb 28].
332. López De Padilla CM, Hein MS, Crowson CS, Choo CS, Green AB, **Petri M**, Bilgic H, Baechler EC, Reed AM. Increased expression of ADAMTS13 mRNA correlates with ischemic cerebrovascular disease in systemic lupus erythematosus patients. *SAGE Open Med.* 2013 Nov 29;1:2050312113514404. [doi: 10.1177/2050312113514404. eCollection 2013].
333. Bernatsky S, Ramsey-Goldman R, Joseph L, Boivin J-F, Costenbader KH, Urowitz MB, Gladman D, Fortin PR, Nived O, **Petri M**, Jacobsen S, Manzi S, Ginzler EM, Eisenberg D, Rahman A, Gordon C, Ruiz-Irastorza G, Yelin E, Bae S-C, Wallace DJ, Peschken CA, Dooley MA, Edworthy SM, Aranow C, Kamen DL, Romero-Diaz J, Askanase A, Witte T, Barr SG, Criswell LA, Sturfelt G, Blanco I, Feldman CH, Dreyer L, Patel NM, St Pierre Y, Clarke AE. Lymphoma risk in systemic lupus erythematosus: effects of disease activity versus treatment. *Ann Rheum Dis* 73:138-142, 2014.
334. Pons-Estel GJ, Wojdyla D, McGwin Jr G, Magder LS, **Petri MA**, Pons-Estel BA, on behalf of the Grupo Latino Americano De Estudio del Lupus (GLADEL) and Alarcon GS on behalf of the LUMINA cohort. The American College of Rheumatology and the Systemic Lupus International Collaborating Clinics Classification Criteria for systemic lupus erythematosus in two multiethnic cohorts: a commentary. *Lupus* 23:3-9, 2014.
335. Oomatia A, Fang H, **Petri M**, Birnbaum J. Peripheral neuropathy in systemic lupus erythematosus. *Arthritis Rheum* 66:1000-1009, 2014.
336. Ginzler EM, Wallace DJ, Merrill JT, Furie RA, Stohl W, Chatham WW, Weinstein A, McKay JD, McCune WJ, Zhong ZJ, Freimuth WW, **Petri MA**, On behalf of the LBSI02/99 Study Group. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. *J Rheumatol* 41:300-309, 2014. [Epub ahead of print 2013 November 1; doi: 10.3899/jrheum.121368].
337. Freedman B, Langefeld CD, Andringa KK, Croker JA, Williams AH, Garner NE, Birmingham DJ, Hebert LA, Hicks PJ, Segal MS, Edberg JC, Brown EE, Costenbader KH, Comeau ME, Criswell LA, Harley JB, James JA, Kamen DL, Lim SS, Merrill JT, Sivils KM, Niewold TB, Patel NM, Petri M, Ramsey-Goldman R, Reveille JD, Salmon JE, Tsao BP, Gibson KL, Byers JR, Vinnikova AK, Lea JP, Julian BA, Kimberly RP, on behalf of the Lupus Nephritis-End-Stage Renal Disease Consortium. End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. *Arthritis Rheum* 66:390-396, 2014.
338. Furie RA, Leon G, Thomas M, **Petri MA**, Chu AD, Hislop C, Martin RS, Scheinberg MA, for the PEARL-SC Study. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. *Ann Rheum Dis* 74:1667-1675, 2015 [epub April 19, 2014] doi:10.1136/annrheumdis-2013-205144.
339. Strand V, Levy RA, Cervera R, **Petri MA**, Birch H, Freimuth WW, Zhong ZJ, Clarke AE, for the BLISS-52 and -76. Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials. *Ann Rheum Dis.* 73:838-844, 2014.
340. Shi L, Zhang Z, Yu A, Wang W, Wei Z, Akhter E, Maurer K, Costa-Reis P, Song L, **Petri M**, Sullivan K. The SLE transcriptome exhibits evidence of chronic endotoxin exposure and has widespread dysregulation of non-coding and coding RNAs. *PLOS One* 9:e93846, 2014. doi:10.1371/journal.pone.0093846.

341. Dong C, Ptacek TS, Redden DT, Zhang K, Brown EE, Edberg JC, McGwin Jr G, Alarcón GS, Ramsey-Goldman R, Reveille JD, Vilá LM, **Petri M**, Qin A, Wu J, Kimberly R. Fcγ Receptor IIIa Single-Nucleotide Polymorphisms and haplotypes affect human IgG binding and are associated with lupus nephritis in African Americans. *Arthritis Rheum* 66:1291-9, 2014.
342. Urowitz MB, Gladman DD, Ibañez D, Sanchez-Guerrero J, Romero-Diaz J, Gordon C, Bae SC, Clarke AE, Bernatsky S, Fortin PR, Hanly JG, Isenberg D, Rahman A, Wallace DJ, Ginzler E, **Petri M**, Bruce IN, Merrill JT, Nived O, Sturfelt G, Dooley MA, Alarcón GS, Fessler B, Steinsson K, Ramsey-Goldman R, Zoma A, Khamashta M, Manzi S, van Vollenhoven R, Ramos-Casals M, Aranow C, Stoll T. American College of Rheumatology Criteria at inception, and accrual over 5 Years in the SLICC inception cohort. *J Rheumatol*. 41(5):875-80, 2014.
343. Chung SA, Brown EE, Williams AH, Ramos PS, Berthier CC, Bhangale T, Alarcon-Riquelme M, Behrens TW, Criswell LA, Graham DC, Demirci FY, Edberg JC, Gaffney PM, Harley JB, Jacob CO, Kamboh MI, Kelly JA, Manzi S, Moser-Sivils KL, Russell LP, **Petri M**, Tsao BP, Vyse TJ, Zidovetzki R, Kretzler M, Kimberly RP, Freedman BI, Graham RR, Langefeld CD, for the International Consortium for Systemic Lupus Erythematosus Genetics (SLEGEN). Lupus nephritis susceptibility loci in women with systemic lupus erythematosus. *JASN*, 2014 [epub June 12, 2014; doi: 10.1681/ASN.2013050446].
344. Fangtham M, Magder LS, **Petri MA**. Oral candidiasis in systemic lupus erythematosus. *Lupus* 23:684-690, 2014.
345. Lertratanakul A, Wu P, Dyer A, Urowitz M, Gladman D, Fortin P, Bae SC, Gordon C, Clarke A, Bernatsky S, Hanly JG, Isenberg D, Rahman A, Merrill J, Wallace DJ, Ginzler E, Khamashta M, Bruce I, Nived O, Sturfelt G, Steinsson K, Manzi S, Dooley MA, Kalunian K, **Petri M**, Aranow C, Font J, van Vollenhoven R, Stoll T, Ramsey-Goldman R. 25-hydroxyvitamin D and cardiovascular disease in patients with systemic lupus erythematosus: data from a large international inception cohort. *Arthritis Care Res* 66:1167-1176, 2014.
346. Orbai AM, Truedsson L, Sturfelt G, Nived O, Fang H, Alarcon GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg DA, Wallace DJ, Ramsey-Goldman R, Bae S-C, Hanly JG, Sanchez-Guerrero J, Clarke AE, Aranow CB, Manzi S, Urowitz MB, Gladman DD, Kalunian KC, Costner MI, Werth VP, Zoma A, Bernatsky S, Ruiz-Irastorza G, Khamashta MA, Jacobsen S, Buyon JP, Maddison P, Dooley MA, Van Vollenhoven RF, Ginzler E, Stoll T, Peschken C, Jorizzo JL, Callen JP, Lim SS, Fessler BJ, Inanc M, Kamen DL, Rahman A, Steinsson K, Franks AG Jr, Sigler L, Hameed S, Pham N, Brey R, Weisman MH, McGwin G Jr, Magder LS, **Petri M**. Anti-C1q antibodies in systemic lupus erythematosus. *Lupus* 24:42-49, 2015 [epub August 14, 2014, doi: 10.1177/0961203314547791].
347. Huang X, Magder LS, **Petri M**. Predictors of incident depression in systemic lupus erythematosus. *J Rheumatol* 41:1823-1833, 2014. [epub August 15, 2014, doi:10.3899/jrheum.140111]
348. **Petri M**, Bechtel B, Dennis G, Shah M, McLaughlin T, Kan H, Molta C. Burden of corticosteroid use in patients with systemic lupus erythematosus: results from a Delphi panel. *Lupus* 23:1006-1013, 2014.
349. Urowitz M., Gladman DD, Ibañez D, Bae SC, Gordon C, Fortin PR, Clarke A, Bernatsky S, Hanly JG, Wallace D, Isenberg D, Rahman A, Merrill J, Ginzler E, Alarcon G, Fessler B, Khamashta M, Steinsson K, **Petri M**, Dooley M, Bruce I, Manzi S, Sturfelt G, Nived O, Ramsey-Goldman R, Zoma A, Maddison P, Kalunian K, van Vollenhoven R, Aranow C, Stoll T. Changes in Quality of Life in the first 5 years of disease in a multicentre cohort of patients with Systemic Lupus Erythematosus (SLE). *Arthritis Care Res* 66:1374-1379, 2014.
350. Bernatsky S, Ramsey-Goldman R, Boivin JF, Joseph L, **Petri M**, Zoma A, Manzi S, Urowitz MB, Gladman D, Fortin PR, Ginzler E, Yelin E, Bae SC, Wallace DJ, Edworthy S, Jacobsen S, Gordon C, Dooley MA, Peschken CA, Hanly JG, Alarcon GS, Nived O, Ruiz-Irastorza G, Isenberg D, Rahman A, Witte T, Aranow C, Kamen DL, Steinsson K, Askanase A, Barr S, Criswell LA, Sturfelt G, Patel NM, Senecal JL, Zimmer M, Pope JE, Ensworth S, El-Gabalawy H, McCarthy T, Dreyer L, Labrecque J, St Pierre Y, Sibley J, Clarke AE. Cancer risk factors in systemic lupus: multivariate regression analysis in 16,409 patients. *J Autoimmune Dis Rheumatol* 2:100-103, 2014. [DOI: <http://dx.doi.org/10.12970/2310-9874.2014.02.03.4>]
351. Alderaan K, Sekicki V, Magder LS, **Petri M**. Risk Factors for Cataracts in Systemic Lupus Erythematosus. *Rheumatol Intrntl* 35:701-708, 2015 [epub September 26, 2014, doi:10.1007/s00296-014-3129-5].
352. Giles JT, Danielides S, Szklo M, Post W, Blumenthal RS, **Petri M**, Schreiner PJ, Robert Detrano R, Bathon JM. Insulin Resistance in Rheumatoid Arthritis: Disease Associated Indicators and Associations with the Presence and Progressions of Subclinical Coronary and Carotid Atherosclerosis. *Arthritis Rheumatol* 67:626-636, 2015 [epub Dec 10. doi: 10.1002/art.38986].

353. Watson P, Brennan A, Birch H, Fang H, **Petri M**. An integrated extrapolation of long-term outcomes in systemic lupus erythematosus: analysis and simulation of the Hopkins Lupus Cohort. *Rheumatology*, 2014 [epub October 8, 2014, doi: 10.1093/rheumatology/keu375]
354. Beinkowska J, Allaire N, Thai A, Goyal J, Plavina T, Ranger A, Nirula A, Weaver M, Newman C, **Petri M**, Beckman E, Browning JL. Lymphotoxin-LIGHT pathway regulates the interferon signature in rheumatoid arthritis. *PLoS ONE* 9(11): e112545. doi:10.1371/journal.pone.0112545, 2014.
355. Bruce IN, O'Keefe AG, Farewell V, Hanly JG, Manzi S, Su L, Gladman DD, Bae SC, Sanchez-Guerrero J, Romero-Diaz J, Gordon C, Wallace DJ, Clarke AE, Bernatsky S, Ginzler EM, Isenberg DA, Rahman A, Merrill JT, Alarcón GS, Fessler BJ, Fortin PR, **Petri M**, Steinsson K, Dooley MA, Khamashta MA, Ramsey-Goldman R, Zoma AA, Sturfelt GK, Nived O, Aranow C, Mackay M, Ramos-Casals M, van Vollenhoven RF, Kalunian KC, Ruiz-Irastorza G, Lim S, Kamen DL, Peschken CA, Inanc M, Urowitz MB. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. *Ann Rheum Dis* 74:1706-1713, 2015. doi: 10.1136/annrheumdis-2013-205171. [Epub ahead of print May 16, 2014]
356. Guthridge JM, Lu R, Sun H, Sun C, Wiley GB, Dominguez N, Macwana SR, Lessard CJ, Kim-Howard X, Cobb BL, Kaufman KM, Kelly JA, Langfield CD, Adler AJ, Harley IT, Merrill JT, Gilkeson GS, Kamen DL, Niewold TB, Brown EE, Edberg JC, **Petri MA**, Ramsey-Goldman R, Reveille JD, Villa LM, Kimberly RP, Freedman BI, Stevens AM, Boackle SA, Criswell LA, Vyse TJ, Behrens TW, Jacob CO, Alarcón-Riquelme ME on behalf of the BIOLUPUS Network, Sivils KL, Bae S-C, Cho SK, Bang SY, Kim IL, Choi C-B, Shen N, Qian X, Tsao BP, Harley JB, Scofield RH, Webb CF, Wakeland EK, James JA, Nath SK, Graham RR, Gaffney PM. Two functional lupus associated BLK promoter variants control cell-type and developmental stage specific transcription. *Am J Human Genetics* 94(4):586-598, 2014.
357. Chen TK, Gelber AC, Witter FR, **Petri M**, Fine DM. Renal biopsy in the management of lupus nephritis during pregnancy. *Lupus* 24:147-154, 2015. [Epub ahead of print, Sep 23, 2014]
358. Zimmerman S, **Petri M**, Corona-Villalobos C, Kiani A. Myocardial T2 Mapping by Cardiovascular Magnetic Resonance reveals subclinical myocardial inflammation in patients with Systemic Lupus Erythematosus. *Int J Cardiovasc Imaging* 2014 Oct 29. [Epub ahead of print].
359. Dong C, Ptacek TS, Redden DT, Zhang K, Brown EE, Edberg JC, McGwin G Jr, Alarcón GS, Ramsey-Goldman R, Reveille JD, Vilá LM, **Petri M**, Qin A, Wu J, Kimberly RP. Fcγ receptor IIIa single-nucleotide polymorphisms and haplotypes affect human IgG binding and are associated with lupus nephritis in African Americans. *Arthritis Rheumatol.* 66:1291-1299, 2014.
360. Kaiser R, Tang LF, Taylor KE, Sterba K, Nititham J, Brown EE, Edberg JC, McGwin G, Alarcon GS, Ramsey-Goldman R, Reveille JD, Vila LM, **Petri M**, Kimberly RP, Rauch J, Miller E, Mesznick K, Kwok P-Y, Salmon JE, Criswell LA. A polymorphism in TLR2 is associated with arterial thrombosis in a multiethnic population of patients with systemic lupus erythematosus. *Arthritis Rheumatol.* 66:1882-1887, 2014.
361. Furie R, **Petri MA**, Strand V, Gladman DD, Zhong ZJ, Freimuth WW, the BLISS-52 and BLISS-76 Study Groups. Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials. *Lupus Sci Med.* 1:e000031, 2014. [doi: 10.1136/lupus-2014-000031].
362. Martins M, Williams AH, Comeau ME, Marion M, Ziegler JT, Freedman BI, Merrill JT, Glenn SB, Kelly JA, Sivils KM, James JA, Guthridge JM, Alarcon-Riquelme M, Bae SC, Kim JH, Kim D, Anaya JM, Childress SA, Criswell LA, Kimberly RP, Alarcon GS, Brown EE, Vila LM, **Petri M**, Ramsey-Goldman R, Niewold TB, Tsao BP, Gilkeson GS, Kamen DL, Jacob CO, Stevens AM, Gaffney PM, Harley JB, Langefeld CD, Fesl C. Genetic association of SLE with CD247 (CD3ζ) in a large-scale multiethnic study. *Genes Immun.* 16:142-50, 2015. [Epub January 8 2015. doi: 10.1038/gene.2014.73]
363. Bourre-Tessier J, Urowitz MB, Clarke AE, Bernatsky S, Krantz MJ, Huynh T, Joseph L, Belisle P, Bae S-C, Hanly JG, Wallace DJ, Gordon C, Isenberg D, Rahman A, Gladman DD, Fortin PR, Merrill JT, Romero-Diaz J, Sanchez-Guerrero J, Fessler B, Alarcón GS, Steinsson K, Bruce IN, Ginzler E, Dooley MA, Nived O, Sturfelt G, Kalunian K, Ramos-Casals M, **Petri M**, Zoma A, Pineau CA. Electrocardiographic findings in systemic lupus erythematosus: data from an international inception cohort. *Arthritis Care Res.* 67:128-135, 2015.
364. Al Sawah S, Zhang X, Zhu B, Magder L, Foster SA, Iikuni N, **Petri M**. Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus—the Hopkins Lupus Cohort. *Lupus Sci Med* 2:e000066 doi:10.1136/lupus-2014-000066, 2015.

365. Kiani AN, Fang H, Akhter E, Quiroga C, Simpson N, Alaupovic P, Magder LS, **Petri M**. Apolipoprotein-containing lipoprotein subclasses and subclinical atherosclerosis in systemic lupus erythematosus. *Arthritis Care Rheum* 67:442-446, 2015.
366. Zhang Z, Shi L, Ephrem E, **Petri M**, Sullivan KE. Interferon Regulatory Factor 1 marks activated genes and can induce target gene expression in systemic lupus erythematosus. *Arthritis Rheumatol* 67:785-796, 2015.
367. Leung YT, Shi L, Maurer K, Song L, Zhang Z, **Petri M**, Sullivan KE. Interferon regulatory factor 1 and Histone H4 acetylation in systemic lupus erythematosus. *Epigenetics* 10:191-199, 2015.
368. Arroyo-Ávila M, Santiago-Casas Y, McGwin Jr G, Cantor RS, Petri M, Ramsey-Goldman R, Reveille JD, Kimberly RP, Alarcón GS, Vilá LM, Brown EE. Clinical associations of anti-Smith antibodies in PROFILE: a multi-ethnic lupus cohort. *Clin Rheumatol*, 2015. [Epub ahead of print April 21, 2015; 10.1007/s10067-015-2941-y].
369. Vaughn SE, Foley C, Lu X, Patel ZH, Zoller EE, Magnusen AF, Williams AH, Ziegler JT, Comeau ME, Marion MC, Glenn SB, Adler A, Shen N, Nath S, Stevens AM, Freedman BI, Tsao BP, Jacob CO, Kamen DL, Brown EE, Gilkeson GS, Alarcón GS, Reveille JD, Anaya JM, James JA, Moser KL, Criswell LA, Vilá LM, Alarcón-Riquelme ME, Petri M, Scofield RH, Kimberly RP, Ramsey-Goldman R, Binjoo Y, Choi J, Bae SC, Boackle SA, Vyse TJ, Guthridge JM, Namjou B, Gaffney PM, Langefeld CD, Kaufman KM, Kelly JA, Harley IT, Harley JB, Kottyan LC. Lupus risk variants in the PXX1 locus alter B-cell receptor internalization. *Front Genet* 5:450, 2015. [doi: 10.3389/fgene.2014.00450. eCollection 2014]
370. Lu X, Zoller EE, Weirauch MT, Wu Z, Namjou B, Williams AH, Ziegler JT, Comeau ME, Marion MC, Glenn SB, Adler A, Shen N, Nath S, Stevens AM, Freedman BI, Tsao BP, Jacob CO, Kamen DL, Brown EE, Gilkeson GS, Alarcón GS, Reveille JD, Anaya J-M, James JA, Moser KL, Criswell LA, Vilá LM, Alarcón-Riquelme ME, **Petri M**, Scofield RH, Kimberly RP, Ramsey-Goldman R, Joo YB, Choi J, Bae S-C, Boackle SA, Vyse TJ, Guthridge JM, Gaffney PM, Langefeld CD, Kelly JA, Greis KD, Kaufman KM, Harley JB, Kottyan LC. Lupus risk-variant increases pSTAT1 binding and decreases ETS1 expression. *Am J Hum Genet*. 96(5):731-9, 2015. [Epub ahead of print April 9, 2015; doi: 10.1016/j.ajhg.2015.03.002].
371. Subedi A, Magder LS, **Petri M**. Effect of mycophenolate mofetil on the white blood cell count and the frequency of infection in systemic lupus erythematosus. *Rheumatol Int* 35:1687-92, 2015.
372. Bourre-Tessier J, Urowitz MB, Clarke AE, Bernatsky S, Krantz MJ, Huynh T, Joseph L, Belisle P, Bae S-C, Hanly JG, Wallace DJ, Gordon C, Isenberg D, Rahman A, Gladman DD, Fortin PR, Merrill JT, Romero-Diaz J, Sanchez-Guerrero J, Fessler B, Alarcon GS, Steinsson K, Bruce IN, Ginzler E, Dooley MA, Nived O, Sturfelt G, Kalunian K, Ramos-Casals M, **Petri M**, Zoma A, Pineau CA. Mood disorders in systemic lupus erythematosus: results from an international, inception cohort. *Arthritis Rheum* 67:1837-1847, 2015.
373. Parker B, Urowitz MB, Gladman DD, Lunt M, Donn R, Bae SC, Sanchez-Guerrero J, Romero-Diaz J, Gordon C, Wallace DJ, Clarke AE, Bernatsky S, Ginzler E, Isenberg D, Rahman A, Merrill JT, Alarcón GS, Fessler BJ, Fortin PR, Hanly JG, **Petri M**, Steinsson K, Dooley MA, Manzi S, Khamashta M, Ramsey-Goldman R, Zoma AA, Sturfelt G, Nived O, Aranow C, Mackay M, Ramos-Casals M, Van Vollenhoven R, Kalunian K, Ruiz-Irastorza G, Lim S, Kamen DL, Peschken CA, Inanc M, Bruce IN. Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. *Ann Rheum Dis* 74:1530-36, 2015.
374. Kiani AN, Magder LS, Post WS, Szklo M, Bathon JM, Schreiner PJ, O'Leary D, **Petri M**. Coronary calcification in SLE: comparison with the Multi-Ethnic Study of Atherosclerosis. *Rheumatology (Oxford)* 54:1976-81, 2015. [doi: 10.1093/rheumatology/kev198. Epub 2015 Jun 22]
375. Hanly JG, O'Keefe AG, Su L, Urowitz MB, Romero-Diaz J, Gordon C, Bae S-C, Bernatsky S, Clarke AE, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, Fortin P, Gladman DD, Sanchez-Guerrero J, **Petri M**, Bruce IN, Dooley MA, Ramsey-Goldman R, Aranow C, Alarcón GS, Fessler BJ, Steinsson K, Nived O, Sturfelt GK, Manzi S, Khamashta MA, van Vollenhoven RF, Zoma AA, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Stoll T, Inanc M, Kalunian KC, Kamen DL, Maddison P, Peschken CA, Jacobsen S, Askanase A, Buyon J, Theriault C, Thompson K, Farewell V. The frequency and outcome of lupus nephritis: results from an international, inception, cohort study. *Rheumatology* 2015. [Epub ahead of print September 5, 2015; doi:10.1093/rheumatology/kev311].
376. Costa-Reis P, Russo PA, Zhang Z, Colonna L, Maurer K, Gallucci S, Schulz SW, Kiani AN, **Petri M**, Sullivan KE. The role of microRNAs and human epidermal growth factor Receptor 2 in proliferative lupus nephritis. *Arthritis Rheumatol* 67:2415-2426, 2015.

377. Durcan L, Clarke WA, Magder LS, **Petri M**. Hydroxychloroquine blood levels in systemic lupus erythematosus: clarifying dosing controversies and improving adherence. *J Rheumatol* 42:2092-2097, 2015.
378. Hui-Yuen JS, Reddy A, Taylor J, Li X, Eichenfield AH, Bermudez LM, Starr AJ, Imundo LF, Buyon J, Furie RA, Kamen DL, Manzi S, **Petri M**, Ramsey-Goldman R, van Vollenhoven FR, Wallace DJ, Akanase A. Safety and efficacy of belimumab to treat systemic lupus erythematosus in academic clinical practices. *J Rheumatol* 42:2288-2295, 2015.
379. Shi L, Zhang Z, Song L, Leung YT, **Petri MA**, Sullivan KE. Monocyte enhancers are highly altered in systemic lupus erythematosus. *Epigenomics* 7:921-935, 2015.
380. Zollars E, Bienkowska J, Czerkowicz J, Allaire N, Ranger AM, Magder L, **Petri M**. BAFF (B-cell Activating Factor) transcript level in peripheral blood of SLE patients is associated with same day disease activity as well as global activity over the next year. *Lupus Sci Med*, Jun 18;2(1):e000063 [doi: 10.1136/lupus-2014-000063], 2015.
381. Thapa DR, Tonikian R, Sun C, Liu M, Dearth A, **Petri M**, Pepin F, Emerson RO, Ranger A. Longitudinal analysis of peripheral blood T cell receptor diversity in patients with systemic lupus erythematosus by next-generation sequencing. *Arthritis Res Therapy* 17:132, 2015.
382. Baer A, **Petri M**, Sohn J, Rosen A, Casciola-Rosen L. Association of antibodies to Interferon-Inducible Protein-16 with markers of more severe disease in Primary Sjögren's Syndrome. *Arthritis Care Res* 68:254-60, 2016 [Epub ahead of print June 2, 2015. doi: 10.1002/acr.22632].
383. Kottyan LC, Zoller EE, Lu X, Kelly JA, Rupert AM, Lessard CJ, Vaughn SE, Marion M, Weirauch MT, Namjou B, Adler A, Rasmussen A, Glenn S, Montgomery CG, Hirschfield GM, Zie G, Coltescu C, Amos C, Li H, Ice JA, Swapan KN, Mariette X, Bowman S for UK primary Sjogren's syndrome registry, Rischmueller M, Lester S, Brun JG, Goransson LG, Harboe E, Omdal R, Cunninghame-Graham DS, Vyse T, Miceli-Richard C, Brennan MT, Lessard JA, Wahren-Herlenius M, Kvarnstrom M, Illei GG, Witte T, Jonsson R, Eriksson P, Nordmark G, Ng W-F for UK primary Sjogren's syndrome registry, Anaya J-M, Rhodus NL, Segal BM, Merrill JT, James JA, Guthridge J, Scofield RH, Alarcón-Riquelme ME, Bae S-C, Boackle SA, Criswell LA, Gilkeson GS, Kamen DL, Jacob CO, Kimberly R, Brown E, Edberg JC, Alarcón GS, Reveille JD, Vila LM, **Petri M**, Ramsey-Goldman R, Freedman BI, Niewold T, Stevens AM, Tsao B, Ying J, Mayes MD, Gorlova OY, Wakeland W, Radstake T, Martin E, Martin J, Siminovitch K, Sivils KLM, Gaffney PM, Langefeld CD, Harley JB, Kaufman KM. The IRF5-TNPO3 association has two components in systemic lupus erythematosus (SLE) that other autoimmune disorders variably share. *Hum Mol Genet.* 24:582-96, 2015.
384. Fiorentino DF, Presby M, Baer AN, Christopher-Stine L, **Petri M**, Rieger KE, Soloski M, Rosen A, Mammen AL, Casciola-Rosen L. PUF60: a prominent new target of the autoimmune response in dermatomyositis and Sjögren's syndrome. *Ann Rheum Dis* Epub ahead of print August 7, 2015 [doi: 10.1136/annrheumdis-2015-207509].
385. Henault J, Riggs JM, Karnell JL, Liarsky VM, Shirinian LA, Casey KA, Smith MA, Li J, Izhak L, Clarke L, Ettinger C, Herbst R, **Petri M**, Clark MR, Mustelin T, Kolbeck R, Sanjuan MA. Self-reactive IgE exacerbates interferon responses associated with autoimmunity. *Nature Immunol* 17(2):196-203, 2015 [Epub ahead of print Dec 21 2015, doi: 10.1038/ni.3326].
386. **Petri M**, Daly RP, Pushparajah DS. Healthcare Costs of Pregnancy in Systemic Lupus Erythematosus: Retrospective Observational Analysis from a US Health Claims Database. *J Med Econ* 18:967-73, 2015. [Epub Aug 14, 2015, doi: 10.3111/13696998.2015.1066796].
387. Zhao J, Wu H, Langefeld CD, Kaufman KM, Kelly JA, Bae S-C, Alarcón-Riquelme ME for the BIOLUPUS and GENLES networks, Alarcón GS, Anaya J-M, Criswell LA, Freedman BI, Kamen DL, Gilkeson GS, Jacob CO, James JA, Merrill JT, Gaffney PM, Sivils KM, Niewold TB, **Petri MA**, Ramsey-Goldman R, Reveille JD, Scofield RH, Stevens AM, Boackle SA, Vilá LM, Chang D-M, Song YW, Vyse TJ, Harley JB, Brown EE, Edberg JC, Kimberly RP, Hahn BH, Grossman JM, Tsao BP, Cava AL. Genetic associations of leptin-related polymorphisms with systemic lupus erythematosus. *Clin Immunol* 161:157-162. [Epub Sep 16 2015, doi: 10.1016/j.clim.2015.09.007]
388. Mankee A, **Petri M**, Magder LS. Lupus anticoagulant, disease activity and low complement in the first trimester are predictive of pregnancy loss. *Lupus Sci Med.* 2:e000095, 2015. [doi: 10.1136/lupus-2015-000095]
389. Buyon JP, Kim MY, Guerra MM, Laskin CA, **Petri M**, Lockshin MD, Sammaritano L, Branch DW, Porter TF, Sawitzke A, Merrill JT, Stephenson MD, Cohn E, Garabet L, Salmon JE. Predictors of Pregnancy Outcomes in Patients With Lupus: A Cohort Study. *Ann Intern Med.* 163:153-63, 2015. [doi: 10.7326/M14-2235]

390. Deng Y, Zhao J, Sakurai D, Sestak AL, Osadchiy V, Langefeld CD, Kaufman KM, Kelly JA, Bae S-C, Alarcón-Riquelme ME for the BIOLUPUS and GENLES networks, Alarcón GS, Anaya J-M, Criswell LA, Freedman BI, Kamen DL, Gilkeson GS, Jacob CO, James JA, Merrill JT, Gaffney PM, Sivils KM, Niewold TB, **Petri MA**, Ramsey-Goldman R, Reveille JD, Scofield RH, Stevens AM, Boackle SA, Vilá LM, Chang D-M, Song YW, Vyse TJ, Harley JB, Brown EE, Edberg JC, Kimberly RP, Cantor RM, Hahn BH, Grossman JM, Tsao BP. Decreased SMG7 expression associates with lupus-risk variants and elevated antinuclear antibody production. *Ann Rheum Dis* 75:2007-2013. [Epub ahead of print January 18, 2016, 10.1136/annrheumdis-2015-208441].
391. Zhao J, Giles BM, Taylor RL, Yette GA, Lough KM, Ng HL, Abraham LJ, Wu H, Kelly JA, Glenn SB, Adler AJ, Williams AH, Comeau ME, Ziegler JT, Marion M, Alarcón-Riquelme ME; BIOLUPUS and GENLES Networks, Alarcón GS, Anaya JM, Bae SC, Kim D, Lee HS, Criswell LA, Freedman BI, Gilkeson GS, Guthridge JM, Jacob CO, James JA, Kamen DL, Merrill JT, Sivils KM, Niewold TB, **Petri MA**, Ramsey-Goldman R, Reveille JD, Scofield RH, Stevens AM, Vilá LM, Vyse TJ, Kaufman KM, Harley JB, Langefeld CD, Gaffney PM, Brown EE, Edberg JC, Kimberly RP, Ulgiati D, Tsao BP, Boackle SA. Preferential association of a functional variant in complement receptor 2 with antibodies to double-stranded DNA. *Ann Rheum Dis*. 75:242-52, 2016. [doi: 10.1136/annrheumdis-2014-205584. Epub 2014 Sep 1]
392. Isenberg DA, **Petri M**, Kalunian K, Tanaka Y, Urowitz MB, Hoffman RW, Morgan-Cox M, Iikuni N, Silk M, Wallace DJ. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. *Ann Rheum Dis* 75:323-331, 2016.
393. Putterman C, Wu A, Reiner-Benaim A, Batty Jr DS, Sanz I, Oates J, Jakobi K, **Petri M**, Safer P, Gerwien R, Sorek R, Blumenstein Y, Cohen IR. SLE-key[®] rule-out serologic test for excluding the diagnosis of systemic lupus erythematosus: developing the ImmunArray iCHIP[®]. *J Immunological Meth*. 429:1-6, 2016.
394. Kim MY, Buyon JP, Guerra MM, Rana S, Zhang D, Laskin CA, **Petri M**, Lockshin MD, Sammaritano LR, Branch DW, Porter TF, Merrill JT, Stephenson MD, Gao Q, Karumanchi SA, Salmon JE. Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. *Am J Obstet Gynecol*. 214:108, 2016. [e1-108.e14. doi: 10.1016/j.ajog.2015.09.066. Epub 2015 Sep 29.]
395. Yelnik CM, Laskin CA, Porter TF, Branch DW, Buyon JP, Guerra MM, Lockshin MD, **Petri M**, Merrill JT, Sammaritano LR, Kim MY, Salmon JE. Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results. *Lupus Sci Med*. 3:e000131, 2016. [doi: 10.1136/lupus-2015-000131]
396. Van Vollenhaven RF, **Petri M**, Wallace DJ, Roth D, Molta CT, Hammer AE, Tang Y, Thompson A. Cumulative corticosteroids over 52 weeks in patients with systemic lupus erythematosus: pooled analyses from the phase III belimumab trials. *Arthritis Rheum* 68:2184-2192, 2016 [Epub ahead of print March 18, 2016. DOI: 10.1002/art.39682].
397. Henault J, Riggs JM, Karnell JL, Liarsky VM, Shirinian LA, Xu L, Casey KA, Smith MA, Khattry DB, Izhak L, Clarke L, Herbst R, Ettinger C, **Petri M**, Clark MR, Mustelin T, Kolbeck R, Sanjuan MA. Self-reactive IgE exacerbates interferon responses associated with autoimmunity. *Nature Immunol* 17:196-203, 2016.
398. Huang XY, Magder LS, **Petri M**. Predictors of incident seizure in systemic lupus erythematosus. *J Rheumatol* 43:565-575, 2016.
399. Lloyd TE, Christopher-Stine L, Pinal-Fernandez I, Tiniakou E, **Petri M**, Baer A, Danoff SK, Pak K, Casciola-Rosen LA, Mammen AL. Cytosolic 5'-Nucleotidase 1A as a target of circulating autoantibodies in autoimmune diseases. *Arthritis Care Res* 68:66-71, 2016.
400. Durcan L, Winegar DA, Connelly MA, Otvos JD, Magder LS, **Petri M**. Longitudinal evaluation of lipoprotein variables in systemic lupus erythematosus reveals adverse changes with disease activity and prednisone and more favorable profiles with hydroxychloroquine therapy. *J Rheumatol* 43:745-750, 2016.
401. Wallace DJ, Hobbs K, Clowse M, **Petri MA**, Strand V, Pike M, Merrill JT, Leszczynski P, Neuwelt CM, Jeka S, Houssiau FA, Keiserman M, Ordi-Ros J, Bongardt S, Kilgallen B, Galateanu C, Kalunian K, Furie R Gordon C. Long-term safety and efficacy of epratuzumab in the treatment of moderate-to-severe systemic lupus erythematosus: results from an open-label extension study. *Arthritis Care Res* 68:534-543, 2016.
402. Willis R, Pierangeli SS, Jaskowski TD, Malmberg E, Guerra M, Salmon JE, **Petri M**, Branch DW, Tebo AE. Performance Characteristics of Commercial Immunoassays for the Detection of IgG and IgM Antibodies to b2 Glycoprotein I and an Initial Assessment of Newly Developed Reference Materials for Assay Calibration. *Am J Clin Pathol*, 2016. [Epub June 6, 2016; DOI: 10.1093/ajcp/aqw065]

403. **Petri MA**, Martin RS, Scheinberg MA, Furie RA. Assessments of fatigue and disease activity in patients with systemic lupus erythematosus enrolled in the phase 2 clinical trial with blisibimod. *Lupus* 26(1):27-37, 2017. [Epub June 26, 2016; doi:10.1177/0961203316654767]
404. Wolf BJ, Spainhour JC, Arthur JM, Janech MG, **Petri M**, Oates JC. Development of biomarker models to predict outcomes in lupus nephritis. *Arthritis Rheumatol* 68:1955-1963, 2016.
405. Hanly J, Su L, Urowitz MB, Romero-Díaz J, Gordon C, Bae S-C, Bernatsky S, Clarke A, Wallace D, Merrill JT, Isenberg D, Rahman A, Ginzler E, **Petri M**, Bruce I, Dooley MA, Fortin P, Gladman D, Sanchez-Guerrero J, Steinsson K, Ramsey-Goldman R, Khamashta M, Aranow C, Alarcón G, Fessler B, Manzi S, Nived O, Sturfelt G, Zoma A, van Vollenhoven R, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Kalunian K, Inanc M, Kamen D, Peschken C, Jacobsen S, Askenase A, Theriault C, Farewell V. A longitudinal analysis of outcomes of lupus nephritis in an international inception cohort using a multistate model approach. *Arthritis Rheumatol* 68:1932-1944, 2016.
406. Yelnik CM, Porter TF, Branch DW, Laskin CA, Merrill JT, Guerra MM, Lockshin MD, Buyon JP, **Petri M**, Sammaritano LR, Stephenson MD, Kim MY, Salmon JE. Changes in antiphospholipid antibody titers during pregnancy: effects on pregnancy outcomes. *Arthritis Rheumatol* 68:1964-1969, 2016.
407. Zollars E, Courtney S, Wolf B, Allaire N, Ranger A, Hardiman G, **Petri M**. Clinical application of a modular genomics technique in systemic lupus erythematosus. *Progress towards precision medicine. Int J Genomics*, 2016. [Epub August 31, 2016, doi:10.1155/2016/7862962].
408. Domingues V, Madger L, **Petri M**. Assessment of the independent associations of IgG, IgM, and IgA isotypes of anticardiolipin with thrombosis in SLE. *Lupus Sci Med* 3:1 e00010, 2016. [Epub 2016 June 20, doi:10.1136/lupus-2015-000107].
409. Wallace DJ, Strand V, Merrill JT, Popa S, Spindler AJ, Eimon A, **Petri M**, Smolen JS, Wajdula J, Christensen J, Li C, Diehl A, Vincent M, Beebe J, Healey P, Sridharan S. Efficacy and safety of an interleukin-6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial. *Ann Rheum Dis* 76:534-542, 2017. [Epub September 26, 2016 doi: 10.1136/annrheumdis-2016-209668]
410. Gladstone DE, **Petri M**, Bolanos-Meade J, Dezern AE, Jones RJ, Fine D, Brodsky RA. Long-term systemic lupus erythematosus disease control after allogeneic bone marrow transplantation. *Lupus* 26:773-776, 2017. [Epub September 30, 2016 doi: 10.1177/0961203316669242] 1
411. Wilhelm TR, Magder LS, **Petri M**. Remission in systemic lupus erythematosus – durable remission is rare. *Ann Rheum Dis* 76:547-553, 2017. [Epub August 24, 2016, doi:10.1136/annrheumdis-2016-209489]
412. Clowse ME, Wallace DJ, Furie RA, **Petri MA**, Pike MC, Leszczyński P, Neuwelt CM, Hobbs K, Keiserman M, Duca L, Kalunian KC, Galateanu C, Bongardt S, Stach C, Beaudot C, Kilgallen B, Gordon C; EMBODY Investigator Group. Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results from the Phase 3, Randomized, Double-blind, Placebo-controlled Trials, EMBODY™ 1 and EMBODY™ 2. *Arthritis Rheumatol*, 2016. [Epub September 6 2016. doi: 10.1002/art.39856]
413. Stearns NA, Zhou S, **Petri M**, Binder SR, Pisetsky DS. The use of Poly-L-Lysine as a capture agent to enhance the detection of antinuclear antibodies by ELISA. *PLOS ONE*, 2016. [Epub September 9, 2016, doi:10.1371/journal.pone.0161818]
414. Zhang Z, Shi L, Dawany N, Kelsen J, **Petri MA**, Sullivan KE. H3K4 tri-methylation breadth at transcription start sites impacts the transcriptome of systemic lupus erythematosus. *Clin Epigenetics*. 8:14, 2016. [doi: 10.1186/s13148-016-0179-4]
415. Urowitz MB, Gladman DD, Anderson NM, Su J, Romero-Diaz J, Bae SC, Fortin PR, Sanchez-Guerrero J, Clarke A, Bernatsky S, Gordon C, Hanly JG, Wallace DJ, Isenberg D, Rahman A, Merrill J, Ginzler E, Alarcón GS, Fessler BF, **Petri M**, Bruce IN, Khamashta M, Aranow C, Dooley M, Manzi S, Ramsey-Goldman R, Sturfelt G, Nived O, Steinsson K, Zoma A, Ruiz-Irastorza G, Lim S, Kalunian KC, Inanc M, van Vollenhoven R, Ramos-Casals M, Kamen DL, Jacobsen S, Peschken C, Askanase A, Stoll T. Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the Systemic Lupus Erythematosus International Collaborating Clinics cohort. *Lupus Sci Med* 3:e000143, 2016. [doi: 10.1136/lupus-2015-000143]
416. Lloyd TE, Christopher-Stine L, Pinal-Fernandez I, Tiniakou E., **Petri M**, Baer A, Danoff S, Pak K, Casciola-Rosen L, Mammen AL. Cytosolic 5'-Nucleotidase 1A As a Target of Circulating Autoantibodies in Autoimmune Diseases. *Arthritis Care Res*. 68:66-71, 2016. [doi: 10.1002/acr.22600]
417. Wu T, Ding HH, Han J, Arriens C, Wei C, Han W, Pedroza C, Jiang S, Anolik J, **Petri M**, Sanz I, Saxena R, Mohan C. Antibody array based proteomic screening of serum markers in systemic lupus erythematosus: a discovery study. *J Proteome Res*.15:2102-2114, 2016. [doi: 10.1021/acs.jproteome.5b00905]

418. Lee J-R, Haddon DJ, Wand HE, Price JV, Diep VK, Hall DA, **Petri M**, Baechler EC, Balboni IM, Utz PJ, Wang SX. Multiplex giant magnetoresistive biosensor microarrays identify interferon-associated autoantibodies in systemic lupus erythematosus. *Sci Rep* 6:27623, 2016. [doi: 10.1038/srep27623]
419. Wang G, Pierangeli SS, Willis R, Gonzalez EB, **Petri M**, Khan MF. Significance of lipid-derived reactive aldehyde-specific immune complexes in Systemic Lupus Erythematosus. *PLOS ONE*, 2016. [Epub October 17, 2016, doi:10.1371/journal.pone.0164739]
420. Bernatsky S, Ramsey-Goldman R, **Petri M**, Urowitz MB, Gladman DD, Fortin PF, Ginzler E, Romero-Diaz J, Peschken C, Jacobsen S, Hanly JG, Gordon C, Nived O, Yelin EH, Isenberg D, Rahman A, Bae S-C, Joseph L, Witte T, Ruiz-Irastorza G, Aranow C, Kamen D, Sturfeldt G, Foulkes WD, Hansen JE, St. Pierre Y, Raymer PC, Tessier-Cloutier B, Clarke AE. Breast cancer in systemic lupus. *Lupus* 26:311–315, 2017. [Epub September 29 2016. pii: 0961203316664595]
421. Hoffman RW, Merrill JT, Alarcón-Riquelme MM, **Petri M**, Dow ER, Nantz E, Nisenbaum LK, Schroeder KM, Komocsar WJ, Perumal NB, Linnik MD, Airey DC, Liu Y, Rocha GV, Higgs RE. Gene Expression and Pharmacodynamic-Induced Changes in 1,760 SLE Patients from Two Phase III Trials of B Cell Activating Factor Blockade with Tabalumab. *Arthritis Rheumatol* 69:643-654, 2017. [Epub October 9 2016. doi: 10.1002/art.39950]
422. Zuo Y, Willis R, Papalardo E, **Petri M**, Harris EN, Schleh A, De Ceulaer K, Smikle M, Vila LM, Reveille JD, Alarcon GS, Gonzalez EB. A unique antiphospholipid assay recognizing phospholipid mixture compared to criteria antiphospholipid immunoassays in lupus patients. *Lupus* 26:606-615, 2017. [Epub October 16 2016. pii: 0961203316671812].
423. Eudy A, Siega-Riz AM, Engel SM, Franceschini N, Howard AG, Clowse M, **Petri M**. Gestational weight gain in women with systemic lupus erythematosus. *Lupus* 26:623-632, 2017. [Epub October 4 2016. pii: 0961203316671811].
424. Khan A, Arbab-Zadeh A, Kiani AN, Magder LS, **Petri M**. Progression of noncalcified and calcified coronary plaque by CT angiography in SLE. *Rheumatol Int* 37:59-65, 2017. [Epub November 23, 2016. doi: 10.1007/s00296-016-3615-z]
425. van Vollenhoven R, Voskuyl A, Bertsias G, Aranow C, Aringer M, Arnaud L, Askanase A, Balázová P, Bonfa E, Bootsma H, Boumpas D, Bruce I, Cervera R, Clarke A, Coney C, Costedoat-Chalumeau N, Czirják L, Derksen R, Doria A, Dörner T, Fischer-Betz R, Fritsch-Stork R, Gordon C, Graninger W, Györi N, Houssiau F, Isenberg D, Jacobsen S, Jayne D, Kuhn A, Le Guern V, Lerstrøm K, Levy R, Machado-Ribeiro F, Mariette X, Missaykeh J, Morand E, Mosca M, Inanc M, Navarra S, Neumann I, Olesinska M, **Petri M**, Rahman A, Rekvig OP, Rovensky J, Shoenfeld Y, Smolen J, Tincani A, Urowitz M, van Leeuw B, Vasconcelos C, Voss A, Werth VP, Zakharova H, Zoma A, Schneider M, Ward M. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). *Ann Rheum Dis* 76:554-561, 2017 [Epub November 24 2016. pii: annrheumdis-2016-209519. doi: 10.1136/annrheumdis-2016-209519]
426. Lee JR, Haddon DJ, Gupta N, Price JV, Credo GM, Diep VK, Kim K, Hall DA, Baechler EC, **Petri M**, Varma M, Utz PJ, Wang SX. High-Resolution Analysis of Antibodies to Post-Translational Modifications Using Peptide Nanosensor Microarrays. *ACS Nano* 10:10652-10660, 2016.
427. Wang Y, Cohghlin J, Ma S, Endres CJ, **Petri M**, Pomper MG. Neuroimaging of translocator protein in patients with systemic lupus erythematosus: a pilot study using [¹¹C]DPA-713 positron emission tomography. *Lupus*, 2016. [Epub July 6 2016. pii: 0961203316657432]
428. Kiani AN, Aukrust P, Ueland T, Hollan I, Barr E, Magder LS, **Petri M**. Serum osteoprotegerin (OPG) in subclinical atherosclerosis in systemic lupus erythematosus. *Lupus* 26:865-870, 2017. [Epub 2016 Dec 6. pii: 0961203316682101]
429. Tebo AE, Jaskowski TD, Willis R, Branch DW, **Petri M**. Persistence of IgA antibodies to Beta2 Glycoprotein I in patients with systemic lupus erythematosus. *Clin Chim Acta* 460:107-113, 2016. [doi: 10.1016/j.cca.2016.06.025]
430. Choi M, Clarke A, St. Pierre Y, Hanly J, Urowitz MB, Romero-Díaz J, Gordon C, Bae S-C, Bernatsky S, Wallace D, Merrill JT, Buyon J, Isenberg D, Rahman A, Ginzler EM, **Petri M**, Bruce IN, Dooley MA, Fortin P, Gladman D, Steinsson K, Ramsey-Goldman R, Khamashta M, Aranow C, Alarcón G, Manzi S, Nived O, Zoma A, van Vollenhoven R, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Kalunian K, Inanc M, Kamen D, Peschken C, Jacobsen S, Askanase A, Sanchez-Guerrero J, Mahler M, Fritzler MJ. The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients. *Lupus*, 2017 [Epub Jan 1, 2017, doi 10.1177/0961203317692437].

431. Clowse M, Wallace DJ, Furie R, **Petri MA**, Pike M, Leszczynski P, Neuwelt CM, Hobbs K, Keiserman M, Duca L, Kalunian K, Galateanu C, Bongardt S, Stach C, Beaudot C, Kilgallen B, Gordon C on behalf of the EMBODY Investigator Group. Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: Results from two phase III randomized, double-blind placebo-controlled trials. *Arthritis Rheumatol* 69:362-375, 2017.
432. Wei R, Gao B, Shih F, Ranger A, Dearth A, Mischak H, Siwy J, Wisniacki N, **Petri M**, Burkly LC. Alterations in urinary collagen peptides in lupus nephritis subjects correlate with renal dysfunction and renal histopathology. *Nephrol Dialysis Transplant Nephrol Dial Transplant* 2017;32:1468-1477. [Epub February 23, 2017; doi.org/10.1093/ndt/gfw446].
433. Miloslavsky EM, Naden RP, Bijlsma JWJ, Brogran PA, Brown ES, Brunetta P, Buttgerit F, Choi HK, DiCaire J-F, Gelfand JM, Heaney LG, Lightstone L, Lu N, Murrell DF, **Petri M**, Rosenbaum JT, Saag KS, Urowitz MB, Winthrop KL, Stone JH. Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis. *Ann Rheum Dis* 76:543-546, 2017.
434. Willis R, Smikle M, DeCeulaer K, Romay-Penabad Z, Papalardo E, Jajorial P, Harper B, Murthy V, **Petri M**, Gonzalez EB. Clinical associations of proinflammatory cytokines, oxidative biomarkers and Vitamin D levels in systemic lupus erythematosus. *Lupus* 26:1517-1527, 2017. [doi: 10.1177/0961203317706557]
435. Buyon JP, Kim MY, Guerra MM, Lu S, Reeves E, **Petri M**, Laskin CA, Lockshin MD, Sammaritano LR, Branch DW, Porter TF, Sawitzke A, Merrill JT, Stephenson MD, Cohn E, Salmon JE.. Kidney outcomes and risk factors for nephritis (flare/de novo) in a multicenter multiethnic cohort of pregnant patients with lupus. *Clin J Am Soc Nephrol*. 12:940-946, 2017. [doi: 10.2215/CJN.11431116. Epub 2017 Apr 11]
436. Isenberg D, Sturgess J, Allen E, Aranow C, Askanase A, Sang-Cheol B, Bernatsky S, Bruce I, Buyon J, Cervera R, Clarke A, Dooley MA, Fortin P, Ginzler E, Gladman D, Hanly J, Inanc M, Jacobsen S, Kamen D, Khamashta M, Lim S, Manzi S, Nived O, Peschken C, **Petri M**, Kalunian K, Rahman A, Ramsey-Goldman R, Ruiz-Irastorza G, Sanchez-Guerrero J, Steinsson K, Sturfelt G, Urowitz M, van Vollenhoven R, Wallace DJ, Zoma A, Merrill J, Gordon C. A study of flare assessment in systemic lupus erythematosus based on paper patients. *Arthritis Care Res* 70:98-103, 2018 [Epub December 8, 2017; doi: 10.1002/acr.23252].
437. Langefeld CD, Ainsworth HC, Graham DSC, Kelly JA, Comeau ME, Marion MC, Howard TD, Ramos PR, Croker JA, Morris DL, Sandling JK, Almlöf JC, Acevedo-Vázquez EM, Alarcón GS, Babini AM, Baca V, Bengtsson AA, Berbotto GA, Bijl M, Brown EE, Brunner HI, Cardiel MH, Catoggio L, Cervera R, Cucho-Venegas JM, Rantapää Dahlqvist S, D'Alfonso S, Da Silva BM, de la Rúa Figueroa I, Doria A, Edberg JC, Endreffy E, Esquivel-Valerio JA, Fortin PR, Freedman BI, Frostegård J, García MA, de la Torre IG, Gilkeson GS, Gladman DD, Gunnarsson I, James JA, Kallenberg CGM, Kamen DL, Karp DR, Kaufman KM, Kottyan L, Kovács L, Lastrup H, Lauwerys BR, Li Q-Z, Maradiaga-Ceceña MA, Martín J, McCune WJ, McWilliams DR, Merrill JT, Miranda P, Moctezuma JF, Nath SK, Niewold TB, Orozco L, Ortego-Centeno N, **Petri M**, Pineau C, Pons-Estel BA, Pope J, Raj P, Ramsey-Goldman R, Reveille JD, Russell LP, Sabio JM, Arce-Salinas CA, Scherbarth HR, Scorza R, Seldin MF, Sjöwall C, Svenungsson E, Thompson SD, Toloza SMA, Truedsson L, Tusié-Luna T, Vasconcelos C, Vilá LM, Wallace DJ, Weisman MH, Wither JE, Bhangale T, Oksenberg JR, Rioux JD, Gregersen PK, Syvänen A-C, Rönnblom L, Criswell LC, Jacob CO, Sivils KL, Tsao BP, Schanberg LE, Behrens TW, Silverman ED, Alarcón-Riquelme ME, Kimberly RP, Harley JB, Wakeland EK, Graham RR, Gaffney PM, Vyse TJ. Transancestral mapping and genetic load in systemic lupus erythematosus, *Nature*, 2017 [Epub July 17, 2017. doi:10.1038/ncomms16021].
438. Ferreira I, Croca S, Raimondo MG, Matharu M, Miller S, Giles I, Isenberg D, Ioannou Y, Hanly JG, Urowitz MB, Anderson N, Aranow C, Askanase A, Bae S-C, Bernatsky S, Bruce IN, Buyon J, Clarke AE, Dooley MA, Fortin P, Ginzler E, Gladman D, Gordon C, Inanc M, Jacobsen S, Kalunian K, Kamen D, Khamashta M, Lim S, Manzi S, Merrill J, Nived O, Peschken C, **Petri M**, Ramsey-Goldman R, Ruiz-Irastorza G, Sanchez-Guerrero J, Steinsson K, Sturfelt GK, van Vollenhoven R, Wallace DJ, Zoma A, Rahman A. Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study. *Arthritis Res Therapy* 19:287, 2017. <https://doi.org/10.1186/s13075-017-1495-6>
439. Timlin H, Magder L, **Petri M**. Clinical Outcomes Observed among Biopsy Proven Lupus Nephritis Patients Treated with Mycophenolate Mofetil as First-line Therapy. *Cureus*. 2017;9:e1907. [doi: 10.7759/cureus.1907].
440. Ryu S, Fu W, **Petri M**. Associates and predictors of pleurisy or pericarditis in systemic lupus erythematosus. *Lupus Sci Med* 4:e000221, 2017. [Epub October, 2017. doi:10.1136/lupus-2017-000221]
441. Györi N, Giannakou I, Chatzidionysiou K, Magder L, Vollenhoven RF van, **Petri M**. Disease activity patterns over time in patients with SLE: analysis of the Hopkins Lupus Cohort. *Lupus Sci Med* 4:e000192, 2017.

442. Duarte-García A, Barr E, Magder LS, **Petri M**. Predictors of incident proteinuria among patients with systemic lupus erythematosus. *Lupus Sci Med* 4(1):e000200, 2017. [doi: 10.1136/lupus-2016-000200]
443. Ng X, dosReis S, Beardsley R, Magder L, Mullins CD, **Petri M**. Understanding systemic lupus erythematosus patients' desired outcomes and their perceptions of the risks and benefits of using corticosteroids. *Lupus* 27:475-483, 2018.
444. Barber MRW, Hanly JG, Su L, Urowitz MB, Pierre YS, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Wallace DJ, Isenberg DA, Rahman A, Ginzler EM, **Petri M**, Bruce IN, Fortin PR, Gladman DD, Sanchez-Guerrero J, Ramsey-Goldman R, Khamashta MA, Aranow C, Mackay M, Alarcón GS, Manzi S, Nived O, Jönsen A, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Sam Lim S, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Theriault C, Farewell V, Clarke AE. Economic evaluation of lupus nephritis in the Systemic Lupus International Collaborating Clinics inception cohort using a multistate model approach. *Arthritis Care Res* 70:1294-1302, 2018 [Epub Nov 28, 2017; doi: 10.1002/acr.23480].
445. Costedoat-Chalumeau N, Houssiau F, Izmirly P, Le Guern V, Navarra S, Jolly M, Ruiz-Irastorza G, Baron G, Hachulla E, Agmon-Levin N, Shoenfeld Y, Dall'Ara F, Buyon J, Deligny C, Cervera R, Lazaro E, Bezanahary H, Leroux G, Morel N, Viallard J-F, Pineau C, Galicier L, Van Vollenhoven R, Tincani A, Nguyen H, Gondran G, Zahr N, Pouchot J, Piette J-C, **Petri M**, Isenberg D. A prospective international study on adherence to treatment in 305 patients with flaring systemic lupus erythematosus: assessment by drug levels and by self-administered questionnaires. *Clin Pharmacol Therapeutics* 103:1074-1082, 2018. [Epub 9 Nov 2017, DOI: 10.1002/cpt.885]
446. Kalunian KC, Urowitz MB, Isenberg D, Merrill JT, **Petri M**, Furie RA, Morgan-Cox MA, Taha R, Watts S, Silk M, Linnik MD. Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index. *Rheumatology* 2018;57:125-133. [doi: 10.1093/rheumatology/kex368]
447. Kaplowitz E, Ferguson S, Guerra M, Laskin CA, Buyon J, **Petri M**, Lockshin MD, Sammaritano L, Branch DW, Merrill J, Katz PP, Salmon JE. Contribution of socioeconomic status to racial/ethnic disparities in adverse pregnancy outcomes among women with systemic lupus erythematosus. *Arthritis Care Res* 70:230-235 2018. [Epub 30 Dec 2017, DOI: 10.1002/acr.23263]
448. Bernatsky S, Ramsey-Goldman R; **Petri M**, Urowitz MB; Gladman D; Fortin PR, Yelin E; Ginzler E, Hanly JG, Peschken C; Gordon C, Nived O, aranow C, Bae S-C, Isenberg D, Rahman A, Hansen JE; St Pierre Y, Clarke AE; SLICC, Systemic Lupus International Collaborating Clinics. Smoking is the most significant modifiable lung cancer risk factor in SLE. *J Rheumatol* 45:393-396, 2018.
449. Little J, Parker B, Lunt M, Hanly JG, Urowitz MB, Clarke AE, Romero-Diaz J, Gordon C, Bae S-C, Bernatsky S, Wallace DJ, Merrill JT, Buyon J, Isenberg DA, Rahman A, Ginzler EM, **Petri M**, Dooley MA, Fortin P, Gladman DD, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Mackay M, Alarcón GS, Manzi S, Nived O, Jönsen A, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim S, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Sanchez-Guerrero J, Bruce IN. Glucocorticoid use and factors associated with its variability in the Systemic Lupus International Collaborating Clinics Inception Cohort. *Rheumatology*, 2018. [Epub January 18, 2018; doi.org/10.1093/rheumatology/kex444]
450. Hanly J, Li Q, Su L, Urowitz M, Gordon PC, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Clarke AE, Wallace D, Isenberg D, Rahman A, Merrill JT, Fortin P, Gladman D, Bruce I, **Petri M**, Ginzler E, Dooley M, Stein KR, Ramsey RG, Zoma A, Manzi S, Nived O, Jonsen A, Khamashta M, Alarcon G, Chatham W, van Vollenhoven R, Aranow C, Mackay M, Irastorza R, Ramos-Casals M, Lim SS, Drinanc, Kalunian K, SJ, Peschken C, Amend K, ADA20, Theriault C, Farewell V, and SLICC. Cerebrovascular events in systemic lupus erythematosus: results from an international, inception cohort study. *Arthritis Care Res* 70:1478-1487, 2018 [Epub Jan 5, 2018; doi: 10.1002/acr.23509].
451. Chan K, Clarke AE, Ramsey-Goldman R, Foulkes W, Tessier Cloutier B, Urowitz MB, Gladman D, Nived O, Romero-Diaz J, **Petri M**, Ginzler E, Fortin PR, Bae S-C, Wallace DJ, Yelin EH, Bernatsky S. Breast cancer in systemic lupus (SLE): Receptor status and treatment. *Lupus* 27:120-123, 2018.
452. Pejchinovski M, Siwy J, Mullen W, Mischak H, **Petri MA**, Burkly LC, Wei R. Urine peptidomic biomarkers for diagnosis of patients with systematic lupus erythematosus. *Lupus* 27:6-16, 2018.
453. Zhang Z, Shi L, Song L, Maurer K, **Petri MA**, Sullivan KE. Overall downregulation of mRNAs and enrichment of H3K4me3 change near genome-wide association study signals in systemic lupus erythematosus: cell-specific effects. *Frontiers Immunol* 9:497, 2018. [doi: 10.3389/fimmu.2018.00497]

454. Kim MY, Guerra MM, Kaplowitz E, Laskin CA, **Petri M**, Branch DW, Lockshin MD, Sammaritano LR, Merrill JT, Porter TF, Sawitzke A, Lynch AM, Buyon JP, Salmon JE. Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies. *Ann Rheum Dis* 77:549-555, 2018.
455. Davidson JE, Fu Q, Ji B, Rao S, Roth D, Magder LS, **Petri M**. Renal remission status and long-term survival in patients with lupus nephritis: a retrospective cohort analysis. *J Rheumatol* 45:671-677, 2018.
456. Unlu O, Erkan D, Barbhaiya M, Andrade D, Nascimento I, Rosa R, Banzato A, Pengo V, Ugarte A, Gerosa M, Ji L, Efthymiou M, Branch DW, de Jesus GR, Tincani A, Belmont HM, Fortin PR, **Petri M**, Rodriguez E, Pons-Estel GJ, Knight JS, Atsumi T, Willis R, Zuily S, Tektonidou MG; On Behalf of APS ACTION. The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody Positive Patients: Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and International Clinical Database and Repository. *Arthritis Care Res* 71:134-141, 2019 [Epub Apr 18, 2018; doi: 10.1002/acr.23584.2018]
457. Merrill JT, **Petri M**, Buyon J, Ramsey-Goldman R, Kalunian K, Putterman C, Conklin J, Furie R, Dervieux T. Erythrocyte bound C4d in combination with complement and autoantibody status for the monitoring of systemic lupus erythematosus. *Lupus Sci Med*, 2018 [Epub May 2018;5:e000263. doi:10.1136/lupus-2018-000263].
458. Castanon A, Pierre G, Willis R, Harris EN, Papalardo E, Romay-Penabad Z, Jajoria P, Smikle M, DeCeulaer K, Tebo A, Jaskowski T, Guerra M, Branch W, Salmon J, **Petri M**, Gonzalez EB. Performance evaluation and clinical associations of immunoassays that detect antibodies to negatively-charged phospholipids other than cardiolipin. *Am J Clin Pathol*. 2018;149:401-411. [doi: 10.1093/ajcp/aqy003].
459. Putterman C, Pisetsky D, **Petri M**, Caricchio R, Wu A, Sanz I, Oates J, Wallace S, Sorek R, Gerwien R, Safer P, Jakobi-Brook K, Cohen IR. The SLE-key test serologic signature: New insights into the course of lupus. *Rheumatology* 57:1632-1640, 2018 [Epub June 2018; doi:10.1093/rheumatology/key149].
460. **Petri M**, Magder LS. Comparison of remission and lupus low disease activity state in damage prevention in a United States systemic lupus erythematosus cohort. *Arthritis Rheumatol* 70:1790-1795, 2018 [Epub May 27, 2018; doi: 10.1002/art.40571].
461. Eudy A, Siega-Riz AM, Engel SM, Franceschini N, Howard AG, Clowse M, **Petri M**. Effect of pregnancy on disease flares in patients with systemic lupus erythematosus. *Ann Rheum Dis*. 2018;77:855-860. [Epub Feb 20, 2018; doi: 10.1136/annrheumdis-2017-212535].
462. Davidson JE, Fu Q, Rao S, Magder LS, **Petri M**. Quantifying the burden of steroid-related damage in systemic lupus erythematosus in the Hopkins Lupus Cohort. *Lupus Sci Med* 5(1):e000237, 2018. [doi: 10.1136/lupus-2017-000237].
463. Shi L, Song L, Mauer K, Zhang Z, Petri MA, Sullivan KE. Enhancer RNA and NFκB-dependent P300 regulation of ADAMDEC1. *Molec Immunol* 103:312-321, 2018.
464. Choi M, Clarke AE, St. Pierre Y, Hanly J, Urowitz MB, Romero-Díaz J, Gordon C, Bae S-C, Bernatsky S, Wallace D, Merrill JT, Isenberg D, Rahman A, Ginzler EM, **Petri M**, Bruce IN, Dooley MA, Fortin P, Gladman D, Sanchez-Guerrero J, Steinsson K, Ramsey-Goldman R, Khamashta M, Aranow C, Alarcón G, Manzi S, Nived O, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askenase A, Stoll T, Buyon J, Mahler M, Fritzler MJ. Antinuclear antibody-negative systemic lupus erythematosus in an international inception cohort. *Arthritis Care Res* 71:893-902, 2019 [epub July 30, 2018; doi: 10.1002/acr.23712].
465. Toro Dominguez D, Martorell-Marugán J, Goldman D, **Petri M**, Carmona-Saez P, Alarcón-Riquelme ME. Longitudinal stratification of gene expression reveals three SLE groups of disease activity progression. *Arthritis Rheum* 70: 2025-35, 2018. [Epub June 18, 2018; doi: 10.1002/art.40653]
466. Jenks SA, Cashman KS, Zumaquero-Martinez E, Marigorta UM, Patel AV, Wang X, Tomar D, Woodruff MC, Simon Z, Bugrovsky R, Blalock E, Scharer CD, Tipton C, Wei C, Lim SS, **Petri M**, Niewold T, Anolik J, Gibson G, Lee FEH, Boss JM, Lund F, Sanz I. Distinct effector B cells induced by unregulated Toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus. *Immunity* 49(4):725-739.e6, 2018. [doi.org/10.1016/j.immuni.2018.08.015].
467. Giannakou I, Chatzidionysiou K, Magder L, van Vollenhoven R, **Petri M**. Predictors of persistent disease activity and long quiescence in systemic lupus erythematosus – results from the Hopkins Lupus Cohort. *Lupus Sci Med* 5:e000287, 2018. [doi: 10.1136/lupus-2018-000287]

468. Jorge AM, Melles RB, Zhang Y, Lu N, Rai SK, Young LH, Costenbader KH, Ramsey-Goldman R, Lim SS, Esdaile JM, Clarke AE, Urowitz M, Askanase A, Aranow C, **Petri M**, Choi H. Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines. *Arthritis Res Ther*. 20:133, 2018. [doi: 10.1186/s13075-018-1634-8].
469. Hanscombe KB, Morris DL, Noble JA, Dilthey AT, Tombleson P, Kaufman KM, Comeau M, Langefeld CD, Alarcon-Riquelme ME, Gaffney PM, Jacob CO, Sivils KL, Tsao BP, Alarcon GS, Brown EE, Croker J, Edberg J, Gilkeson G, James JA, Kamen DL, Kelly JA, McCune J, Merrill JT, **Petri M**, Ramsey-Goldman R, Reveille JD, Salmon JE, Scofield H, Utset T, Wallace DJ, Weisman MH, Kimberly RP, Harley JB, Lewis CM, Criswell LA, Vyse TJ. Genetic fine mapping of systemic lupus erythematosus MHC associations in Europeans and African Americans. *Hum Mol Genet* 27(21):3813-3824, 2018. [doi: 10.1093/hmg/ddy280]
470. Hardt U, Larsson A, Elvin K, Gunnarsson I, Clancy RM, **Petri M**, Buyon JP, Silverman GJ, Svenungsson E, Grönwall C. Autoimmune reactivity to malondialdehyde adducts in systemic lupus erythematosus is associated with disease activity and nephritis. *Arthritis Res Therapy* 20:36, 2018. [doi: 10.1186/s13075-018-1530-2]
471. Mendel A, Bernatsky B, Hanly JG, Urowitz MB, Clarke AE, Romero-Diaz J, Gordon C, Bae SC, Wallace DJ, Merrill JT, Buyon J, Isenberg DA, Rahman A, Ginzler EM, **Petri M**, Dooley MA, Fortin P, Gladman DD, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Mackay M, Alarcón GS, Manzi S, Nived O, Jönsen A, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim S, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Sanchez-Guerrero J, Bruce IN, Vinet E. Low aspirin use and high prevalence of preeclampsia risk factors among pregnant women in a multi-national SLE inception cohort. *Ann Rheum Dis* 8:1010-1012, 2019. [Epub ahead of print Dec 20 2018. doi: 10.1136/annrheumdis-2018-214434]
472. Kelly M, Lihua S, Zhe Z, Li S, Yoselin P, **Petri M**, Sullivan K. Transposable element dysregulation in systemic lupus erythematosus and regulation by histone conformation and Hsp90. *Clin Immunol* 197:6-18, 2018. [doi: 10.1016/j.clim.2018.08.011. Epub 2018 Aug 24].
473. Eudy AM, Siega-Riz, AM, Engel SM, Franceschini N, Howard AG, Clowse MEB, Petri M. Preconceptional cardiovascular health and pregnancy outcomes in women with systemic lupus erythematosus. *J Rheumatol* 46:70-77, 2019 [Epub July 25 2018; doi:10.3899/jrheum.171066].
474. Thomas DE, Lyons JS, Greene BS, **Petri MA**. Low hydroxychloroquine blood levels in patients who have had gastric bypass surgery. *Lupus Sci Med*. 6(1):e000335, 2019. [doi: 10.1136/lupus-2019-000335].
475. Hanly JG, Li Q, Su L, Urowitz MB, Gordon C, Bae S-C, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Clarke AE, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, Fortin PR Gladman DD, Bruce IN, **Petri M**, Ginzler EM, Dooley MA, Steinsson K, Ramsey-Goldman R, Zoma AA, Manzi S, Nived O, Jonsen A, Khamashta MA, Alarcón GS, Svenungsson E, van Vollenhoven RF, Aranow C, Mackay M, Ruiz-Irastorza G, Ramos-Casals M, Lim SS, Inanc M, Kalunian KC, Jacobsen S, Peschken CA, Kamen DL, Askanase A, Theriault C, Farewell V. Psychosis in systemic lupus erythematosus: results from an international inception cohort study. *Arthritis Rheum* 71:281-289, 2019. [Epub January 17, 2019; doi:10.1002/art.40764].
476. Sciascial S, Willis R, Pengo V, Krilis S, Andrade D, Tektonidou M, Ugarte A, Chighizolah C, Branch DW, Levy A, Paul CN, Fortin PR, **Petri M**, Rodriguez E, Rodriguez-Pintoo I, Atsumi T, Nasciementno I, Rosa R, Banzato A, Erkan D, Cohen H, Efthymiou M, Mackie I, and Bertolaccini ML on behalf of APS ACTION. The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis. *Thrombosis Res* 175:32-36, 2019.
477. Iftikhar M, Kaur R, Nefalar A, Usmani B, Kherani S, Rashid I, Schönbach E, **Petri M**, Scholl HPN, Shah SM. Microperimetry as a screening test for hydroxychloroquine retinopathy: The HARD-RISK-1 Study. *Retina* 39:485-491, 2019. [doi: 10.1097/IAE.0000000000002313]
478. Mackay M, Sall'Era M, Fishbein J, Kalunian K, Lesser M, Sanchez-Guerrero J, Levy D Silverman E, **Petri M**, Arriens C, Lewis E, Korbet S, Conti F, Tesar V, Hruskova Z, Borba EF, Bonfa E, Chan DTM, Rathi M, Gupta KL, Jha V, Hasni S, West MR, Silverman E, Solomons N, Houssiau F, Romero-Diaz J, Mejia-Vilet J, Rovin BH. Establishing surrogate kidney endpoints for lupus nephritis clinical trials: development and validation of a novel approach to predict future kidney outcomes. *Arthritis Rheumatol* 71:411-419, 2019. [Epub 17 September 2018; doi.org/10.1002/art.40724]

479. Patel Z, Lu X, Miller D, Forney CR, Lee J, Lynch A, Schroeder C, Parks L, Magnusen A, Chen X, Pujato M, Maddox A, Zoller EE, Namjou B, Brunner HI, Ting T, Henrickson M, Huggins JL, Williams AH, Ziegler JT, Comeau ME, Marion MC, Glenn SB, Adler A, Shen N, Nath SK, Stevens AM, Freedman BI, Tsao BP, Jacob CO, Kamen DL, Brown EE, Gilkeson GS, Alarcón GS, Reveille JD, Anaya J-M, James JA, Sivils KL, Criswell LA, Vilá LM, Alarcón-Riquelme ME, **Petri M**, Scofield RH, Kimberly RP, Edberg JC, Ramsey-Goldman R, Joo YB, Choi J, Bae S-C, Boackle SA, Cunninghame Graham D, Vyse DJ, Pons-Estel BA, Martin J, Merrill JT, Niewold TB, Ainsworth HC, Silverman ED, Oksenberg JR, Wallace DJ, McCune WJ, Guthridge JM, Gaffney PM, Langefeld CD, Kelly JA, Wakeland EK, Kaufman KM, Weirauch MT, Harley JB, Kottyan LC. A plausibly causal functional lupus-associated risk variant in the STAT1-STAT4 locus. *Hum Mol Genet*. 2019 [Epub ahead of print Apr 18, 2018. doi: 10.1093/hmg/ddy140.]
480. Wallace DJ, Furie RA, Tanaka Y, Kalunian KC, Mosca M, **Petri MA**, Dörner T, Cardiel MH, Bruce IN, Gomez E, Carmack T, Janes JM, Linnik MD, de Bono S, Silk MT, Hoffman, RW. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled phase 2 study. *Lancet* 392:222-231, 2019. [doi: 10.1016/S0140-6736(18)31363-1].
481. Wirestam L, Enocsson H, Skogh T, Padyukov L, Jönsen A, Urowitz M, Gladman D, Romero-Diaz J, Bae S-C, Fortin PR, Sanchez-Guerrero J, Clarke A, Bernatsky S, Gordon C, Hanly JG, Wallace D, Isenberg D, Rahman A, Merrill J, Ginzler E, Alarcón GS, Fessler BJ, **Petri M**, Khamashta M, Aranow C, Dooley MA, Manzi S, Ramsey-Goldman R, Nived, Svenungsson E, Steinsson K, Zoma A, Ruiz-Irastorza G, Lim S, Kalunian K, Inanc M, van Vollenhoven R, Ramos-Casals M, Kamen D, Jacobsen S, Peschken C, Askanase A, Stoll T, Bruce IN, Wetterö J, Sjöwall C. Osteopontin and disease activity with recent-onset systemic lupus erythematosus: Results from the SLICC inception cohort. *J Rheumatol* 46:492-500, 2019. [doi:10.3899/jrheum.180713]
482. Legge A, Kirkland S, Rockwood K, Andreou P, Bae S-C, Gordon C, Romero-Díaz J, Sanchez-Guerrero J, Wallace D, Bernatsky S, Clarke A, Merrill JT, Ginzler E, Fortin P, Gladman D, Urowitz MB, Bruce I, Isenberg D, Rahman A, Alarcón G, **Petri M**, Khamashta M, Dooley MA, Ramsey-Goldman R, Manzi S, Steinsson K, Zoma A, Aranow C, Mackay M, Ruiz-Irastorza G, Lim SS, Inanc M, van Vollenhoven R, Jönsen A, Nived O, Ramos-Casals M, Kamen D, Kalunian K, Jacobsen S, Peschken C, Askanase A, Hanly J;. Evaluating the properties of a frailty index and its association with mortality risk among patients with systemic lupus erythematosus. *Arthritis Rheumatol* 71:1297-11307, 2019. [Epub ahead of print Feb 16, 2019. doi: 10.1002/art.40859].
483. Legge A, Kirkland S, Rockwood K, Andreou P, Bae S-C, Gordon C, Romero-Díaz J, Sanchez-Guerrero J, Wallace D, Bernatsky S, Clarke A, Merrill JT, Ginzler E, Fortin P, Gladman D, Urowitz MB, Bruce I, Isenberg D, Rahman A, Alarcón G, **Petri M**, Khamashta M, Dooley MA, Ramsey-Goldman R, Manzi S, Steinsson K, Zoma A, Aranow C, Mackay M, Ruiz-Irastorza G, Lim SS, Inanc M, van Vollenhoven R, Jönsen A, Nived O, Ramos-Casals M, Kamen D, Kalunian K, Jacobsen S, Peschken C, Askanase A, Hanly J. Construction of a frailty index as a novel health measure in systemic lupus erythematosus. *J Rheumatol* 47:72-81, 2020. [Epub August 15, 2019; doi:10.3899/jrheum.181338].
484. Hong S, Banchereau R, Maslow B, Guerra M, Cardenas J, Baisch J, Branch DW, Porter TF, Sawitzke A, Laskin C, Buyon J, Merrill J, Sammaritano L, **Petri M**, Gatewood E, Cepika AM, Ohouo M, Obermoser G, Anguiano E, Kim TW, Nulsen J, Nehar-Belaid D, Blankenship D, Turner J, Banchereau J, Salmon J, Pascual V. Longitudinal blood transcriptome profiling in healthy and Lupus pregnancies uncovers immune pathways associated with complications. *J Exp Med* 216:1154-1169, 2019. [doi: 10.1084/jem.20190185]
485. Mendel A, Bernatsky S, Pineau CA, St-Pierre Y, Hanly JG, Urowitz MB, Clarke AE, Romero-Diaz J, Gordon C, Bae SC, Wallace DJ, Merrill JT, Buyon J, Isenberg DA, Rahman A, Ginzler EM, **Petri M**, Dooley MA, Fortin P, Gladman DD, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Mackay M, Alarcón G, Manzi S, Nived O, Jönsen A, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim S, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Sanchez-Guerrero J, Bruce IN, Costedoat-Chalumeau N, Vinet E. Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. *Rheumatology (Oxford)* 58:1259-1267, 2019 [Epub ahead of print Feb 8 2019. doi: 10.1093/rheumatology/kez014]
486. **Petri M**, Fu W, Ranger A, Allaire N, Cullen P, Magder L, Zhang Y. Association between changes in gene signatures expression and disease activity among patients with systemic lupus erythematosus. *BMC Medical Genomics* 12(1):4, 2019. [doi: 10.1186/s12920-018-0468-1]
487. Barbacki A, **Petri M**, Avina-Zubieta JA, Alarcón GS, Bernatsky S. Fatigue measurements in systemic lupus erythematosus. *J Rheumatol* 46:1470-1477, 2019. [Epub ahead of print Feb 1 2019. doi: 10.3899/jrheum.180831]

488. Wallace DJ, Ginzler EM, Merrill JT, Furie RA, Stohl W, Chatham W, Weinstein A, McKay J, McCune WJ, **Petri M**, Fettiplace J, Roth D, Ji B, Heath A. Safety and efficacy of belimumab plus standard therapy for up to thirteen years in patients with systemic lupus erythematosus. *Arthritis Rheum* 71:1125-1134, 2019. [Epub ahead of print Feb 16, 2019. doi: 10.1002/art.40861]
489. de Jesús GR, Sciascia S, Andrade D, Barbhैया M, Tektonidou M, Banzato A, Pengo V, Ji L, Meroni PL, Ugarte A, Cohen H, Branch DW, Andreoli L, Belmont HM, Fortin PR, **Petri M**, Rodriguez E, Cervera R, Knight JS, Atsumi T, Willis R, Nascimento IS, Rosa R, Erkan D, Levy RA; APS ACTION. Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (APS) in the APS Alliance for Clinical Trials and International Networking Clinical Database and Repository: a retrospective study. *BJOG* 126(5):656-661, 2019. [Epub 2018 Oct 24. doi: 10.1111/1471-0528.15469]
490. Radin M, Sciascia S, Erkan D, Pengo V, Tektonidou MG, Ugarte A, Meroni P, Ji L, Belmont HM, Cohen H, Ramires de Jesús G, Branch DW, Fortin PR, Andreoli L, **Petri M**, Rodriguez E, Rodriguez-Pinto I, Knight JS, Atsumi T, Willis R, Gonzalez E, Lopez-Pedreira R, Rossi Gandara AP, Borges Gualhardo Vendramini M, Banzato A, Sevim E, Barbhैया M, Efthymiou M, Mackie I, Bertolaccini ML, Andrade D. The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort. *Semin Arthritis Rheum* 2019. [Epub 2019 May 2;. doi: 10.1016/j.semarthrit.2019.04.009]
491. Arazi A, Rao DA, Berthier CC, Davidson A, Liu Y, Hoover P, Chicoin A, Eisenhaure TM, Jonsson AH, Li S, Lieb DJ, Zhang F Slowikowski K, Browne EP, Noma A, Sutherby D, Steelman S, Smilek DE, Tosta P, Apruzzese W, Massarotti E, Dall'Era M, Park M, Kamen DL, Furie RA, Payan-Schober F, Pendergraft III WF, McInnis EA, Buyon JP, **Petri MA**, Putterman C, Kalunian KC, Woodle ES, Lederer JA, Hildeman DA, Nusbaum C, Raychaudhuri S, Kretzler M, Anolik JH, Brenner MB, Wofsy D, Hachohen N, Diamond B, the Accelerating Medicines Partnership in SLE network. The immune cell landscape in kidneys of lupus nephritis patients. *Nature Immunology* 20:902-914, 2019. [doi: 10.1038/s41590-019-0398-x]
492. Goules A, Li J, Antiochos B, Goldman D, Rosen A, **Petri M**, Casciola-Rosen L. Anti-Retinoblastoma protein antibodies: a new specificity in SLE associated with protection against lupus nephritis. *ACR Open Rheumatol* 1:287-291, 2019. [Epub June 6, 2019. doi: 10.1002/acr2.1036]
493. **Petri M**, Conklin J, O'Malley T, Apilado R, Dervieux T. Platelet bound C4d, low complement C3 and lupus anticoagulant associate with thrombosis in systemic lupus erythematosus. *Lupus Sci Med* 6:e000318, 2019. [doi: 10.1136/lupus-2019-000318]
494. Qin L, Stanley S, Ding H, Truong V, Celhar T, Fairhurst A-M, Pedroza C, **Petri M**, Mohan C, Saxena R. Urinary pro-thrombotic, anti-thrombotic and fibrinolytic molecules as biomarkers of lupus nephritis. *Arthritis Res Ther.* 21:176, 2019. [doi: 10.1186/s13075-019-1959-y].
495. Stojan G, Magder LS, **Petri M**. Blood pressure variability and age-related blood pressure patterns in systemic lupus erythematosus. *J Rheumatol.* 47:387-393, 2020 [Epub June 15, 2019; doi: 10.3899/jrheum.181131].
496. Hanly J, Li Q, Su L, Urowitz MB, Gordon C, Bae S-C, Romero-Díaz J, Sanchez-Guerrero J, Bernatsky S, Clarke A, Wallace D, Isenberg D, Rahman A, Merrill J, Fortin P, Gladman D, Bruce I, **Petri M**, Ginzler E, Dooley MA, Steinsson K, Ramsey-Goldman R, Zoma A, Manzi S, Nived O, Jönsen A, Khamashta M, Alarcón G, Svenungsson E, van Vollenhoven R, Aranow C, Mackay M, Ruiz-Irastorza G, Ramos-Casals M, Lim SS, Inanc M, Kalunian K, Jacobsen S, Peschken C, Kamen D, Askanase A, Theriault C, Farewell V. Peripheral nervous system disease in systemic lupus erythematosus: Results from an international, inception cohort study. *Arthritis Rheumatol* 72:67-77, 2020 [Epub Aug 7 2019; doi: 10.1002/art.41070]
497. Efthymiou M, Mackie I, Lane P, Andrade D, Willis R, Erkan D, Sciascia S, Krilis S, Bison E, Vendramini M, Romay-Penabad Z, Qi M, Tektonidou M, Ugarte A, Chighizolah C, Belmont HM, Aguirre MA, Ji L, Branch DW, de Jesus G, Fortin PR, Andreoli L, **Petri M**, Cervera R, Rodriguez E, Knight JS, Atsumi T, Vega J, Sevim E, Bertolaccini ML, Pengo V, Cohen H, on behalf of APS ACTION. Comparison of real world and core laboratory lupus anticoagulant results from the Antiphospholipid Syndrome (APS) ACTION clinical database and repository. *J Thromb Haemost* 17:2069-2090, 2019. [Epub July 30 2019; doi: 10.1111/jth.14596]
498. Reiss AB, Arain H, Kasselmann LJ, Kaplan L, Siegert NM, De Leon J, Carsons SE, **Petri M**. Statin treatment of SLE patients does not correct pro-atherogenic cholesterol transport gene expression induced by lupus plasma in human macrophages in vitro: a mechanistic LAPS substudy. *Medicina* 55(9):514, 2019, [doi.org/10.3390/medicina55090514].
499. **Petri M**, Elkhalfi M, Li J, Magder LS, Goldman DW. Hydroxychloroquine blood levels predict hydroxychloroquine retinopathy. *Arthritis Rheum* 72:448-453, 2020. [Epub Sept 18, 2019; doi:10.1002/art.41121]

500. Legge A, Kirkland S, Rockwood K, Andreou P, Bae S-C, Gordon C, Romero-Díaz J, Sanchez-Guerrero J, Wallace D, Bernatsky S, Clarke A, Merrill JT, Ginzler E, Fortin P, Gladman D, Urowitz MB, Bruce I, Isenberg D, Rahman A, Alarcón G, **Petri M**, Khamashta M, Dooley MA, Ramsey-Goldman R, Manzi S, Aranow C, Mackay M, Ruiz-Irastorza G, Lim SS, Inanc M, van Vollenhoven R, Jönsen A, Nived O, Ramos-Casals M, Kamen D, Kalunian K, Jacobsen S, Peschken C, Askanase A, Hanly J. Prediction of damage accrual in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI). *Arthritis Rheumatol* 72:658-666, 2020. [Epub October 15, 2019; doi: 10.1002/ACR.24092]
501. **Petri MA**, Barr E, Magder LS. Development of a systemic lupus erythematosus cardiovascular risk equation. *Lupus Science & Medicine* 6:e000346, 2019. [Epub October 10, 2019; doi:10.1136/lupus-2019-000346]
502. Babaoglu H, Li J, Goldman D, Magder LS, **Petri M**. Time to lupus low disease activity state in the Hopkins lupus cohort: role of African-American ethnicity. *Arthritis Care Res* 72:225-232, 2020. [Epub Sept 10, 2019; doi: 10.1002/acr.24063]
503. Babaoglu H, Li J, Goldman D, Magder LS, **Petri M**. Predictors of predominant lupus low disease activity state (LLDAS-50). *Lupus* 28:1648-1655, 2019. [Epub Nov 6, 2019; doi: 10.1177/0961203319886028]
504. Toro-Dominguez D, López-Domínguez R, García-Moreno A, Villatoro-García JA, Martorell-Marugán J, Goldman D, **Petri M**, Wojdyla D, Pons-estel B, Isenberg D, Morales-Montes de Oca G, Trejo-Zambrano MI, García-Gonzalez B, Rosetti F, Gómez-Martín D, Romero-Díaz J, Carmona-Saez P, Alarcón-Riquelme ME. Differential Treatments Based on Drug-induced Gene Expression Signatures and Longitudinal Systemic Lupus Erythematosus Stratification. *Sci Rep* 9:15502, 2019. [Epub October 29, 2019; doi:10.1038/s41598-019-51616-9].
505. Li Y, Higgs RE, Hoffman RW, Dow ER, Liu X, **Petri M**, Wallace DJ, Dörner T, Eastwood BJ, Miller BB, Liu Y. A Bayesian gene network reveals insight into the JAK-STAT pathway in systemic lupus erythematosus. *PLoS ONE* 14: e0225651, 2019. [doi.org/10.1371/journal.pone.0225651]
506. Smith MA, Henault, Karnell JL, Parker ML, Riggs JM, Sinibaldi D, Taylor DK, Ettinger R, Grant EP, Sanjuan MA, Kolbeck R, **Petri MA**, Casey KA. SLE plasma profiling identifies unique signatures of lupus nephritis and discoid lupus. *Sci Rep.* 9:14433, 2019. [doi: 10.1038/s41598-019-50231-y]
507. Bocharnikov AV, Keegan J, Wacleche VS, Cao Y, Fonseka CY, Wang G, Muise E, Zhang KX, Arazi A, Keras G, Li ZJ, Qu Y, Gurish MF, Accelerating Medicines Partnership RA/SLE Network, **Petri M**, Buyon JP, Putterman C, Wofsy D, James JA, Guthridge JM, Diamond B, Anolik JH, Mackey MF, Alves SE, Nigrovic PA, Costenbader KH, Brenner MB, Lederer JA, Rao DA. PD-1^{hi} CXCR5- T peripheral helper cells promote B cells responses in lupus via MAF and IL-21. *JCI Insight.* 4(20):pii: 130062, 2019. [doi: 10.1172/jci.insight.130062]
508. Wallace D, Tse K, Hanrahan L, Davies R, **Petri M**. Hydroxychloroquine usage in US patients, their experiences of tolerability and adherence, and implications for treatment: survey results from 3127 SLE patients conducted by the Lupus Foundation of America. *Lupus Sci Med.* 6:e000317, 2019. [doi: 10.1136/lupus-2019-000317]
509. Chaturvedi S, Braunstein EM, Yuan X, Yu J, Alexander A, Chen H, Gavriilaki E, Alluri R, Streiff MB, **Petri M**, Crowther MA, McCrae KR, Brodsky RA. Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. *Blood* 135:239-251, 2020. [doi: 10.1182/blood.2019003863]
510. Hanly JG, Urowitz MB, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Clarke A, Wallace DJ, Isenberg D, Rahman A, Merrill JT, Fortin P, Gladman D, Bruce I, **Petri M**, Ginzler E, Dooley MA, Ramsey-Goldman R, Manzi S, Jönson A, Alarcon GS, Van Vollenhoven R, Aranow C, McKay M, Ruiz-Irastorza, Lim S, Inanc M, Kalunian K, Jacobsen S, Peschken CA, Kamen DL, Askanase A, Farewell V. Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis in an international inception cohort using a multistate model approach. *Ann Rheum Dis* 79:356-362, 2020.
511. Shi L, Song L, Maurer K, Dou Y, Patel VR, Su C, Leonard ME, Lu S, Hodge KM, Torres A, Chesi A, Grant SFA, Wells AD, Zhang Z, **Petri MA**, Sullivan KE. IL-1 transcriptional responses to LPS are regulated by a complex of RNA-binding proteins. *J Immunol.* 204:1334-1344, 2020. [doi: 10.4049/jimmunol.1900650. Epub 2020 Jan 17]
512. Zhang T, Li H, Vanarsa K, Gidley G, Mok CC, **Petri M**, Saxena R, Mohan C. Association of urine sCD163 with proliferative lupus nephritis, fibrinoid necrosis, cellular crescents and intrarenal M2 macrophages. *Front Immunol* 11:671, 2020. [Epub April 2020 doi.org/10.3389/fimmu.2020.00671].

513. Enocsson H, Wirestam L, Dahle C, Padyukov L, Jönsen A, Urowitz M, Gladman D, Romero-Diaz J, Bae S-C, Fortin PR, Sanchez-Guerrero J, Clarke AE, Bernatsky S, Gordon C, Hanly JG, Wallace D, Isenberg D, Rahman R, Merrill J, Ginzler E, Alarcón GS, Chatham WW, **Petri M**, Khamashta M, Aranow C, Mackay M, Dooley MA, Manzi S, Ramsey-Goldman R, Nived O, Steinsson K, Zoma A, Ruiz-Irastorza G, Lim S, Kalunian K, Inanc M, van Vollenhoven R, Ramos-Casals M, Kamen DL, Jacobsen S, Peschken C, Askanase A, Stoll T, Bruce IN, Wetterö J, Sjöwall C. Soluble urokinase plasminogen activator receptor predicts damage accrual in patients with recent-onset systemic lupus erythematosus: Results from the SLICC inception cohort. *J Autoimmunity* 106:102340, 2020. [Epub 2019 Oct 17; doi: 10.1016/j.jaut.2019.102340]
514. **Petri M**, Magder LS, Barr E. Risk of renal failure within ten or twenty years of SLE diagnosis. *J Rheumatol.* 48:222-227, 2021. [Epub November 15, 2020. doi: 10.3899/jrheum.191094]
515. Davis-Porada J, Kim MY, Guerra MM, Laskin CA, **Petri M**, Lockshin MD, Sammaritano LR, Branch DW, Sawitzke A, Merrill JT, Buyon JP, Salmon JE. Low frequency of flares during pregnancy and post-partum in stable lupus patients. *Arthritis Res Therapy* 22(1):52, 2020. [doi: 10.1186/s13075-020-2139-9]
516. Stojan G, Kvit A, Curriero FC, **Petri M**. A spatiotemporal analysis of organ-specific lupus flares in relation to atmospheric variables and fine particulate matter pollution. *Arthritis Rheumatol* 72:1134-1142, 2020. [Epub Feb 3 2020. doi: 10.1002/art.41217]
517. Kallas R, Li J, **Petri M**. Association of African-American ethnicity and smoking status with total and individual damage index in systemic lupus erythematosus. *Clin Rheumatol.* 39:365-373, 2020. [Epub 2019 Nov 8. doi: 10.1007/s10067-019-04800-1]
518. Mizus M, Li J, Goldman DW, **Petri MA**. Autoantibody clustering of lupus-associated pulmonary hypertension. *Lupus Sci Med.* 6:e000356, 2019. [doi: 10.1136/lupus-2019-000356]
519. Fava A, Zhang Y, Magder L, Buyon J, Belmont HM, Izmirly P, Clancy R, Mohan C, Zhang T, Trujillo JM, Fine D, Arazi A, Rao DA, Berthier CC, Diamond B, Hachohen N, Wofsy D, the Accelerating Medicines Partnership in SLE network, Raychaudhuri S, **Petri M**. Integration of urine proteomics and renal single-cell genomics identifies an interferon-gamma response gradient in lupus nephritis. *JCI Insight.* 2020 [Epub May 12 2020; doi: 10.1172/jci.insight.138345]
520. Stanley S, Vanarsa K, Soliman S, Habazi D, Pedroza C, Gidley G, Zhang T, Mohan S, Der E, Suryawanshi H, Tuschl T, Buyon J, Putterman C, Mok CC, **Petri M**, Saxena R, Mohan C. Comprehensive aptamer-based screening identifies a spectrum of urinary biomarkers of lupus nephritis across ethnicities. *Nature Communications* 11:2197, 2020. [doi: 10.1038/s41467-020-15986-3]
521. Zuily S, Clerc-Urmès I, Bauman C, Andrade D, Sciascia S, Pengo V, Tektonidou MG, Ugarte A, Gerosa M, Belmont HM, Zamorano MAA, Fortin P, Ji L, Efthymiou M, Cohen H, Branch DW, de Jesus GR, Nalli C, **Petri M**, Rodriguez E, Cervera R, Knight JS, Atsumi T, Willis R, Bertolaccini ML, Vega J, Wahl D, Erkan D, APS ACTION Investigators. Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry. *Lupus* 29:1353-1363, 2020. [Epub July 23, 2020; <http://dx.doi.org/10.1177/0961203320940776>]
522. Urowitz MB, Gladman D, Farewell V, Su J, Romero-Diaz J, Bae S-C, Fortin P, Sanchez-Guerrero J, Clarke A, Bernatsky S, Gordon C, Hanly J, Wallace D, Isenberg D, Rahman A, Merrill JT, Ginzler E, Alarcón G, Chatham WW, **Petri M**, Bruce I, Khamashta M, Aranow C, Dooley MA, Manzi S, Ramsey-Goldman R, Nived O, Jonsen A, Steinsson K, Zoma A, Ruiz-Irastorza, Lim S, Kalunian K, Inanc M, van Vollenhoven R, Ramos-Casals M, Kamen DL, Jacobsen S, Peschken C, Askanase A, Stoll T. Accrual of atherosclerotic vascular events in a multicentre inception SLE cohort. *Arthritis Rheumatol* 72: 1734-1740, 2020 [Epub June 9, 2020; doi.org/10.1002/art.41392].
523. Barber MRW, Hanly JG, Su L, Urowitz MB, Pierre YS, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, **Petri M**, Bruce IN, Dooley MA, Fortin PR, Gladman DD, Sanchez-Guerrero J, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Mackay M, Alarcón GS, Manzi S, Nived O, Jönsen A, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Sam Lim S, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Farewell V, Stoll T, Buyon J, Clarke AE. Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. *Arthritis Care Res* 72:1800-1808, 2020 [Epub Oct 14, 2019; doi.org/10.1002/acr.24092].
524. Hair PS, Goldman D, Li J, **Petri M**, Cunnion KM. Classical complement activation on human erythrocytes in subjects with Systemic Lupus Erythematosus (SLE) and a history of Autoimmune Hemolytic Anemia (AIHA). *Lupus* 29:1179–1188, 2020. [Epub July 12, 2020; doi.org/10.1177/0961203320936347]

525. **Petri M**, Avci M, Magder LS. Evaluation of different ways to identify persistent positivity of lupus anticoagulant in systemic lupus erythematosus. *Lupus Sci Med* 7:e000406, 2020. [doi:10.1136/lupus-2020-000406].
526. Khawaja M, Magder L, Goldman D, **Petri M**. Loss of antiphospholipid antibody positivity post thrombosis in secondary antiphospholipid syndrome: implications on stopping anticoagulation. *Lupus Sci Med* 7:e000423, 2020. [doi: 10.1136/lupus-2020-000423]
527. Sevim E, Zisa D, Andrade D, Sciascia S, Pengo V, Tektonidou MG, Ugarte A, Gerosa M, Belmont HM, Zamorano MAA, Fortin P, Ji L, Efthymou M, Cohen H, Branch DW, de Jesus GR, Nalli C, **Petri M**, Rodriguez E, Cervera R, Knight JS, Atsumi T, Willis R, Roubey R, Bertolaccini ML, Erkan D, Barbhaiy M, on behalf of APS ACTION Investigators. Characteristics of Antiphospholipid Antibody Positive Patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking. *Arthritis Care Res*, 2020 [Epub September 28, 2020: doi: 10.1002/acr.24468]
528. Legge A, Kirkland S, Rockwood K, Andreou P, Bae S-C, Gordon C, Romero-Díaz J, Sanchez-Guerrero J, Wallace D, Bernatsky S, Clarke A, Merrill JT, Ginzler E, Fortin P, Gladman D, Urowitz MB, Bruce I, Isenberg D, Rahman A, Alarcón G, **Petri M**, Khamashta M, Dooley MA, Ramsey-Goldman R, Manzi S, Aranow C, Mackay M, Ruiz-Irastorza G, Lim SS, Inanc M, van Vollenhoven R, Jönsen A, Nived O, Ramos-Casals M, Kamen D, Kalunian K, Jacobsen S, Peschken C, Askanase A, Hanly J. Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI). *Arthritis Care Res* 74:638-647, 2022. [Epub November 5, 2020: doi: 10.1002/acr.24504]
529. Vanarsa K, Soomro S, Strachan BC, Pedroza C, Zhang T, Nidhi M, Cicalese P, Gidley C, Dasari S, Mohan S, Thai N, **Petri M**, Mohan C. Quantitative planar array screens of 1000 proteins uncovers novel urinary protein biomarkers of lupus nephritis. *Ann Rheum Dis* 79:1349-1361, 2020. [doi: 10.1136/annrheumdis-2019-216312. Epub 2020 Jul 10]
530. Yip TC-F, Saria S, **Petri M**, Magder LS. Predictors of the start of declining eGFR in patients with systemic lupus erythematosus. *Lupus* 30:15-24, 2021. [Epub October 28, 2020; doi: 10.1177/0961203320966393]
531. Kallas R, Li J, **Petri M**. Predictors of osteonecrosis in systemic lupus erythematosus: A prospective cohort study. *Arthritis Care Res* 74:1122-1132, 2022. [Epub December 20, 2020: doi: 10.1002/acr.24541]
532. Chew C, Reynolds JA, Lertratanakul A, Wu P, Urowitz M, Gladman DD, Fortin PR, Bae SC, Gordon C, Clarke AE, Bernatsky S, Hanly JG, Isenberg D, Rahman A, Sanchez-Guerrero J, Romero-Diaz J, Merrill J, Wallace D, Ginzler E, Khamashta M, Nived O, Jönsen A, Steinsson K, Manzi S, Kalunian K, Dooley MA, **Petri M**, Aranow C, van Vollenhoven R, Stoll T, Alarcón GS, Lim SS, Ruiz-Irastorza G, Peschken CA, Askanase AD, Kamen DL, İnanc M, Ramsey-Goldman R, Bruce IN. Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort. *Rheumatology (Oxford)*. 8:keab090, 2021. [Epub February 8, 2021, doi: 10.1093/rheumatology/keab090]
533. Stojan G, Li J, Kane M, **Petri M**. Intracellular homocysteine metabolites in SLE: plasma S-adenosylhomocysteine correlates with coronary plaque burden. *Lupus Sci Med*, 8(1):e000453, 2021. [doi: 10.1136/lupus-2020-000453].
534. **Petri M**, Konig MF, Li J, Goldman DW. Higher hydroxychloroquine blood levels are associated with reduced thrombosis risk in systemic lupus erythematosus. *Arthritis Rheumatol* 73:997-1004, 2021. [Epub Jan 5 2021; doi: 10.1002/art.41621].
535. Lopez-Dominguez R, Toro-Dominguez D, Martorell-Marugan J, Garcia-Moreno A, Holland C, Saez-Rodriguez J, Goldman D, **Petri M**, Alarcon-Riquelme M, Carmona-Sáez P. Transcription Factor Activity Inference in Systemic Lupus Erythematosus. *Life* 11(4):299, 2021. [https://doi.org/10.3390/life11040299].
536. Stojan G, Giammarino F, **Petri M**. Systemic Lupus Erythematosus and Geomagnetic Disturbances: A Time Series Analysis. *Environmental Health*, 20(1):28, 2021. [doi: 10.1186/s12940-021-00692-4].
537. Fitzgerald KC, Mecoli CA, Douglas M, Harris S, Aravidis B, Albayda J, Sotirchos ES, Hoke A, Orbai AM, Petri M, Christopher-Stine L, Baer AN, Paik JJ, Adler BL, Tiniakou E, Timlin H, Bhargava P, Newsome SD, Venkatesan A, Chaudhry V, Lloyd TE, Pardo CA, Stern BJ, Lazarev M, Truta B, Saidha S, Chen ES, Sharp M, Gilotra N, Kasper EK, Gelber AC, Bingham CO, Shah AA, Mowry EM. Risk factors for infection and health impacts of the COVID-19 pandemic in people with autoimmune diseases. *medRxiv*. 2021 [Epub Feb 5, 2021: doi: 10.1101/2021.02.03.21251069]

538. **Petri M**, Goldman DW, Alarcón GS, Gordon C, Merrill J, Fortin PR, Bruce IN, Isenberg D, Wallace D, Nived O, Ramsey-Goldman R, Bae S-C, Hanly JG, Sanchez-Guerrero J, Clarke AE, Aranow C, Manzi S, Urowitz M, Gladman DD, Kalunian K, Werth VP, Zoma A, Bernatsky S, Khamashta M, Jacobsen S, Buyon J, Dooley MA, van Vollenhoven R, Ginzler E, Stoll T, Peschken C, Jorizzo JL, Callen JP, Lim S, Inanc M, Kamen DL, Rahman A, Steinsson K, Franks Jr AG, Magder LS. A Comparison of 2019 EULAR/ACR SLE Criteria with Two Sets of Earlier SLE Classification Criteria. *Arthritis Care Res* 73:1231-1235, 2021. [Epub 2020 May 20. doi: 10.1002/acr.24263]
539. Gkrouzman E, Sevim E, Finik J, Andrade D, Pengo V, Sciascia S, Tektonidou MG, Ugarte A, Gerosa M, Belmont HM, Pedrera RL, Ji L, Fortin P, Efthymiou M, de Jesus GR, Branch DW, Nalli C, **Petri M**, Rodriguez E, Cervera R, Knight J, Atsumi T, Willis, Bertolaccini ML, Cohen H, Rand J, Erkan D, on Behalf of APS ACTION. Antiphospholipid antibody profile stability over time: prospective results from APS ACTION clinical database and repository. *J Rheumatol* 48:541-547, 2021. [Epub February 1, 2021: doi: 10.3899/jrheum.200513]
540. Demir S, Li J, Magder LS, **Petri M**. Antiphospholipid patterns predict risk of thrombosis in systemic lupus erythematosus. *Rheumatology* 60:3770-3777, 2021. [Epub December 20, 2020: doi: 10.1093/rheumatology/keaa857].
541. **Petri M**, Watts S, Higgs R, Linnik M. Sub-Setting Systemic Lupus Erythematosus by Combined Molecular Phenotypes Defines Divergent Populations in Two Phase III Randomized Trials. *Rheumatology* 60:5390-5396, 2021. [Epub Feb 12 2021; doi: 10.1093/rheumatology/keab144]
542. Shah AA, Igusa T, Goldman D, Li J, Casciola-Rosen L, Rosen A, **Petri M**. Association of systemic lupus erythematosus autoantibody diversity with breast cancer protection. *Arthritis Res Ther* 23(1):64, 2021. [doi: 10.1186/s13075-021-02449-3].
543. Hill D, Eudy A, Egger P, Fu Q, **Petri M**. Impact of systemic lupus erythematosus disease activity, hydroxychloroquine and NSAID on the risk of subsequent organ system damage and death: Analysis in a single United States medical center. *Lupus Sci Med* 8:e000446. [Epub April 8, 2021: doi:10.1136/lupus-2020-000446]
544. Sadras V, **Petri M**, Jones SR, Peterlin L, Chatterjee S. Glycosphingolipid-associated β -1,4 galactosyltransferase is elevated in patients with systemic lupus erythematosus. *Lupus Sci Med* 7(1), 2020. [Epub July 2020; doi: 10.1136/lupus-2019-000368].
545. Catalina MD, Bachali P, Yeo AE, Geraci NS, **Petri MA**, Grammer AC, Lipsky, PE. Patient ancestry significantly contributes to molecular heterogeneity of systemic lupus erythematosus. *JCI Insights* 5(15), 2020. Epub Aug 6 2020; doi: 10.1172/jci.insight.140380]
546. Durcan L, **Petri M**. The clinical and serological associations of hypocomplementemia in a longitudinal SLE cohort. *Sem Arthritis Rheum* 50:1081-1086, 2020. [doi: 10.1016/j.semarthrit.2020.06.009. Epub 2020 Jun 30]
547. Kallas R, Goldman D, **Petri M**. Cutaneous vasculitis in systemic lupus erythematosus. *Lupus Sci Med* 7(1), 2020 [Epub Sep 2020; doi: 10.1136/lupus-2020-000411].
548. Stojan G, Li J, Budoff M, Arbab-Zadeh A, **Petri M**. High Risk Coronary Plaque in SLE: Low Attenuation Non-Calcified Coronary Plaque and Positive Remodeling Index. *Lupus Sci Med* 7(1), 2020. [Epub July 2020; doi: 10.1136/lupus-2020-000409]
549. Stojan G, Li J, **Petri M**. Cachexia in systemic lupus erythematosus: risk factors and relation to disease activity and damage. *Arthritis Care Res* 73:1577-1582, 2021. [Epub August 2, 2020; doi: 10.1002/acr.24395]
550. Bernatsky S, Ramsey-Goldman R, Urowitz MB, Hanly JG, Gordon C, **Petri MA**, Ginzler EM, Wallace DJ, Bae SC, Romero-Diaz J, Dooley MA, Peschken CA, Isenberg DA, Rahman A, Manzi S, Jacobsen S, Lim SS, van Vollenhoven R, Nived O, Kamen DL, Aranow C, Ruiz-Irastorza G, Sanchez-Guerrero J, Gladman DD, Fortin PR, Alarcón GS, Merrill JT, Kalunian KC, Ramos-Casals M, Steinsson K, Zoma A, Askanase A, Khamashta MA, Bruce I, Inanc M, Clarke AE. Cancer risk in a large inception SLE cohort: Effects of demographics, smoking, and medications. *Arthritis Care Res* 73:1789-1795, 2021. [Epub Aug 19, 2020; doi: 10.1002/acr.24425]
551. Dorner T, Tanaka Y, **Petri M**, Smolen JS, Wallace DJ, Dow ER, Fantini D, Higgs RE, Rocha G, Crowe B, Benschop RJ, Abel AG, Byers NL, Silk ME, de Bono S, Hoffman RW. Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathway. *Lupus Sci Med* 7(1), 2020. [Epub October 2020; doi: 10.1136/lupus-2020-000424]
552. Elkhalfifa M, Orbai A-M, Magder LS, **Petri M** and SLICC. Anti-beta 2 Glycoprotein 1 IgA in the SLICC Classification Criteria Dataset. *Lupus* 30:1283-1288, 2021 [Epub May 6 2021; doi: 10.1177/09612033211014248].

553. Hanly JG, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Clarke A, Wallace DJ, Isenberg D, Rahman A, Merrill JT, Fortin P, Gladman D, Urowitz MB, Bruce I, **Petri M**, Ginzler E, Dooley MA, Ramsey-Goldman R, Manzi S, Jönson A, Alarcon GS, Van Vollenhoven R, Aranow C, McKay M, Ruiz-Irastorza, Lim S, Inanc M, Kalunian K, Jacobsen S, Peschken CA, Kamen DL, Askanase A, Farewell V. Neuropsychiatric events in systemic lupus erythematosus: predictors of occurrence and resolution in a longitudinal analysis of an international inception cohort. *Arthritis Rheum* 73: 2293-2302, 2021. [Epub May 27, 2021. doi.org/10.1002/art.41876]
554. Wang X, Gkrouzman E, Andrade DCO, Andreoli L, Barbhैया M, Belmont HM, Branch DW, de Jesús GR, Efthymiou M, Ríos-Garcés R, Gerosa M, El Hasbani G, Knight J, Meroni PL, Pazzola G, **Petri M**, Rand J, Salmon J, Tektonidou M, Tincani A, Uthman IW, Zuily S, Zuo Y, Lockshin M, Cohen H, Erkan D, on Behalf of APS ACTION. COVID-19 and antiphospholipid antibodies: A position statement and management guidance from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION). *Lupus*. December 2021. [Epub Dec 16, 2021; doi:10.1177/09612033211062523]
555. Sevim E, Zisa D, Andrade D, Sciascia S, Pengo V, Tektonidou MG, Ugarte A, Gerosa M, Belmont HM, Zamorano MAA, Fortin PR, Ji L, Efthymiou M, Cohen H, Branch DW, de Jesus GR, Andreoli L, **Petri M**, Rodriguez E, Cervera R, Knight JS, Atsumi T, Willis R, Roubey R, Bertolaccini ML, Erkan D, Barbhैया M, APS ACTION Investigators. Characteristics of Patients With Antiphospholipid Antibody Positivity in the APS ACTION International Clinical Database and Repository. *Arthritis Care Res* 74:324-335, 2022. [doi: 10.1002/acr.24468]
556. Monaco DR, Kottapalli S, Breitwieser FP, Anderson DE, Wijaya L, Tan K, Chia WN, Kammers K, Caturegli M, Waugh K, Roederer M, **Petri M**, Goldman DW, Rewers M, Wang LF, Larman HB. Deconvoluting virome-wide antibody epitope reactivity profiles. *EBioMedicine* 75:103747, 2021. [doi.org/10.1016/j.ebiom.2021.103747]
557. Ugarte-Gil MF, Mak A, Leong JW-Y, Dharmadhikari B, Kow NY, Reategui-Sokolova C, Elera-Fitzcarrald C, Aranow C, Arnaud L, Askanase A, Bae S-C, Bernatsky S, Bruce IN, Buyon JP, Costedoat-Chalumeau N, Dooley MA, Fortin PR, Ginzler EM, Gladman DD, Hanly JG, Inanc M, Isenberg D, Jacobsen S, James JA, Jonsen A, Kalunian K, Kamen DL, Lim S, Morand E, Mosca M, Peschken CA, Pons-Estel BA, Rahman A, Ramsey-Goldman R, Reynolds JA, Romero-Diaz J, Ruiz-Irastorza G, Sanchez-Guerrero J, Svenungsson E, Urowitz MB, Vinet E, van Vollenhoven RF, Voskuyl A, Wallace DJ, **Petri M**, Manzi S, Clarke AE, W.-L.-Cheung M, Farewell V, Alarcón GS. Impact of glucocorticoids on the incidence of lupus-related major organ damage – a systematic literature review and meta-regression analysis of longitudinal observational studies. *Lupus Sci Med* 8:e000590, 2021. [Epub December 20, 2021; doi:10.1136/lupus-2021-000590]
558. Deonaraine KK, Carlucci PM, Fava A, Li J, Wofsy D, James JA, Putterman C, Diamond B, Davidson A, Fine D, Monroy-Trujillo J, Atta M, Haag K, Apruzzese W, Belmont HM, Izmirly PM, Wu, Connery S, Payan-Schober F, Furie R, Berthier C, Dall’Era M, Cho K, Kamen D, Kalunian K, Anolik J, Weisman M, the Accelerating Medicines Partnership in SLE network, **Petri M**, Buyon JP. Safety of Procuring Research Tissue During a Clinically Indicated Kidney Biopsy from Lupus Patients: Data from the Lupus Accelerating Medicines Partnership. *Lupus Sci Med* 8:e000522, 2021. [Epub Aug 2021; doi:10.1136/lupus-2021-000522]
559. Antiochos B, Paz M, Li J, Goldman D, **Petri M**, Darrach E, Cashman K, Sanz I, Burns K, Ardeljan D, Andrade F, Rosen A. Autoantibodies targeting LINE-1-encoded ORF1p are associated with SLE diagnosis but not disease activity. *Clin Exp Rheumatol* 40:1636-1641, 2022. [Epub 2021 Oct 13. doi:10.55563/clinexprheumatol/bfz387]
560. Fava A, Fenaroli P, Rosenberg A, Bagnasco S, Li J, Monroy-Trujillo J, Fine D, Atta MG, **Petri M**. History of proliferative glomerulonephritis predicts end stage kidney disease in pure membranous lupus nephritis. *Rheumatology* 61:2483–2493, 2022. [Epub 2021 Oct 19; doi: 10.1093/rheumatology/keab775]
561. The DORIS Task Force: van Vollenhoven R, Bertsias G, Doria A, Isenberg D, Morand E, **Petri M**, Pons-Estel B, Rahman A, Ugarte-Gil M, Voskuyl A, Arnaud L, Bruce I, Cervera R, Costedoat-Chalumeau N, Gordon C, Houssiau F, Mosca M, Schneider M, Ward M, Alarcon G, Aringer M, Askanase A, Bae S-C, Bootsma H, Boumpas D, Brunner H, Clarke A, Coney C, Czirkjak L, Dörner T, Faria R, Fischer-Betz R, Fritsch R, Ginzler E, Goldman D, Graninger W, Le Guern V, Hak L, Inanc M, Jacobsen S, Jayne D, Khamashta M, Kuhn A, van Leeuw B, Limper M, Ribeiro FM, Mariette X, Navarra S, Neumann I, Nikpour M, Olesinska M, Pons-Estel G, Rekvig O, Romero-Diaz J, Rovensky J, Rubio B, Saccon F, Shoenfeld Y, Dutra ES, Smolen J, Teng O, Tincani A, Tsang-A-Sjoe M, Urowitz M, Vasconcelos C, Voss A, Werth V, Zakhárova H, Zoma A, Aranow C. The 2021 DORIS Definition Of Remission In Systemic Lupus Erythematosus – Final recommendations from an international task force. *Lupus Sci Med* 8:e000538, 2021. [Epub Nov 2021; doi: 10.1136/lupus-2021-000538]

562. Almeida-Brasil CC, Hanly JG, Urowitz MB, Clarke AE, Ruiz-Irastorza G, Gordon C, Ramsey-Goldman R, **Petri MA**, Ginzler EM, Wallace DJ, Bae SC, Romero-Diaz J, Dooley MA, Peschken CA, Isenberg DA, Rahman A, Manzi S, Jacobsen S, Lim SS, van Vollenhoven R, Nived O, Jönsen A, Kamen DL, Aranow C, Sanchez-Guerrero J, Gladman DD, Fortin PR, Alarcón GS, Merrill JT, Kalunian KC, Ramos-Casals M, Steinsson K, Zoma A, Askanase A, Khamashta MA, Bruce I, Inanc M, Abrahamowicz M, Bernatsky S. Flares after hydroxychloroquine reduction or discontinuation: Results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. *Annals Rheum Dis* 81:370-378, 2022. [Epub Dec 15, 2021; doi:10.1136/annrheumdis-2021-221295]
563. Chalmers SA, Ramachandran RA, Garcia S, Der E, Herlitz L, Ampudia J, Chu D, Zhang T, Parodis I, Ding H, Shen N, **Petri M**, Mok CC, Saxena R, Polu K, Connelly S, Ng CT, Mohan C, Putterman C. The CD6-ALCAM pathway promotes lupus nephritis via T cell mediated responses. *J Clin Invest* 132:e147334, 2022. [doi: 10.1172/JCI147334]
564. Fava A, Rao DA, Mohan C, Zhang T, Rosenberg A, Fenaroli P, Belmont HM, Izmirly P, Clancy R, Trujillo JM, Fine D, Arazi A, Berthier CC, Davidson A, James JA, Diamond B, Hacoheh N, Wofsy D, Rayhaudhuri S, Apruzzese W, the AMP in RA/SLE network, Buyon J, **Petri M**. Urine proteomics and renal single-cell transcriptomics implicate interleukin-16 in lupus nephritis. *Arthritis Rheum* 74:829-839, 2022 [Epub November 16, 2021; doi:10.1002/art.42023].
565. Weeding E, Fava A, Magder L, Goldman D, **Petri M**. One Third of Lupus Nephritis Patients Classified as Complete Responders Continue to Accrue Progressive Renal Damage Despite Resolution of Proteinuria. *Lupus Sci Med* 9:e000684, 2022. [doi:10.1136/lupus-2022-000684]
566. Soomro S, Stanley S, Lei R, Saxena R, Petri M and Mohan C. Comprehensive Urinomic Identification of Protein Alternatives to Creatinine Normalization for Diagnostic Assessment of Lupus Nephritis. *Front. Immunol.* 13:853778, 2022. [Epub, 14 June 2022; doi: 10.3389/fimmu.2022.853778]
567. Johnson S, Gladman D, Brunner H, Isenberg D, Clarke A, Barber M, Arnaud L, Fortin P, Mosca M, Voskuyl A, Manzi S, Aranow C, Askanase A, Alarcón G, Bae S-C, Costedoat-Chalumeau N, English J, Pons-Estel G, Pons-estel B, Gilman R, Ginzler E, Hanly J, Jacobsen S, Kalunian K, Kamen D, Lambalgen C, Legge A, Lim SS, Mak A, Morand E, Peschken C, **Petri M**, Rahman A, Ramsey-Goldman R, Reynolds J, Romero-Díaz J, Ruiz-Irastorza G, Sanchez-Guerrero J, Svenungsson E, Touma Z, Urowitz MB, Vinet E, van Vollenhoven R, Waldhauser H, Wallace D, Zoma A, Bruce I. Evaluating the construct of damage in systemic lupus erythematosus. *Arthritis Care Res* 75: 998-1006, 2023 [Epub Dec 28 2021; doi: 10.1002/acr.24849].
568. Carlucci PM, Fava A, Deonaraine K, Li J, DeJanger W, Wofsy D, James JA, Putterman C, Diamond B, Fine D, Monroy-Trujillo J, Haag K, Apruzzese W, Belmont HM, Izmirly P, Connery S, Payan-Schober F, Furie R, Berthier C, Dall’Era M, Cho K, Kamen D, Kalunian K, the Accelerating Medicines Partnership in SLE network, **Petri M**, Buyon JP. High incidence of proliferative and membranous nephritis in SLE patients with low proteinuria in the Accelerating Medicines Partnership. *Rheumatology*, 2022. [Epub Feb 25 2022; doi: 10.1093/rheumatology/keac067]
569. Clowse MEB, Eudy AM, Balevic S, Sanders-Schmidler G, Fischer-Betz R, Gladman D, Molad Y, Nalli C, Nabil A, Tincani A, Urowitz M, Bay C, van Noord M, **Petri M**. Hydroxychloroquine in the pregnancies of women with a history of lupus nephritis: A meta-analysis of individual participant data. *Lupus Sci Med.* 9:e000651, 2022. [doi: 10.1136/lupus-2021-000651]
570. Tiniakou E, Goldman DW, Corse A, **Petri M**, Mammen AL. Clinical and Histopathologic Features of Myositis in Systemic Lupus Erythematosus. *Lupus Sci Med* 9(1):e000635, 2022. [doi: 10.1136/lupus-2021-000635]
571. Choi MY, Clarke AE, St. Pierre Y, Hanly JG, Urowitz MB, Romero-Diaz J, Gordon C, Bae S-C, Bernatsky S, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, **Petri M**, Bruce IN, Dooley MA, Fortin P, Gladman DD, Sanchez-Guerrero J, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Alarcón GS, Manzi S, Nived O, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Stoll T, Buyon J, Mahler M, Fritzler MJ. Longitudinal Analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. *Ann Rheum Dis* 81(8):1143-1150, 2022. [Epub March 25 2022; doi: 10.1136/annrheumdis-2022-222168]
572. Bello N, Birt J, Workman J, Zhou X, Ross-Torres J, **Petri M**. Treatment patterns and clinical characteristics of systemic lupus erythematosus patients with musculoskeletal symptoms: A retrospective, observational study. *Adv Ther*, 2022, <https://doi.org/10.1007/s12325-022-02148-8>. [Epub May 9, 2022]

573. Piga M, Chessa E, Morand E, Ugarte-Gil M, Tektonidou M, Van Vollenhoven R, **Petri M**, Arnaud L, for the PISCOS Investigator Group. International Expert Consensus for the Standardization of the Physician Global Assessment (PGA) in Systemic Lupus Erythematosus: the PISCOS study. *Lancet Rheumatology* 4:e441-e449, 2022. [Epub May 4, 2022; [https://doi.org/10.1016/S2665-9913\(22\)00107-2](https://doi.org/10.1016/S2665-9913(22)00107-2)]
574. Antiochos B, Fenaroli P, Rosenberg A, Baer A, Sohn J, Li J, **Petri M**, Goldman D, Mercoli C, Casciola-Rosen L, Rosen A. The DNA sensors AIM2 and IFI16 are NET-binding SLE autoantigens. *eLife* 11:e72103, 2022. [Epub May 22, 2022; <https://doi.org/10.7554/eLife.72103>]
575. Erton ZB, Sevim E, de Jesus GR, Cervera R, Ji L, Pengo V, Ugarte A, Andrade D, Andreoli L, Atsumi T, Fortin PR, Gerosa M, Zuo Y, **Petri M**, Sciascia S, Tektonidou MG, Aguirre- Zamorano MA, Branch DW, Erkan D, on behalf of APS ACTION. Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (‘Registry’). *Lupus Sci Med* 2022 9: p. e000633. [doi: 10.1136/lupus-2021-000633]
576. Connolly CM, Li J, Goldman DW, Fava A, Magder L, **Petri M**. Lipoprotein(a) in systemic lupus erythematosus is associated with history of proteinuria and reduced renal function. *Lupus* 31:1367-1372, 2022. [Epub July 2022, doi:10.1177/09612033221111958]
577. Kallas R, Li J, Goldman DW, **Petri M**. Trajectory of Damage Accrual in Systemic Lupus Erythematosus based on Ethnicity, Socioeconomic Factors and Comorbidities. *J Rheumatol* 49;1229-1235, 2022. [Epub August 1, 2022; doi: 10.3899/jrheum.211135].
578. Gomez-Bañuelos E, Wahadat MJ, Li J, Paz M, Darrah E, Goldman D, **Petri M**, Andrade F. Alternative exon usage in TRIM21 determines the antigenicity of Ro52/TRIM21 in systemic lupus erythematosus. *JCI Insight* 7(19):e163795, 2022. [Epub August 30, 2022; doi:/10.1172/jci.insight.163795]
579. Cooper-Blenkinsopp S, Fu Q, Green Y, Madan A, Juliao P, Goldman DW, Roth DA, **Petri M**. Renal Response at 2 years Post Biopsy to Predict Long-term Renal Survival in Lupus Nephritis: a Retrospective Analysis of the Hopkins Lupus Cohort. *Lupus Sci Med* 9:e000598, 2022. [doi: 10.1136/lupus-2021-000598].
580. Juliao P, Wurst K, Pimenta JM, Gemzoe K, Landy H, Moody MA, Tilson H, Covington D, Moore T, Marino R, Gilbride J, Liu A, Meizlik P, **Petri M**. Belimumab use during pregnancy: Interim results of the Belimumab Pregnancy Registry. *Birth Defects Res.* 2022. [Epub Sep 30 2020. doi: 10.1002/bdr2.2091]
581. Dörner T, Tanaka Y, Dow ER, Koch AE, Silk ME, Ross Terres JA, Sims JT, Sun Z, De La Torre I, **Petri M**. Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus. *Ann Rheum Dis* 81(9):1267-72, 2022. [doi: 10.1136/annrheumdis-2022-222335]
582. Jonsson AH, Zhang F, Dunlap G, Gomez-Rivas E, Watts GFM, Faust HJ, Rupani KV, Mears JR, Meednu N, Wang R, Keras G, Coblyn JS, Massarotti EM, Todd DJ, Anolik JH, McDavid A; **Accelerating Medicines Partnership RA/SLE Network**; Wei K, Rao DA, Raychaudhuri S, Michael B Brenner MB. Granzyme K+ CD8 T cells form a core population in inflamed human tissue. *Sci Transl Med.* 14(649):eabo0686, 2022. [Epub 2022 Jun 15; doi: 10.1126/scitranslmed.abo0686]
583. Wang S, Spielman A, Ginsberg M, **Petri M**, Rovin BH, Buyon J, Broder A. Short- and Long-Term Progression of Kidney Involvement in Systemic Lupus Erythematosus Patients with Low-Grade Proteinuria. *Clin J Amer Soc Nephrology (CJASN)* 17(8):1150-1158, 2022. [doi: 10.2215/CJN.01280122. Epub 2022 Jul 26]
584. Costa Reis P, Maurer K, **Petri MA**, Erez DL, Zhao X, Faig W, Burnham JM, O’Neil K, Klein-Gitelman M, von Scheven E, Schanberg LE, Sullivan K. Urinary HER2, TWEAK, and VCAM-1 Levels are Associated with New-Onset Proteinuria in Pediatric Lupus Nephritis. *Lupus Sci Med* 9(1):e000719, 2022. [doi: 10.1136/lupus-2022-000719]
585. Toro-Dominguez D, Martinez-Bueno M, Lopez-Dominguez R, Martorell-Marugan J, Carnero-Montoro E, Barturen G, Goldman D, **Petri M**, Carmona-Saez P, Alarcon-Riquelme ME. Scoring personalized molecular portraits identifies systemic lupus erythematosus subtypes and predict drug responses, symptomatology and disease progression. *Brief Bioinform* 23(5):bbac332, 2022. [doi: 10.1093/bib/bbac332]

586. Ugarte-Gil MF, Hanly J, Urowitz M, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Clarke AE, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, Fortin PR, Gladman DD, Bruce IN, **Petri M**, Ginzler EM, Dooley MA, Ramsey-Goldman R, Manzi S, Jönsen A, van Vollenhoven RF, Aranow C, Mackay M, Ruiz-Irastorza G, Lim S, Inanc M, Kalunian K, Jacobsen S, Peschken C, Kamen DL, Askanase A, Pons-Estel BA, Alarcón GS. Remission and Low Disease Activity (LDA) Prevent Damage Accrual in Systemic Lupus Erythematosus Patients. Results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. *Ann Rheumatic Dis* 81:1541-1548, 2022. [doi: 10.1136/ard-2022-222487. Epub 2022 Aug 9].
587. **Petri M**, Landy H, Clowse MEB, Gemzoe K, Khamashta M, Kurtinecz M, Levy RA, Liu A, Marino R, Meizlik P, Pimenta JM, Sumner K, Tilson H, Connolly MB, Wurst K, Harris J, Quasny H, Juliao P, Roth DA. Belimumab use during pregnancy: A summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry, and postmarketing reports. *Ann Rheum Dis* annrheumdis-2022-222505, 2022. [Epub Oct 5 2022; doi: 10.1136/ard-2022-222505]
588. Weeding E, Fava A, Mohan C, Magder L, Goldman DW, **Petri M**. Urine Proteomic Insights from the Belimumab in Lupus Nephritis Trial. *Lupus Sci Med* 9:e000763, 2022. [doi: 10.1136/lupus-2022-000763]
589. Lucas A, Eudy AM, Gladman D, **Petri M**, Urowitz M, Wyatt CM, Clowse ME. The association of lupus nephritis with adverse pregnancy outcomes among women with lupus in North America. *Lupus* 31:1401-1407, 2022. [doi: 10.1177/09612033221123251. Epub 2022 Aug 26]
590. Erton ZB, Leaf RK, Andrade D, Clarke AE, Tektonidou MG, Pengo V, Sciascia S, Ugarte A, Belmont HM, Gerosa M, Fortin PR, Lopez-Pedraza C, Atsumi T, Zhang Z, Cohen H, deJesus GR, Branch DW, Wahl D, Andreoli L, Rodriguez-Almaraz E, **Petri M**, Barilaro G, Zuo Y, Artim-Esen b, Willis R, Quintana R, Vendramini MBG, Barber MW, Bertolaccini ML, Roubey R, Erkan D. Immunosuppression use in primary antiphospholipid antibody-positive patients: Descriptive analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (Registry). *Lupus* 31:1770-1776, 2022. [doi: 10.1177/09612033221128742]
591. Cardwell FS, Elliott SJ, Chin R, St. Pierre Y, Choi MY, Urowitz MB, Ruiz-Irastorza G, Bernatsky S, Wallace DJ, **Petri M**, Manzi S, Bae S-C, Shin J-M, Mak A, Cho J, Peschken CA, Ramsey-Goldman R, Fortin PR, Hanly JG, Pons-Estel BA, Nieto R, Askanase A, Romero-Diaz J, Mosca M, Bruce IN, Rowbottom L, Mielczarek L, Tse K, Marion A, FELUPUS contact, ALUA contact, Cornet A, Clarke AE. Health information use by patients with systemic lupus erythematosus pre and during the COVID-19 pandemic. *Lupus Sci Med* 9:e000755, 2022. [doi: 10.1136/lupus-2022-000755].
592. Almeida-Brasil CC, Hanly J, Urowitz M, Clarke AE, Ruiz-Irastorza G, Gordon C, Ramsey-Goldman R, **Petri M**, Ginzler E, Wallace DJ, Bae S-C, Romero-Diaz J, Dooley M-A, Peschken C, Isenberg D, Rahman A, Manzi S, Jacobsen S, Lim SS, van Vollenhoven R, Nived O, Jönsen A, Kamen D, Aranow C, Gladman D, Fortin PR, Alarcon G, Merrill J, Kalunian K, Ramos-Casals M, Steinsson K, Zoma A, Askanase A, Khamashta M, Bruce I, Inanc M, Lukusa L, Bernatsky S. Retinal toxicity in a multinational inception cohort of systemic lupus patients on hydroxychloroquine. *Lupus Sci Med* 9:e000789, 2022. [doi: 10.1136/lupus-2022-000789]
593. Moore J, Lakshmanan S, Manubolu VS, Kinninger A, Stojan G, Budoff M, Goldman D, **Petri M**, Karpouzas GA. Coronary plaque progression is greater in systemic lupus erythematosus than rheumatoid arthritis. *Coronary Artery Dis* 34:52-58, 2023. [doi: 10.1097/MCA.0000000000001205. Epub 2022 Nov 24].
594. **Petri M**, Joyce D, Haag K, Fava A, Goldman DW, Zhong D, Shao S, Milstone AM, Magder LS. Effect of Systemic Lupus and Immunosuppressives on COVID Vaccination Antibody Response. *Arthritis Care Res* 75:1878–1885, 2023. [doi: 10.1002/acr.25094]
595. Clarke AE, Hanly JG, Urowitz MB, St. Pierre Y, Gordon C, Bae S-C, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, Fortin PR, Gladman DD, Bruce I, **Petri M**, Ginzler EM, Dooley MA, Ramsey-Goldman R, Manzi S, Jönsen A, Alarcón GS, van Vollenhoven R, Aranow C, Mackay M, Ruiz-Irastorza G, Lim SS, Inanc M, Kalunian KC, Jacobsen S, Peschken CA, Kamen DL, Askanase A, Farewell V. Assessing the Costs of Neuropsychiatric Disease in the Systemic Lupus International Collaborating Clinics (SLICC) Cohort using Multistate Modelling. *Arthritis Care Res* 75: 1859-1870, 2023. [Epub Feb 23, 2023; doi.org/10.1002/acr.25090].
596. Morand EF, Vital EM, **Petri M**, Van Vollenhoven R, Wallace DJ, Mosca M, Furie RA, Silk ME, Dickson CL, Meszaros G, Jia B, Crowe B, De La Torre I, Dorner T. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). *Lancet* 401:1001-1010, 2023. [Epub Feb 24, 2023; doi:10.1016/S0140-6736(22)02607-1]

597. **Petri M**, Bruce I, Dorner T, Tanaka Y, Morand EF, Kalunian KC, Cardiel M, Silk ME, Dickson CL, Meszaros G, Zhang L, Jia B, Zhao Y, McVeigh CJ, Mosca M. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II). *Lancet* 401:1011-1019, 2023. [Epub Feb 24, 2023; doi:10.1016/S0140-6736(22)02546-6]
598. Gartshteyn Y, Conklin J, **Petri MA**, Kyttaris VC, Goldman DW, Kammesheidt A, Askanase AD, Alexander RV. Role of platelet-bound C4d (PC4d) in predicting risk of future thrombotic events in systemic lupus erythematosus. *Arthritis Care Res* 75: 2088-2095, 2023. [Epub February 21, 2023; DOI: 10.1002/acr.25107]
599. Chighizola CB, Pregnotato F, Andrade D, Tektonidou M, Pengo V, Ruiz-Irastorza G, Belmont HM, Gerosa M, Fortin P, Branch DW, Andreoli L, **Petri MA**, Cervera R, Knight JS, Willis R, Efthymiou M, Cohen H, Erkan D, Bertolaccini ML, on behalf of AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking (APS ACTION). Fluctuation of anti-domain 1 and anti- β 2 glycoprotein I antibody titers over time in patients with persistently positive antiphospholipid antibodies. *Arthritis Rheumol* 75:984-995, 2023. [Epub Jan 27, 2023; doi.org/10.1002/art.42459]
600. Gkrouzman E, Willis R, Andrade D, Tektonidou MG, Pengo V, Ruiz-Irastorza G, Belmont HM, Fortin PR, Gerosa M, Signorelli F, Atsumi T, Branch DW, Nalli C, Rodriguez-Almaraz E, **Petri MA**, Cervera R, Knight JS, Efthymiou M, Cohen H, Bertolaccini ML, Erkan D, Roubey R, on Behalf of APS ACTION. Associations Among Antiphospholipid Antibody Types, Isotypes, and Titers: An APS ACTION Study. *Lab Invest*, 2023. [Epub April 11, 2023; doi.:10.1016/j.labinv.2023.100147]
601. Neupane B, Shukla P, Slim M, Martin A, **Petri M**, Bertsias GK, Kim AHJ, Fanouriakis A, Levy RA, Chauhan D, Ballew N. Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks. *Lupus Sci Med*, 10:e000907, 2023. [Epub May 2023; doi: 10.1136/lupus-2023-000907].
602. Zuo Y, Navaz S, Tsodikov A, Kmetova K, Kluge L, Hoy CK, Yalavarthi S, de Andrade D, Tektonidou MG, Sciascia S, Pengo V, Ugarte A, Belmont HM, Gerosa M, Fortin PR, de Jesus GR, Branch DW, Andreoli L, Rodriguez-Almaraz E, **Petri M**, Cervera R, Willis R, Karp DR, Li Q-Z, Cohen H, Bertolaccini ML, Erkan D, Knight JS, on Behalf of APS ACTION. Anti-neutrophil antibodies in antiphospholipid antibody-positive patients: Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository. *Arthritis Rheumatol* 75:1407-1414, 2023. [doi: 10.1002/art.42489]
603. Gomez-Bañuelos E, Yu Y, Li J, Cashman K, Paz M, Trejo-Zambrano MI, Bugrovsky R, Wang Y, Chida A, Sherman-Baust C, Ferris D, Goldman DW, Darrah E, **Petri M**, Sanz I, Andrade F. Pathogenic anti-dsDNA antibodies arise during affinity maturation of autoantibodies to DNase1L3 in systemic lupus erythematosus. *Nature Commun*, 14:1388, 2023. {doi: 10.1038/s41467-023-37083-x}.
604. Choi M, Chen I, Clarke AE, Fritsler MJ, Buhler KA, Urowitz M, Hanly J, St-Pierre Y, Gordon C, Bae S-C, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Wallace DJ, Isenberg DA, Rahman, Merrill JT, Fortin PR, Gladman DD, Bruce IN, **Petri M**, Ginzler EM, Dooley MA, Ramsey-Goldman R, Manzi S, Jönsen A, Alarcón GS, van Vollenhoven RF, Aranow C, Mackay M, Ruiz-Irastorza G, Lim S, Inanc M, Kalunian K, Jacobsen S, Peschken C, Kamen DL, Askanase A, Buyon JP, Sontag D, Costenbader KH. Machine Learning Identifies Clusters of Longitudinal Autoantibody Profiles Predictive of Systemic Lupus Erythematosus Disease Outcomes. *Ann Rheum Dis* 82:927-936, 2023. [doi: 10.1136/ard-2022-223808. Epub 2023 Apr 21]
605. Balbi GGM, Ahmadzadeh Y, Tektonidou MG, Pengo V, Sciascia S, Ugarte A, Belmont HM, Lopez-Pedraza C, Fortin PR, Wahl D, Gerosa M, de Jesús GR, Ji L, Atsumi T, Efthymiou M, Branch DW, Nalli C, Rodriguez E, **Petri M**, Cervera R, Knight JS, Artim-Esen B, Willis R, Bertolaccini ML, Cohen H, Roubey R, Erkan D, Andrade D for AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (APS ACTION). Damage Measured by DIAPS in Antiphospholipid Antibody-positive Patients Included in APS ACTION Registry. *Rheumatol*, 2023. [Epub June 12, 2023; doi: 10.1093/rheumatology/kead292]

606. Medha Barbhैया M, Zuily S, Naden R, Hendry A, Manneville F, Alessandro C, Amigo M-C, Zahir Amoura Z, Andrade D, Andreoli L, Artim-Esen B, Atsumi T, Avcin T, Belmont MH, Bertolaccini ML, Branch DW, Carvalheiras G, Cervera R, Cohen H, Costedoat-Chalumeau N, Crowther M, de Jesus G, Delluc A, Desai S, De Sancho M, Devreese KM, Diz-Kucukkaya R, Duarte A, Frances C, Garcia D, Gris J-C, Jordon N, Karp-Leaf R, Kello N, Knight J, Laskin C, Lee A, Legault K, Levine SR, Levy RA, Limper M, Lockshin MD, Mayer-Pickel K, Musial J, Meroni PL, Orsolini G, Ortel TL, Pengo V, **Petri M**, Pons-Estel G, Gomez Puerta JA, Raimboug Q, Roubey R, Sanna G, Seshan SV, Sciascia S, Tektonidou MG, Tincani A, Wahl D, Willis R, Yelnik C, Zuily C, Guillemain F, Costenbader K, Erkan D, on Behalf of the ACR/EULAR APS Classification Criteria Collaborators. The 2023 (ACR)/EULAR Antiphospholipid Syndrome Classification Criteria. *Arthritis Rheumatol* 75:1687-1702, 2023. [DOI: 10.1002/art.42624]
607. Nguyen Y, Blanchet B, Urowitz MB, Hanly JG, Gordon C, Bae S-C, Romero-Diaz J, Sanchez-Guerrero J, Clarke AE, Bernatsky S, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, Fortin PR, Gladman DD, Bruce I, **Petri M**, Ginzler EM, Dooley MA, Ramsey-Goldman R, Manzi S, Jönsen A, Alarcón GS, van Vollenhoven R, Aranow C, Le-Guern V, Mackay M, Ruiz-Irastorza G, Lim SS, Inanc M, Kalunian KC, Jacobsen S, Peschken CA, Kamen DL, Askanase A, Buyon J, Costedoat-Chalumeau N. Association between severe non-adherence to hydroxychloroquine and systemic lupus erythematosus flares, damage, and mortality in 660 patients from the SLICC Inception Cohort. *Arthritis Rheumatol* 75:2195-2206, 2023. [Epub July 17, 2023; doi: 10.1002/art.42645]
608. Lei R, Thai N, Li Y, **Petri M**, Mohan C. Analytical validation of urine ALCAM ELISA as a test for lupus nephritis. *Expert Rev Molec Diagnostics (IERO)* 23:729-738, 2023. [doi: 10.1080/14737159.2023.2236022]
609. Morand E, Smolen JS, **Petri M**, Tanaka Y, Silk ME, Dickson CL, Meszaros G, De La Torre I, Issa M, Zhang H, Dörner T. Safety profile of baricitinib in patients with systemic lupus erythematosus: An integrated analysis. *RMD Open*, 9:e003302, 2023. [doi:10.1136/rmdopen-2023-003302]
610. Shen Y, Vanarsa K, Yin Z, Zhang T, Castillo J, Dai M, Zou L, Qin L, Wang J, Guo Q, Saxena R, **Petri M**, Shen N, Ye Z, Mohan C, Ding H, Urine L-selectin reflects clinical and histological renal disease activity and treatment response in lupus nephritis across multi-ethnicity. *Front. Immunol.* 14:1200167, 2023. [doi:10.3389/fimmu.2023.1200167]
611. **Petri M**, Fang C, Goldman DW. East Asian Lupus Nephritis in the Hopkins Lupus Cohort. *Rheumatol Immunol Res* 4:157-161, 2023. [Epub September 27, 2023, doi:10.2478/rir-2023-0022]
612. Crawford J, Wang, H, Trejo-Zambrano D, Cimbri R, Talbot Jr CC, Thomas MS, Curran AM, Girgi AA, Schroeder JT, Fava A, Goldman DW, **Petri M**, Rosen A, Antiochos B, Darrah E. The XIST lncRNA is a sex-specific reservoir of TLR7 ligands in SLE. *JCI Insight* Sep 21:e169344, 2023. [doi: 10.1172/jci.insight.169344]
613. Magder LS, Fava A, Goldman D, **Petri M**. Does the use of corticosteroids and immunosuppressants increase the risk of COVID-19 infection among people with systemic lupus erythematosus? *Lupus Sci Med* 10(2):e000961, 2023. [doi: 10.1136/lupus-2023-000961]
614. Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, Boletis JN, Bruce I, Cervera R, Doria A, Dörner T, Furie R, Gladman DD, Houssiau F, Inês L, Jayne D, Kouloumas M, Kovacs L, Mok CC, Morand E, Moroni G, Mosca M, Mucke J, Mukhtyar CB, Nagy G, Navarra SV, Parodis I, Pego-Reigosa JM, **Petri M**, Pons-Estel BA, Schneider M, Smolen JS, Svenungsson E, Tanaka Y, Tektonidou MG, Teng YKO, Tincani A, Vital E, van Vollenhoven R, Wincup C, Bertsias G, Boumpas DT. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. *Ann Rheum Dis* 83:15-29, 2024. [Epub Oct 12, 2023; doi: 10.1136/ard-2023-224762]
615. Bao A, Petri M, Fava A, Kang J. A case series of anifrolumab for treatment of diverse lupus-related mucocutaneous manifestations in patients with systemic lupus erythematosus. *Lupus Sci Med* 19;10(2):e001007, 2023. [doi: 10.1136/lupus-2023-001007]
616. Fava A, Buyon J, Magder L, Hodgkin J, Rosenberg A, Demeke D, Rao D, Arazi A, Celia AI, Putterman C, Anolik J, Barnas J, Dall'Era M, Wofsy D, Furie R, Kamen D, Kalunian K, James J, Guthridge J, Atta M, Trujillo J, Fine D, Clancy R, Belmont H, Izmirly P, Apruzzese, Goldman D, Berthier C, Hoover P, Hachohen N, Raychaudhuri S, Davidson A, Diamond B, the Accelerating Medicines Partnership in RA/SLE network, **Petri M**. Urine proteomic signatures of histological class, activity, chronicity, and treatment response in lupus nephritis. *JCI Insight*. 2024;9(2):e172569. [https://doi.org/10.1172/jci.insight.172569].

617. Izmirly P, Kim M, Carlucci P, Preisinger K, Deonaraine K, Zaminski D, Dall'Era M, Kalunian K, Fava A, Belmont HM, Wu M, Putterman C, Anolik J, Diamond B, Davidson A, Wofsy D, Kamen D, James J, Apruzzese W, Rao D, Weisman M, The Accelerating Medicines Partnership in SLE Network, **Petri M**, Buyon J, Furie R. Longitudinal Patterns and Predictors of Response to Standard of Care Therapy in Lupus Nephritis: Data from the Accelerating Medicines Partnership Lupus Network. *Arthritis Res Therapy* 26(1):54, 2024. [doi:10.1186/s13075-024-03275-z].
618. Carlucci P, Preisinger K, Deonaraine K, Zaminski D, Dall'Era M, Gold H, Kalunian K, Fava A, Belmont HM, Wu M, Putterman C, Anolik J, Barnas JL, Furie R, Diamond B, Davidson A, Wofsy D, Kamen D, James J, Guthridge JM, Apruzzese W, Rao D, Weisman M, The Accelerating Medicines Partnership in SLE Network, Izmirly P, Buyon J, **Petri M**. Extrarenal symptoms associate with worse quality of life in patients enrolled in the AMP RA/SLE Lupus Nephritis Network. *Rheumatology* 26:keae189. [Epub Mar 2024; doi:10.1093/rheumatology/keae189].
619. Zhang T, Du Y, Wu Q, Li H, Gidley G, Nguyen T, Duran D, Goldman D, **Petri M**, Mohan C. Salivary anti-nuclear antibody (ANA) mirrors serum ANA in systemic lupus erythematosus. *Arthritis Res Ther* 24:3, 2022. [doi: 10.1186/s13075-021-02694-6]
620. Gómez-Bañuelos E, Goldman D, Andrade V, Darrah E, **Petri M**, Andrade F. Uncoupling interferons and the interferon signature explain clinical and transcriptional subsets in SLE. *Cell Reports Med* 5:101569, 2024. [doi: 10.1016/j.xcrm.2024.101569]
621. Jacobson R, Goldman DW, Fava A, Magder L, **Petri M**. Hydroxychloroquine improves low complement levels. *Arthritis Care Res* 76:1396-9 2024. [Epub June 3, 2024; <https://doi.org/10.1002/acr.25381>]
622. Stabach PR, Sims D, Gomez-Banuelos E, Zehentmeier S, Dammen-Brower K, Bernhisel A, Kujawski S, Lopez SG, **Petri M**, Goldman DW, Lester ER, Le Q, Ishaq T, Kim H, Srivastava S, Kumar D, Pereira JP, Yarema KH, Koumpouras F, Andrade F, Braddock DT. A dual-acting DNASE1/DNASE1L3 biologic prevents autoimmunity and death in genetic and induced lupus models. *JCI Insight* 9:e177003, 2024. [<https://doi.org/10.1172/jci.insight.177003>]
623. Krustev E, Hanly JG, Chin R, Buhler KA, Urowitz MB, Gordon C, Bae S-C, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, Fortin PR, Gladman DD, Bruce IN, **Petri M**, Ginzler EM, Dooley MA, Ramsey-Goldman R, Manzi S, Jönsen A, Alarcón GS, van Vollenhoven RF, Aranow C, Mackay M, Ruiz-Irastorza G, Lim S, Inanc M, Kalunian KC, Jacobsen S, Peschken CA, Kamen DL, Askanase A, Buyon J, Fritzler MJ, Clarke AE, Choi MY. Anti-KIF20B Autoantibodies are Associated with Cranial Neuropathy in Systemic Lupus Erythematosus. *Lupus*, in press, 2024.
624. Fava A, Wagner CA, Guthridge CJ, Kheir J, Macwana S, DeJager W, Gross T, Izmirly P, Diamond B, Davidson A, Utz PJ, Weisman MH, the Accelerating Medicines Partnership (AMP) RA/SLE Network, Guthridge JM, **Petri M**, Buyon J, James JA. Association of autoantibody concentrations and trajectories with lupus nephritis histological features and treatment response. *Arthritis Rheum* 76:1611-1622, 2024. [Epub July 29, 2024; doi: 10.1002/art.42941]
625. Bolla E, Semb AG, Kerola AM, Ikdahl E, Petri M, Pons-Estel GJ, Karpouzas GA, Sfrikakis PP, Quintana R, Misra DP, Borba EF, De La Torre IG, Popkova TV, Artim-Esen R, Troldborg A, Fragoso-Loyo H, Ajeganova S, Yazici A, Martinez GA, Direskeneli H, Ugarte-Gil MF, Mosca M, Goyal M, Svenungsson E, Macieira C, Hoi A, Lerang K, Costedoat-Chalumeau N, Tincani A, Mirrakhimov E, Colman IA, Danza A, Massardo L, Blagojevic J, Yilmaz N, Tegzová D, Yavuz S, Korkmaz C, Hachulla E, Alvarez MJM, Muñoz-Louis R, Pantazis N, Tektonidou MG. Prevalence and target attainment of traditional cardiovascular risk factors in 3401 patients with Systemic Lupus Erythematosus from 24 countries: a cross-sectional analysis of data from an international survey. *Lancet Rheumatol*, in press, 2024.
626. Barbhaiya M, Zuily S, Amigo M-C, Andrade D, Avcin T, Bertolaccini M, Branch DW, Costedoat-Chalumeau N, Crowther MA, de Jesús G, Devreese K, Camille Francès C, Garcia D, Gómez-Puerta J, Guillemain F, Levine S, Levy R, Lockshin M, Ortel T, **Petri M**, Sanna G, Sciascia S, Seshan S, Tektonidou M, Wahl D, Willis R, Yelnik C, Hendry A, Naden R, Costenbader K, Erkan D, on Behalf of New APS Classification, Criteria Collaborators. Development of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria, Phase III-D Report: Multi Criteria Decision Analysis. *Arthritis Care Res*, 2024. [Epub August 12, 2024; doi: 10.1002/acr.25415]
627. Orbai A-M, Fiorentino D, Perin J, Darrah E, Yang Q, Gutierrez L, Bingham C, **Petri M**, Rosen A, Casciola-Rosen L. SOX-5 transcription factor is a novel psoriatic autoantigen preferentially found in women. *ACR Open Rheumatol*, 2024. [Epub September 1, 2024; doi: 10.1002/acr2.11740]

Michelle Petri, M.D., M.P.H.

628. Madanchi N, Fava A, Goldman D, Magder L, **Petri M**. Association Between 25(OH) Vitamin D Levels and Adverse Pregnancy Outcomes in Systemic Lupus Erythematosus. *Arthritis Care Res*, 2024. [Epub September 23, 2024; doi: 10.1002/acr.25440]
629. Chu D, Schwartz N, Ampudia J, Guthridge J, James J, Buyon JP, Connelly S, Fung M, Ng CT, AMP SLE/RA consortium, **Petri M**, Mohan C, Putterman C. Soluble Urine ALCAM is a Strong Predictor of Lupus Nephritis. *Rheumatology*, in press, 2024.
630. Sciascia S, **Petri M**, APS ACTION et al. ANA-positive versus ANA-negative Antiphospholipid Antibody-positive Patients: Results from the APS ACTION Clinical Database and Repository. *Rheumatology*, in press, 2024.
631. Hunnicutt JN, Georgiou ME, Richards A, Quasny HA, Magder LS, Goldman DW, **Petri M**. Patients achieving low lupus disease activity state, systemic lupus erythematosus disease control or remission showed lower rates of organ damage during longitudinal follow-up: Analysis of the Hopkins Lupus Cohort. *Lupus Sci Med*, in press 2024.
632. Kitchen H, DeLozier AM, Al-zubeidi T, Paik J, Mathers L, **Petri M**, Coney C; Wallace DJ, Nelson J. A qualitative study to explore patients' disease experience and the content validity of patient-reported outcome measures in a systemic lupus erythematosus population. submitted.
633. Zhang Z, Shi L, Song L, Maurer K, **Petri MA**, Sullivan KE. Aberrant central cell processes link transcriptomic and epigenetic analysis of sorted cells from patients with SLE. submitted.
634. Gómez-Bañuelos E, Li J, Cashman KS, Goldman D, Hartson L, Lee S, Khosroshahi A, Lim SS, Darrah E, **Petri M**, Sanz I, Andrade F. Uncovering the identity of the interferon signature in systemic lupus erythematosus. Submitted.
635. Tiniakou E, Goldman DW, Corse A, **Petri M**, Mammen AL. Lupus myopathy. Submitted 2021.
636. **Petri M**, Naessens D, Ogbomo A, Ratiu A, Gutierrez C, Karyekar C. Epidemiology and Economic Burden Associated with Mental Health Comorbidities in Systemic Lupus Erythematosus and Lupus Nephritis Patients. Submitted.
637. López-Domínguez IR, Villatoro-García JA, Marañón C, Goldman D, **Petri M**, Carmona-Sáez P, Alarcón-Riquelme ME, Toro-Domínguez D. Increased IFITM Gene Signature in Age-associated B and Plasma Cells Defines Non-response to Mycophenolate Mofetil in Systemic Lupus Erythematosus. Submitted 2023.
638. Gómez-Bañuelos E, Celia A, Trejo-Zambrano M, Paz M, Conti F, Alessandri C, Tiniakou E, Goldman D, **Petri M**, Andrade F. Anti-TFAM antibodies link mitochondrial damage with anti-phospholipid syndrome and thrombosis in SLE. Submitted, 2024.
639. Barber MRW, Ugarte-Gil MF, Hanly JG, Urowitz MB, St. Pierre Y, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, Fortin PR, Gladman DD, Bruce IN, **Petri M**, Ginzler EM, Dooley MA, Ramsey-Goldman R, Manzi S, Jönsen A, Van Vollenhoven RF, Aranow C, Mackay M, Ruiz-Irastorza G, Lim SS, Inanc M, Kalunian DC, Jacobsen S, Peschken CA, Kamen DL, Askanase A, Pons-Estel BA, Cardwell F, Alarcón GS, Clarke AE. Remission and low disease activity are associated with lower health care costs: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Submitted 2024.
640. Celia AI, Vescovo G, Sarto G, Alessandri G, Iaconelli A, D'Amario D, Frati G, Biondi-Zoccai G, Conti F, Sciarretta S, Angiolillo DJ, Fava A, **Petri M**, Bikdeli B, Galli M. Direct Oral Anticoagulants versus Vitamin K Antagonists in Antiphospholipid Syndrome: A Comprehensive Meta-analysis. Submitted 2024.

Review Articles [RA]

1. **Petri M**. Outcomes encouraging in mothers with lupus. *Contemporary Ob/Gyn* 31(March):103-115 1988.
2. **Petri M**. Lupus Anticoagulant. *Saudi Medical Journal* 9:367-374 1988.
3. **Petri M**. Don't overlook coronary artery disease in systemic lupus erythematosus. *J Musculoskeletal Med* 8(10):63-69 1991.
4. Carr SR **Petri M** Repke JT Spector SL. Medical illness safe pregnancy. (DL Frey ed.) *Patient Care* April 15 1993 pp 69-90.
5. Hochberg MC **Petri M**. Clinical features of systemic lupus erythematosus. *Curr Opin Rheumatol* 5:575-586 1993.
6. Carr SR **Petri M** Repke JT Spector SL. Medical illness but good pregnancy outcome. *Contemporary Ob/Gyn* 39 (June 15):44-51 1994.

Michelle Petri, M.D., M.P.H.

7. Petri M. Clinical features of systemic lupus erythematosus. *Curr Opin Rheumatol* 6:481-486 1994.
8. Petri M. Antiphospholipid antibodies. *Resident and Staff Physician* 40 (Sept):19-23 1994.
9. Petri M. Lupus and Pregnancy. *Bulletin on the Rheumatic Diseases* 44:1-3 1995.
10. Petri M. Gender-based differences in autoimmunity and autoimmune disease. *J Women's Health* 4:433-436 1995
11. Petri M. Lupus and Pregnancy: Consensus and Controversies. *J Clin Rheumatol* 1:143-148 1995.
12. Petri M. Clinical features of systemic lupus erythematosus. *Curr Opin Rheumatol* 7:395-401 1995.
13. **Petri M.** Invited Response. In: *Proceedings: Early Decisions in DMARD Development IV. Biologic Agents in Autoimmune Disease.* March 2-4 1995 San Francisco CA. Arthritis Foundation Atlanta p 269-273.
14. Petri M. Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids glucose and thrombosis. *Lupus* 5 (Suppl. 1):S16-S22 1996.
15. Khamashta M Petri M. Antiphospholipid antibodies hasten atheroma. *Lancet* 348:1088 1996.
16. **Petri M.** Pathogenesis and Treatment of the Antiphospholipid Antibody Syndrome. *Med Clinics N Am* 81:151-178 1997.
17. **Petri M.** Review: Oral contraceptives and systemic lupus erythematosus. *Arthritis Rheum* 40:797-803 1997.
18. Petri M: Clinical challenges in SLE: moving beyond corticosteroids. *J Musculoskel Med* 14(8):64-75 1997.
19. Petri M: Antiphospholipid Antibody Syndrome: An Acquired Cause of Venous and Arterial Hypercoagulability. *Mt Sinai J Med* 64:376-382 1997.
20. Petri M: Treatment of Systemic Lupus Erythematosus: An Update. *Am Fam Phys* 57:2753-2760 1998.
21. **Petri M.** Dermatologic lupus: Hopkins Lupus Cohort. *Sem Cutaneous Med Surg* 17:219-227 1998.
22. **Petri M.** 1998 Update on Antiphospholipid Antibodies. *Curr Opinion Rheumatol* 10:426-430 1998.
23. **Petri M.** Managing SLE in young women. *Women's Health Primary Care* 1:765-770 1998.
24. **Petri M.** Infection in Systemic Lupus Erythematosus. *Rheumatic Dis Clinics N Am* 24:423-456 1998.
25. Strand V Gladman D Isenberg D **Petri M** Smolen J Tugwell P. Outcome measures to be used in clinical trials in SLE. *J Rheum* 26:490-497 1999.
26. **Petri M** Barr SG Zonana-Nach A Magder L. Measures of disease activity damage and health status: the Hopkins Lupus Cohort Experience. *J Rheum* 26:502-503 1999.
27. Smolen JS Strand V Cardiel M Edworthy S Furst D Gladman D Gordon C Isenberg D Klippel J **Petri M** Simon L Tugwell P Wolfe F. Randomized clinical trials and longitudinal observational studies in SLE: consensus on a preliminary core set of outcome domains. *J Rheum* 26:504-507 1999.
28. Lautenbach GL **Petri M.** *Women's Health.* *Rheum Dis Clinics N Am* 25:539-566 1999.
29. Kim MY Buyon JP **Petri M** Skovron ML Shore RE. Equivalence trials in SLE research: issues to consider. *Lupus* 8:620-626 1999.
30. Buyon JP Kalunian KC Ramsey-Goldman R **Petri MA** Lockshin MD Ruiz-Irastorza G Khamashta M. Assessing disease activity in SLE patients during pregnancy. *Lupus* 8:677-684 1999.
31. **Petri M** Buyon J Kim M. Classification and definition of major flares in SLE clinical trials. *Lupus* 8:685-691 1999.
32. **Petri M.** Hopkins Lupus Cohort: 1999 Update. *Rheum Dis Clinics N Am* 26:199-214 2000.
33. Brodsky RA **Petri M** Jones RJ. Hematopoietic Stem Cell Transplantation for Systemic Lupus Erythematosus. *Rheum Dis Clinics N Am* 26:377-388 2000.
34. **Petri M.** Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort. *Lupus* 9:170-175 2000.
35. **Petri M.** Approach to the Management of Systemic Lupus Erythematosus. *Journal of Clinical Outcomes Management.* 7(8):56-61 2000.
36. **Petri M.** Systemic Lupus Erythematosus: Women's Health Issues. *Bulletin on the Rheumatic Diseases.* 49(8):1-3 2000.
37. **Petri M.** Treatment of the Antiphospholipid Antibody Syndrome: Has There Been Any Progress in the Last Five Years? *Curr Rheumatol Reports* 2:256-261 2000.
38. **Petri M** Buyon J. SELENA: Safety of Estrogens of Lupus Erythematosus: National Assessment. *Lupus News* 21(3):20 2001

Michelle Petri, M.D., M.P.H.

39. Ines LS **Petri M.** Mycophenolate Mofetil: an emerging therapeutic option for systemic lupus erythematosus. *Acta Reumatologica Portuguesa* 26:153-162 2001.
40. **Petri M.** Management of thrombosis in antiphospholipid antibody syndrome. *Rheum Dis Clinics N Am* 27:633-642 2001.
41. **Petri M.** Immunosuppressive drug use in pregnancy. *Autoimmunity* 36:51-56 2003.
42. **Petri M.** Systemic lupus erythematosus: an update for clinicians. *Internat J Adv Rheumatol* 1:53-57 2003.
43. **Petri M.** Prospective study of systemic lupus erythematosus pregnancies. *Lupus* 13:688-689 2004.
44. **Petri M** Magder L. Classification criteria for systemic lupus erythematosus: a review. *Lupus* 13:829-837 2004.
45. **Petri M** Guest Editor. Classification of SLE. *Lupus* 13(11):829-885 2004.
46. **Petri M.** The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort. *Thrombosis Research* 114:593-595 2004.
47. **Petri M.** Systemic lupus erythematosus: New management strategies. *J Musculoskel Med* 22:108-116 2005.
48. Fine DM **Petri M.** Review of classification criteria for systemic lupus erythematosus. *Rheumatic Dis Clinics N Amer* 31:245-254 2005.
49. **Petri M.** Kidney biopsy in lupus nephritis: seize the opportunity. *Acta Reumatologica Portuguesa* 30:121-127 2005.
50. Doria A Iaccarino L Sarzi-Puttini P Atzeni F Turriel M **Petri M.** Cardiac Involvement in Systemic Lupus Erythematosus. *Lupus* 14:683-686 2005.
51. Lam GK **Petri M.** Assessment of systemic lupus erythematosus. *Clin Exp Rheumatol* 5(Suppl 39):S120-132 2005.
52. **Petri M.** Lupus in Baltimore: evidence-based 'clinical pearls' from the Hopkins Lupus Cohort. *Lupus* 14:970-973 2005.
53. **Petri M.** Systemic Lupus Erythematosus: 2006 Update. *J Clin Rheumatol* 12:37-40 2006.
54. **Petri M.** Current Lupus Treatments Neither Control Disease Activity or Prevent Organ Damage: The Case for New Approaches. In: *Regulation of Inflammatory Responses: Influence of Sex and Gender*. NIH Workshop Summary Bethesda Maryland. September 19-20 2006.
55. Outcome measures in systemic lupus erythematosus: practical application in clinical practice and clinical trials. Strand V Gladman D Isenberg D Merrill J **Petri M** Smolen J eds. *Curatio CME Institute LLC* Exton PA 2007.
56. **Petri M.** Clinical features and complications of systemic lupus erythematosus. *Rheumatology News Suppl: Renal and Nonrenal flares in systemic lupus erythematosus: meeting the clinical challenge.* p6-7 2007.
57. **Petri M.** Monitoring systemic lupus erythematosus in standard clinical care. *Best Practice Res Clin Rheumatol* 21:687-697 2007.
58. **Petri M** Guest Editor. *Pregnancy in Rheumatic Diseases.* *Rheum Dis Clin N Am* 2007.
59. **Petri M.** The Hopkins Lupus Pregnancy Center: Ten Key Issues in Management. *Rheum Dis Clin N Am.* 33:227-235 2007.
60. **Petri M.** Disease Activity Assessment in SLE: Do we have the right instruments? In: *Advances in Targeted Therapies IX: Proceedings of the Ninth International Symposium Athens Greece 18-22 April 2007.* *Ann Rheum Dis* 66(Suppl. III):iii61-iii64 2007.
61. Avina-Zubieta A, Alarcon G, Bischoff-Ferrari H, Fischer-Betz R, Gall V, Illei G, Liang M, Mikdashi J, **Petri M,** Pouchot J, Schneider M, Schur PH, St. Clair EW. Measurement of fatigue in systemic lupus erythematosus. A systematic review. *Arthritis Rheum* 57:1348-1357, 2007. [doi: 10.1002/art.23113].
62. **Petri M.** Sex hormones and systemic lupus erythematosus. *Lupus* 17:412-415 2008.
63. Ippolito A **Petri M.** An update on mortality in systemic lupus erythematosus. *Clin Exp Rheumatol* 26 (5 Suppl. 51):S72-S79 2008.
64. **Petri M.** Review of endocrine manifestations of antiphospholipid syndrome. *Curr Rheumatol Rev* 6:50-54 2010.
65. **Petri M.** Update on anti-phospholipid antibodies in SLE: the Hopkins' Lupus Cohort. *Lupus* 19:419-423 2010.
66. Lateef A **Petri M.** Biologics in the Treatment of Systemic Lupus Erythematosus. *Current Opinion in Rheumatology* 22:504-509 2010
67. **Petri M.** Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody positive patients. *Curr Rheumatol Reports* 13:77-80 2011.

68. **Petri M.** Clinical research in systemic lupus erythematosus: immediate relevance to clinical practice. *Internatl J Rheumatic Dis* 14:1-5 2011.
69. Ostensen M, Brucato A, Carp H, Chambers C, Dolhain RJEM, Doria A, Forger F, Gordon C, Hahn S, Khamashta M, Lockshin MD, Matucci-Cerinic M, Meroni P, Nelson JL, Parke A, **Petri M**, Raio L, Ruiz-Irastorza G, Silva CA, Tincani A, Villiger PM, Wunder D, Cutolo M. Pregnancy and reproduction in autoimmune rheumatic diseases. *Rheumatology* 50:657-64 2011.
70. Fairweather D, **Petri MA** Coronado MJ Cooper LT Jr. *Expert Rev Clin Rheumatol* 8:269-84 2012.
71. Baer A, Witter FR, **Petri M.** Lupus and Pregnancy. *Obstetrics Gynecol Surv* 66:639-53, 2011.
72. **Petri M.** Hormone Replacement and contraceptive therapy in autoimmune diseases. *J Autoimmunity.* 2012. DOI: 10.1016/j.jaut.2011.11.002
73. Lateef A, **Petri M.** Management of pregnancy in systemic lupus erythematosus. *Nature Reviews Rheumatology.* 8:710–8 2012.
74. Agmon-Levin N, Mosca M, **Petri M**, Shoenfeld Y. Systemic lupus erythematosus one disease or many? *Autoimmun Rev.* 11:593-5, 2012. [Epub 2011 Oct 25, doi: 10.1016/j.autrev.2011.10.020]
75. Lateef A, **Petri M.** Unmet medical needs in systemic lupus erythematosus. *Arthritis Res Therapy* 14 (Suppl 4):S3.
76. Lateef A, **Petri M.** Managing lupus patients during pregnancy. *Best Practices Res Clin Rheumatol.* 27:435–447, 2013.
77. Timlin H, **Petri M.** Transient ischemic attack and stroke in systemic lupus erythematosus. *Lupus* 22:1251-1258, 2013.
78. Bichile T, **Petri M.** Incidence of lymphoma associated with underlying lupus: lessons learned from observational studies. *Curr Opinion Rheumatol* 26:111–117, 2014.
79. Bertolaccini ML, Amengual O, Atsumi T, Binder WL, de Laat B, Forastiero R, Kutteh WH, Lambert M, Matsubayashi H, Murthy V, **Petri M**, Rand JH, Sanmarco M, Tebo AE, Pierangeli SS. 14th International Congress on Antiphospholipid Antibodies Task Force. Report on Antiphospholipid Syndrome Laboratory Diagnostics and Trends. *Autoimm Rev* 13:917-930, 2014. [epub May 20, 2014; doi:10.1016/j.autrev.2014.05.001]
80. Bichile T, **Petri M.** Prevention and management of co-morbidities in SLE. *La Presse Medicale* 43(6 Pt 2):e187-95, 2014. [Epub May 20 2014, doi: 10.1016/j.lpm.2014.03.009]
81. **Petri M**, Durcan L, Clarke WA. Clinical Update: The Role of Monitoring Drug Levels in Lupus. *Rheumatology News (Suppl)*, September, 2015.
82. Stojan G, **Petri M.** Anti-C1Q in systemic lupus erythematosus. *Lupus* 25:873-877, 2016.
83. Durcan L, **Petri M.** Why targeted therapies are necessary for systemic lupus erythematosus. *Lupus* 25:1070-1079, 2016.
84. Durcan L, **Petri M.** Immunomodulators in SLE: clinical evidence and immunologic actions. *J Autoimmun* 74:73-84, 2016. [doi: 10.1016/j.jaut.2016.06.010]
85. Stojan G, **Petri M.** The risk benefit ratio of glucocorticoids in SLE: have things changed over the past 40 years? *Curr Treatment Options Rheumatol*, 2017 [Epub July 27, 2017, DOI 10.1007/s40674-017-0069-8].
86. Stojan G, **Petri M.** Epidemiology of Systemic Lupus Erythematosus: an update. *Curr Opin Rheumatol.* 2018;30:144-150. [doi: 10.1097/BOR.0000000000000480].
87. Fava A, **Petri M.** Systemic lupus erythematosus: diagnosis and clinical management. *J Autoimmunity* 96:1-13, 2019. [doi: 10.2016/j.jaut.2018.11.001]
88. Durcan L, O'Dwyer T, **Petri M.** Management strategies and future directions in systemic lupus erythematosus in adults. *Lancet* 393:2332-2343, 2019. [doi: 10.1016/S0140-6736(19)30237-5. Epub 2019 Jun 6].
89. Dein E, Douglas H, **Petri M**, Law G, Timlin H. Pericarditis in Lupus. *Cureus.* 11(3):e4166, 2019. [doi: 10.7759/cureus.4166]
90. **Petri M**, Kallas R. Lupus in Pregnancy. *Contemporary OB/GYN* vol 64, issue 3, 2019. <https://www.contemporaryobgyn.net/article/lupus-pregnancy>.
91. **Petri M.** Improvements in diagnosis and risk assessment of primary and secondary antiphospholipid syndrome. *Hematology 2019, the American Society of Hematology Education Program, 61st ASH Annual Meeting and Exposition, Orlando, FL December 7-10.* pp 415-420, 2019.

Michelle Petri, M.D., M.P.H.

92. Hoover P, Der E, Berthier CC, Lederer JA, James J, Buyon JP, **Petri MA**, Belmont M, Izmirly P, Hacoheh N, Diamond B, Putterman C, Davidson A. The Accelerating Medicines Partnership – Organizational structure and preliminary data from the phase 1 studies of lupus nephritis. *Arthritis Care Res* 72:233-242, 2020. [Epub September 9, 2019. DOI:10.1002/acr.24066]
93. **Petri M**. Pregnancy and systemic lupus erythematosus. *Best Pract Res Clin Obstet Gynaecol*. 64:24-30, 2020. [doi: 10.1016/j.bpobgyn.2019.09.002. Epub 2019 Oct 8]
94. **Petri M**. Antiphospholipid Syndrome. *Translational Res*. 2020. [doi: 10.1016/j.trsl.2020.04.006. Epub June 2, 2020]
95. Elera-Fitzcarrald C, Rocha J, Burgos PI, Ugarte-Gil MF, **Petri M**, Alarcón GS. Measures of Fatigue in Patients With Rheumatic Diseases: A Critical Review. *Arthritis Care Res* 72(S10):369-409, 2020. [Epub 22 October 2020 doi: 10.1002/acr.24246]
96. **Petri M**. Systemic Lupus Erythematosus: Clinical Updates in Women’s Health Care Primary and Preventive Care Review. *Obstet Gynecol* 136:226, 2020 [doi: 10.1097/AOG.0000000000003942]
97. Aringer M, **Petri M**. New classification criteria for systemic lupus erythematosus. *Curr Opin Rheumatol*. 32(6):590-596, 2020. [doi: 10.1097/BOR.0000000000000740]
98. Moline E, **Petri M**, Manno R, Williamson L, Williamson L, Timlin H. A prescription for exercise in systemic lupus erythematosus. *Lupus* 30:2183-2190, 2021. [Epub 2021 Dec 13; doi: 10.1177/09612033211061060]
99. **Petri M**. Drug monitoring in systemic lupus erythematosus. *Curr Opin Pharmacol* 64:102225, 2022. [<https://doi.org/10.1016/j.coph.2022.102225>]
100. Urowitz MB, Aranow C, Asukai Y, Bass DL, Bruce IN, Chauhan D, Dall’Era M, Furie R, Fox NL, Gilbride JA, Hammer A, Ginzler EM, Gonzalez-Rivera T, Levy RA, Merrill JT, Holly Quasny H, Roth DA, William Stohl W, van Vollenhoven R, Wallace DJ, **Petri M**. Impact of belimumab on organ damage in systemic lupus erythematosus. *Arthritis Care Res* 74:1822-1828, 2022. [Epub April 19, 2022; doi:10.1002/acr.24901]
101. Beatrice Chighizola C, Willis R, Maioli G, Sciascia S, Andreoli L, Amengual O, Radin M, Gerosa M, Atsumi T, de Jesus G, Trespidi L, Branch DW, Caporali R, Andrade D, Roubey R, Petri M, Bertolaccini ML. Deciphering the clinical significance of longitudinal antiphospholipid antibody titers. *Autoimmunity Rev*, in press 2024.

Case Reports {CR}

1. **Petri M** Ellman L and Carey R. Acquired Factor XIII deficiency with chronic myelomonocytic leukemia. *Ann Intern Med* 99: 638 1983.
2. Hellmann D Laing T **Petri M** Jacobs D Crumley R Stulbarg M. Wegener's granulomatosis: isolated involvement of the trachea and larynx. Case report and review of the literature. *Ann Rheum Dis* 46:628-631 1987.
3. Fitz G **Petri M** Hellmann D. Lupoid hepatitis presenting with rheumatoid nodules and arthritis. *J Rheumatol* 14:595-598 1987.
4. **Petri M** Katzenstein P Hellmann D. Laryngeal infection in lupus: report of nocardiosis and review of laryngeal involvement in lupus. *J Rheumatol* 15:1014-1015 1988.
5. **Petri M** Barr E Cho K Farmer E. Overlap of Granulomatous Vasculitis and Sarcoidosis: Presentation with Uveitis Eosinophilia Leg Ulcers Sinusitis and Past Foot Drop. *J Rheumatol* 15:1171-1173 1988.
6. Smith LW, Gelber AC, **Petri M**. Diffuse lymphadenopathy as the presenting manifestation of systemic lupus erythematosus. *J Clin Rheumatol* 19:397-9, 2013.
7. DiRenzo D, McMahan ZH, Manno R, **Petri M**, Desai N. Cerebral venous thrombosis mimicking a discrete brain mass: A case report and literature review. *Case Reports Rheumatol* vol. 2018, Article ID 5862912, 5 pages, 2018. [<https://doi.org/10.1155/2018/5862912/>]
8. Liebowitz J, Fine D, Seo P, **Petri M**, Machireddy K, Haque U, Manno R, Timlin H. Pauci-immune glomerulonephritis in systemic lupus erythematosus (SLE). *Cureus* 10(7):e2949, 2018: [doi:10.7759/cureus].
9. Tiniakou E, Kontzialis M, **Petri M**. Rheumatoid Pachymeningitis: A Rare Complication of Rheumatoid Arthritis. *J Rheumatol*. 45(9):1325-1326, 2018. [doi: 10.3899/jrheum.171074]

Book Chapters, Monographs [BC]

1. Hellmann D and **Petri M**. *Arthritis In: Current Therapy in Emergency Medicine* (ML Callahan ed.). B.C. Decker Inc. Toronto 1987.

Michelle Petri, M.D., M.P.H.

2. **Petri M** Watson R Hochberg MC. Anti-Ro antibodies and neonatal lupus. *Rheumatic Dis Clinics NA* 15:335-360 1989.
3. Hellmann DB **Petri M**. Systemic Lupus Erythematosus. In: Spivak JL Barnes HV ed. *Manual of Clinical Problems in Internal Medicine* Fourth and Fifth editions. Boston: Little Brown and Co. 1990 and 1992.
4. Hellmann DB **Petri M**. Cryoglobulinemia and mixed connective tissue disease. In: Spivak JL Barnes HV ed. *Manual of Clinical Internal Medicine* Fourth and Fifth editions. Boston: Little Brown and Co. 1990 and 1992.
5. **Petri M** Hellmann DB. Spondyloarthropathies. In: Spivak JL Barnes HV ed. *Manual of Clinical Internal Medicine* Fourth and Fifth editions. Boston: Little Brown and Co. 1990 and 1992.
6. **Petri M**. Antiphospholipid Antibodies: Lupus Anticoagulant and Anticardiolipin Antibody. In: MacKie RM Provost T eds. *Current Problems in Dermatology*. Vol. IV. Mosby-Year Book Inc. St. Louis MO 1992.
7. **Petri M**. Antiphospholipid antibodies and pregnancy loss. In: Schlaff WD Rock JA eds. *Decision Making in Reproductive Endocrinology*. Blackwell Scientific Publications Boston pp 346-348 1993.
8. **Petri M**. Systemic lupus erythematosus and pregnancy. *Rheumatic Dis Clinics NA* 20:87-118 1994.
9. **Petri M**. Diagnosis of antiphospholipid antibodies. *Rheumatic Dis Clinics NA* 20:443-469 1994.
10. **Petri M**. Systemic lupus erythematosus. In: Weisman M Weinblatt M eds. *Drug Therapy for the Rheumatic Diseases*. WB Saunders Philadelphia 1994.
11. **Petri M**. Systemic Lupus Erythematosus. In: Rich RR Fleisher TA Schwartz BD Shearer WT Strober W eds. *Clinical Immunology: Principles and Practice*. Chap. 71 pp 1072-1092. Mosby Year Book St. Louis 1995.
12. **Petri M**. Soft Tissue Rheumatism. In: Stobo J Hellmann D Ladenson P Petty BG Traill TA eds. *Principles and Practice of Medicine*. Twenty-third edition pp 257-260. Appleton and Lange 1996.
13. **Petri M**. Epidemiology of the Antiphospholipid Syndrome. In Asherson RA Cervera R Piette J-C and Shoenfeld Y eds. *The Antiphospholipid Syndrome*. CRC Press Inc Boca Ratan pp 13-28 1996.
14. **Petri M**. Systemic Lupus Erythematosus. In: Lichtenstein LM and Fauci AS eds. *Current Therapy in Allergy Immunology and Rheumatology* Fifth Edition. Mosby Year Book St. Louis pp 219-222 1996.
15. **Petri M**. Gastrointestinal Manifestations. In Schur PH ed. *The Clinical Management of Systemic Lupus Erythematosus* 2nd ed. Lippincott-Raven Publishers Philadelphia pp127-140 1996.
16. **Petri M**. Hormone replacement in SLE. In Klippel JH and Dieppe PA eds. *Rheumatology* 2nd ed. Mosby-Wolfe London chap. 7.08m 1996.
17. **Petri M**. Editor. Pregnancy and Rheumatic Disease. *Rheumatic Dis Clinics N Am* 23 (1):1-212 1997.
18. **Petri M**. Hopkins Lupus Pregnancy Center: 1987 to 1996. *Rheumatic Dis Clinics N Am* 23:1-14 1997.
19. **Petri M**. Clinical and management aspects of the antiphospholipid syndrome. In Wallace DJ and Hahn BH eds. *Dubois' Lupus Erythematosus* Fifth ed. Williams & Wilkins Baltimore chap. 57 1997.
20. **Petri M**. Systemic Lupus Erythematosus. In: Kassirer J and Greene II HL eds. *Current Therapy in Adult Medicine* Fourth Edition. Mosby-Year Book St. Louis pp 1275-1279 1997.
21. **Petri M**. Systemic Lupus Erythematosus and the Heart. In: Lahita RG ed. *Systemic Lupus Erythematosus* Third Edition. Churchill Livingstone New York pp 687-706 1998.
22. **Petri M**. Pregnancy in SLE. In: Gladman DD and Hochberg MC eds. *Baillière's Clinical Rheumatology* vol 12 No. 3. Systemic Lupus Erythematosus. Baillière Tindall London pp 449-476 1998.
23. **Petri M**. Neurologic Presentations of Autoimmune Disorders in Women. In: Kaplan PW ed. *Neurologic Disease in Women*. Demos Medical Publishing Inc New York pp. 229-242 1998
24. **Petri M**. Lupus and the Elderly. In: Aladjem H ed. *The Challenges of Lupus: Insights and Hope*. Avery Publishing Group New York pp. 61-64 1999.
25. Lautenbach GL **Petri M**. Women's Health. *Rheumatic Dis Clin of N Am* 25:539-566 2000.
26. **Petri M**. Infertility Oral Contraceptive Pills Hormone Replacement Therapy and the Antiphospholipid Antibody Syndrome. In: Khamashta MA ed. *Hughes Syndrome Antiphospholipid Syndrome*. Springer-Verlag London pp 426-446 2000.
27. **Petri M**. Systemic Lupus Erythematosus: Clinical Aspects. In: Koopman WJ ed. *Arthritis and Allied Conditions* 14th Edition. Lippincott Williams and Wilkins Philadelphia pp. 1455-1479 2000.
28. **Petri M** Provost TT. Antiphospholipid Syndrome. In: Provost TT and Flynn JA eds. *Cutaneous Medicine: Cutaneous Manifestations of Systemic Disease*. BC Decker Inc. Hamilton Canada pp. 147-157 2001.

Michelle Petri, M.D., M.P.H.

29. **Petri M.** Cardiovascular Morbidity in the Hopkins Lupus Cohort. In: Shoenfeld Y Harats D Wick G eds. Atherosclerosis and Autoimmunity. Elsevier Amsterdam 2001 pp. 249-254.
30. **Petri M.** Homocysteine and vascular disease in the autoimmune connective tissue diseases. In: Cervera R Asherson R eds. Vascular Manifestations of Systemic Autoimmune Diseases. CRC Press New York 2001 pp. 71-80.
31. **Petri M.** Clinical and Management Aspects of the Antiphospholipid Antibody Syndrome. In: Dubois' Lupus Erythematosus. Sixth Edition. Lippincott Williams and Wilkins Philadelphia Chapter 52 2002 pp. 1093-1128.
32. **Petri M.** Antiphospholipid Antibodies. In: Scharschmidt BF ed. Pocket Medicine/Internal Medicine. WB Saunders. Philadelphia 2002. Palm OS program.
33. **Petri M.** Systemic Lupus Erythematosus. In: Goldmann DR ed in chief. Physician's Information and Education Resource (PIER). American College of Physicians – American Society of Internal Medicine Philadelphia 2001. <http://pier.acponline.org>
34. **Petri M.** Epidemiology and Classification of the Antiphospholipid Syndrome. In: Asherson R Cervera R Piette J-C Shoenfeld Y ed. Antiphospholipid Syndrome II: Autoimmune Thrombosis. Elsevier Science Amsterdam 2002 pp 11-20.
35. Asherson R **Petri M.** Endocrine manifestations in the antiphospholipid syndrome. In: Asherson R Cervera R Piette J-C Shoenfeld Y ed. Antiphospholipid Syndrome II: Autoimmune Thrombosis. Elsevier Science Amsterdam 2002 pp245-257.
36. Ferguson TT **Petri M.** Systemic Lupus Erythematosus. In: Cheng A Zaas A ed. The Osler Medical Handbook. Mosby Philadelphia 2003 pp 1045- 1054.
37. **Petri M.** Systemic lupus erythematosus (SLE). In: Aminoff M Daroff RB eds. Encyclopedia of the Neurological Sciences. Elsevier Science Amsterdam 2003 pp 471-475.
38. **Petri M.** Pregnancy in SLE. In: Hochberg MC Silman AJ Smolen JS Weinblatt ME Weisman MH ed. Rheumatology Third edition. CV Mosby St. Louis 2003.
39. **Petri M.** Systemic Lupus Erythematosus. In: Lichtenstein LM Busse WW Geha RS ed. Current Therapy in Allergy Immunology and Rheumatology Sixth Edition. Mosby Inc St. Louis 2004 pp 239-242.
40. Doria A **Petri M.** Cardiac involvement in systemic lupus erythematosus. In: Doria A Pauletto P eds. The Heart in Systemic Autoimmune Diseases. Elsevier New York 2004 pp 145-162.
41. **Petri M.** Cardiovascular Systemic Lupus Erythematosus. In: Lahita RG ed. Systemic Lupus Erythematosus 4th Edition. Elsevier New York 2004 Chapter 31 pp 913-942.
42. **Petri M.** Systemic Lupus Erythematosus. In: Imboden J Hellmann D Stone J eds. Current Rheumatology: Diagnosis and Treatment. McGraw-Hill New York 2004 pp 171-178.
43. **Petri M.** Antiphospholipid Antibody Syndrome. In: Imboden J Hellmann D Stone J eds. Current Rheumatology: Diagnosis and Treatment. McGraw-Hill New York 2004 pp 179-182.
44. **Petri M.** Systemic Lupus Erythematosus: Clinical Aspects. In: Koopman WJ ed. Arthritis and Allied Conditions 15th Edition. Lippincott Williams and Wilkins Philadelphia pp. 1473-1496 2004.
45. **Petri M.** Neurologic Presentations of Autoimmune Disorders in Women. In: Kaplan PW ed Neurologic Diseases in Women 2nd ed. Demos Medical Publishing New York 2006 pp. 335-348.
46. Clowse MEB **Petri M.** Pregnancy and Systemic Lupus Erythematosus. In: Lockshin MD Branch DW ed. Handbook of Systemic Autoimmune Diseases. Vol 4 Reproductive and Hormonal Aspects of Systemic Autoimmune Diseases. Elsevier Amsterdam 2006 pp. 43-57.
47. **Petri M.** Epidemiology of Antiphospholipid Syndrome. In: Khamashta MA ed. Hughes Syndrome: Antiphospholipid Syndrome 2nd ed. Springer-Verlag London 2006 pp. 22-28.
48. **Petri M.** Systemic Lupus Erythematosus Chronic Cutaneous Lupus and Mixed Connective Tissue Disease. In: MacKay Rose ed. The Autoimmune Diseases 4th ed. Academic Press London in press 2006.
49. **Petri M.** Antiphospholipid Antibodies. In: Scharschmidt BF ed. Pocket Medicine/Internal Medicine 2nd ed. WB Saunders. Philadelphia 2006. Palm OS program.
50. **Petri M.** Systemic Lupus Erythematosus. In: Bartlett SJ Bingham CO Maricic MJ Iversen MD Ruffing V eds. Clinical Care in the Rheumatic Diseases 3rd ed. Association of Rheumatology Health Professionals Atlanta chap 28 2006.
51. **Petri M.** Clinical and management aspects of the antiphospholipid antibody syndrome. In Wallace DJ and Hahn BH eds. Dubois' Lupus Erythematosus Seventh ed. Williams & Wilkins Baltimore chap. 65 2006.

52. Clowse MEB **Petri M.** Pregnancy. In: Tsokos Gordon C Smolen eds. Systemic Lupus Erythematosus. Graphic World Publishing Services New York chap. 40 2006.
53. **Petri M.** Systemic Lupus Erythematosus. In: Imboden J Hellmann D Stone J eds. Current Rheumatology: Diagnosis and Treatment 2nd ed. McGraw-Hill New York 2007 pp 203-210.
54. **Petri M.** Antiphospholipid Antibody Syndrome. In: Imboden J Hellmann D Stone J eds. Current Rheumatology: Diagnosis and Treatment 2nd ed. McGraw-Hill New York 2007 pp 218-221.
55. Sule SD **Petri M.** Estrogen in Systemic Lupus Erythematosus: Lessons from the SELENA Study. In: Walker SE Jara LJ eds. Endocrine Manifestations of Systemic Autoimmune Diseases. Handbook of Systemic Autoimmune Diseases vol. 9. Elsevier New York 2008 pp 223-228.
56. Dooley MA Ginzler EM Kalunian KC **Petri M.** The Faces of SLE: Assessing Disease Activity Response to Therapy and Control of Comorbidities. In: The Exam Room. Educational activity sponsored by University of North Carolina School of Medicine at Chapel Hill and Independent Medical Education LLC. Release date January 2009.
57. Taraneh M **Petri M.** Epidemiology of the Antiphospholipid Syndrome. In: RA Asherson editor: Handbook of Systemic Autoimmune Diseases Vol 10 Antiphospholipid Syndrome in Systemic Autoimmune Diseases R Cervera JC Reverter Munther Khamashta series editors. The Netherlands: Elsevier 2009 pp. 13 – 34.
58. **Petri M.** Clasificación. In: Khamashta MA Tarrés MV eds. Lupus Eritematoso Sistémico Tercera Edición. Caduceo Multimedia Barcelona 2009 pp 313-318.
59. **Petri M.** The Hopkins Lupus Pregnancy Center: ten key issues in management. Rheum Dis Clin N Am in press 2007.
60. Sule SD and **Petri M.** Nutritional supplementation in systemic lupus erythematosus. In: Coleman LA ed. Nutrition and Health: Nutrition and Rheumatic Disease. Humana Press Totowa NJ 2008 pp 159-168.
61. **Petri M** Abuav R Boumpas D Goldblatt F Isenberg D Anhalt GJ Werth VP Looney RJ. Systemic Lupus Erythematosus. In: Stone JH ed. A Clinician's Pearls and Myths in Rheumatology. Springer New York NY 2009 pp 131-160.
62. Mehrani T **Petri M.** Oral Contraceptives and Autoimmune Diseases. In: Legato MJ ed. Principles of Gender-Specific Medicine Second Ed. Academic Press Elsevier Amsterdam. Chap 54 2010 pp 645-656.
63. Clowse ME **Petri M** James AH. Rheumatology. In: de Swiet's Medical Disorders in Obstetric Practice. Wiley-Blackwell Oxford 2010 chap 8 pp 209-222.
64. **Petri M.** Systemic lupus erythematosus. In: Horwitz R and Muller D eds. Integrative Rheumatology. Oxford University Press Oxford. Chap. 16 2011 pp 251-264.
65. Lateef A **Petri M.** Systemic Lupus Erythematosus (SLE) in Pregnancy. In: Adu D Emery P Madaio MP. Rheumatology and the Kidney Oxford University Press Oxford. 2nd Edition Chap. 7 2012.
66. **Petri M.** Systemic Lupus Erythematosus. In: Boulware DW Heudebert GR eds. Lippincott's Primary Care Rheumatology. Lippincott Williams and Wilkins Philadelphia. Chap 11 pp 103-110 2012.
67. Lateef A **Petri M.** Hormone replacement and contraceptive therapy in autoimmune diseases. In: Shoenfeld Y Tincani A Gershwin ME eds. Gender sex hormones pregnancy and autoimmunity. Elsevier Amsterdam. 2012 pp J170-176.
68. Bertolaccini ML Amengual O Atsumi T Binder WL Kutteh WH de Laat B Forastiero R M Matsubayashi H Murthy VL **Petri M** Rand JH Sanmarco M Tebo AE Pierangeli SS.. Task Force Report on "Non-criteria" Antiphospholipid Antibody Tests. In: Erkan D Pierangeli SS eds. Antiphospholipid Syndrome - Insights and Highlights from the 13th International Congress on Antiphospholipid Antibodies. Springer London. Chapter 8 pp 133-146 2012.
69. Lateef A, **Petri M.** Rheumatologic disorders. In: Cohen WR, August P eds. Obstetric Medicine: Management of Medical Disorders in Pregnancy. 6th edition. People's Medical publishing House-USA, Shelton CT. Chapter 36 pp 741-66, 2013.
70. Lateef A, **Petri M.** Clinical aspects of the antiphospholipid syndrome. In: Dubois' Lupus Erythematosus and Related Syndromes. eds. 8. Chap. 42. pp 518-525, 2013.
71. **Petri M.** Life-threatening complications of systemic lupus erythematosus. In: Kamashta MA and Ramos-Casals M eds. Autoimmune Diseases: Acute and Complex Situations. Springer Verlag Limited London. Chapter 2 pp 19-17, 2011.
72. Baer AN, **Petri M.** Lupus and Pregnancy. In: Rodgers B Yeh J eds. A Guide to Complex Pregnancy Management. World Scientific Publishing 2014.

Michelle Petri, M.D., M.P.H.

73. Zghaib T, **Petri M**. Systemic Lupus Erythematosus. In: Arps K, Wills B. The Osler Medicine Survival Guide: Adult Hospital Care. Johns Hopkins University 2014-2018 pp 289-292.
74. Durcan L, **Petri M**. Epidemiology of the Antiphospholipid Syndrome. In: Cervera S, Espinosa G, Khamashta M, eds. Antiphospholipid Syndrome in Systemic Autoimmune Disease, 2nd Edition. Chapter 2, pp 17-30. Elsevier, Oxford. 2016.
75. Lateef A, **Petri M**. Systemic lupus erythematosus and pregnancy. In: Sammaritano L, Chakravarty EF, eds. Reproductive Health, Rheumatic Dis Clin North Am. Vol 43(2), pp 215-226. Elsevier, Philadelphia. 2017.
76. Durcan L, **Petri M**. Clinical aspects of antiphospholipid syndrome. In: Dubois' Lupus Erythematosus and Related Syndromes. eds. 9. Chap. 42. pp 532-542, 2013.
77. Alkhunaizi F, **Petri M**. Systemic Lupus Erythematosus. In: Horne A, Pallazola V, Raj S, Zhenged W. The Osler Medicine Survival Guide: Adult Hospital Care. Johns Hopkins University 2019-2020.
78. **Petri M** Abuav R Boumpas D Goldblatt F Isenberg D Anhalt GJ Werth VP Looney RJ. Systemic Lupus Erythematosus. In: Stone JH ed. A Clinician's Pearls and Myths in Rheumatology. 2nd edition. Springer New York NY 2023.
79. Topilow J, **Petri M**. Clinical aspects of antiphospholipid syndrome. In: Dubois' Lupus Erythematosus and Related Syndromes. eds. 10. Chap. 42. pp XXX-XXX, submitted, 2023.
80. Reginato AM, Petri MA, Kay J. Walter Bauer, Marian Wilkins Ropes, and the Massachusetts General Hospital. In: Giants in Rheumatology. Chap. 12, submitted, 2023.

Books, Textbooks [BK] - None

Editorials [ED]

1. **Petri M**. The clinical syndrome associated with aPL [editorial]. J Rheumatol 19:505-507 1992.
2. **Petri M**. Pancreatitis in search of a mechanism [editorial]. J Rheumatol 19:1014-1016 1992.
3. **Petri M**. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective. Scand J Rheumatol 25:191-193 1996.
4. Gladman D Urowitz M Fortin P Isenberg D Goldsmith C Gordon C **Petri M** Systemic Lupus International Collaborating Clinics Group. Systemic Lupus International Collaborating Clinics Conference on Assessment of Lupus Flare and Quality of Life Measures in SLE. J Rheumatol 23:1953-1955 1996.
5. **Petri M** Robinson C. Oral contraceptives and systemic lupus erythematosus. Arthritis Rheum 40:797-803 1997.
6. **Petri M**. Hydroxychloroquine: past present future. Lupus 7:65-67 1998.
7. **Petri M**. The egg and I: preserving fertility in systemic lupus erythematosus. Lupus 9:399-400 2000.
8. **Petri M**. Diet and systemic lupus erythematosus: from mouse and monkey to woman? Lupus 10: 775-777 2001.
9. Brey RL **Petri MA**. Neuropsychiatric Systemic Lupus Erythematosus: Miles to Go Before We Sleep. Neurology 61:1-2 2003.
10. **Petri M**. Classification criteria for antiphospholipid syndrome: the case for cardiac valvular disease. J. Rheumatol. 31:2329-2330 2004.
11. **Petri M** Brodsky R. High Dose Cyclophosphamide and Stem Cell Transplantation for Refractory Systemic Lupus Erythematosus. J Amer Med Assoc 295:559-560 2006.
12. Bihl GR **Petri M** Fine DM. Kidney biopsy in lupus nephritis: Look before you leap. Nephrol Dial Transplant. 21:1749-1752 2006.
13. **Petri M** Buyon JP. Oral contraceptives in systemic lupus erythematosus: the case for (and against). Lupus 17:708-710 2008.

Letters Correspondence [LT]

1. **Petri M**. The dilemma of euploidic abortion. Fertility and Sterility 52:879-880 1989.
2. Hellmann DB **Petri M**. Pulmonary hypertension in systemic lupus erythematosus: Reply. J Rheumatol 17:415 1990.
3. **Petri M** Repke J. Entry criteria influence conclusions about rates of flare in lupus pregnancy: comment on the article by Petri et al. Reply. Arthritis Rheum 35:846-847 1992.
4. **Petri M** Allbritton J. Antibiotic allergy in systemic lupus erythematosus. Reply. J Rheumatol 19:1994 1992.
5. **Petri M** Allbritton J. Drug allergy in Chinese patients with SLE. Reply. J Rheumatol 20:400 1993.

6. Utset TO **Petri M.** Psychiatric disorder and cognitive impairment in SLE. Reply. *J Rheumatol* 22:2187 1995
7. Buyon JP Dooley MA Meyer WR **Petri M** Licciardi F. Recommendations for exogenous estrogen to prevent glucocorticoid-induced osteoporosis in premenopausal women with oligo- or amenorrhea: comment on the American College of Rheumatology recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. *Arthritis Rheum* 40:1548 1997.
8. **Petri M** Mont MA. Risk factors for avascular necrosis in systemic lupus erythematosus Reply. *J Rheumatol* 25:188 1998.
9. Mont MA Jones LC **Petri M.** Anti-annexin V antibodies and osteonecrosis in systemic lupus erythematosus. Reply. *J Rheumatol* 25:2477-2478 1998.
10. **Petri M.** Postmenopausal estrogen replacement therapy and risk of developing systemic lupus erythematosus or discoid lupus. *J Rheumatol* 26:752 1999.
11. **Petri M** Magder L. Characterization of flares in patients with systemic lupus erythematosus: Comment on the Article by Ho et al. Reply. *Arthritis Rheum* 48:582 2003.
12. Costenbader KH Peerzada J Lockman S Karlson EW Kim DJ Nobles-Knight D **Petri M.** Smoking and increased apoptosis in patients with systemic lupus erythematosus. Reply. *Arthritis Rheum* 50: 3733 2004.
13. Musone SL Taylor KE Lu T Nititham J Ortmann W Shiffrin N **Petri M** Manzi S Seldin MF Gregersen PK Behrens TW Ma A Kwok P-Y Criswell LA. Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. *Nature Genetics* 40:1062-1064 2008.
14. Mehta BM Kiani AN Chen C Jani J Kickler TS **Petri M.** Endogenous thrombin potential (ETP) in the assessment of hypercoagulability in systemic lupus erythematosus. *Amer J Hematol* 85:83-5, 2010.
15. Ruiz-Irastorza G, **Petri M,** Gordon C, Khamashta M. Managing lupus nephritis in pregnant women: comment on the article by Hahn et al. *Arthritis Care Res* 65:1391-2, 2013.
16. **Petri M,** Norman GL, Binder W, Shumz Z, Akhter E, Fang H. Reply to Letter Re: Antiphosphatidylserine/prothrombin antibodies in systemic lupus erythematosus. *J Rheumatol* 40:1621, 2013.
17. Birmingham DJ, Shidham G, Perna A, Fine DM, Bissell M, Rodby R, Remuzzi G, **Petri M,** Hebert P, Rovin BH, Hebert LA. Spot PC ratio estimates of 24-hour proteinuria are more unreliable in lupus nephritis than in other forms of chronic glomerular disease. *Ann Rheum Dis* 73:475-6, 2014.
18. Strand V, Levy RA, Cervera R, **Petri M.** Response to: 'Belimumab and the measurement of fatigue' by Mazzoni [Letter]. *Ann Rheum Dis.* 74:e54, 2015. [doi: 10.1136/annrheumdis-2015-207700. Epub 2015 May 19]
19. Durcan L, Magder LS, **Petri M.** Reply to: Retinopathy in the era of routine hydroxychloroquine monitoring. *J Rheumatol* 43:1255, 2016.
20. Wilhelm TR, Magder LS, **Petri M.** Response to: 'Remission in SLE: the duration depends on multiple factors, including the definition' by Doria et al. *Ann Rheum Dis* 75(12):e78, 2016.
21. Assalie NA, Durcan R, Durcan L, **Petri MA.** Hydroxychloroquine-induced erythema multiforme. *J Clin Rheumatol* 23:127-128, 2017.
22. Baer AN, **Petri M,** Sohn J, Rosen A, Livia Casciola-Rosen L. Response to Letter to Editor concerning: Antibodies to interferon-inducible protein-16 in primary Sjögren's syndrome are associated with markers of more severe disease. *Arthritis Care Res* 69:454, 2017. [doi: 10.1002/acr.22917]
23. **Petri M** and Magder L. Reply to: Is Low Disease Activity good enough as a target in Systemic Lupus Erythematosus? *Arthritis Rheum* 70:2099, 2018 [Epub September 24, 2018, DOI: 10.1002/art.40693].
24. Costedoat-Chalumeau N, Isenberg D, **Petri M.** Comment on the 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus by Fanouriakis et al. *Ann Rheum Dis* pii: annrheumdis-2019-215573, 2019. [Epub ahead of print May 2, 2019. doi: 10.1136/annrheumdis-2019-215573]
25. Eudy AM, Siega-Riz AM, Engel SM, Franceschini N, Howard AG, Clowse MEB, **Petri M.** Response to: 'Postpartum breastfeeding status' by Betzold. *Ann Rheum Dis.* 78:e38, 2019. [doi: 10.1136/annrheumdis-2018-213427. Epub 2018 Apr 11]
26. **Petri M,** Li J, Magder LS, Goldman DW. Reply to Letter to the Editor: "Hydroxychloroquine blood levels predict hydroxychloroquine retinopathy". *Arthritis Rheum* 72:694, 2020. [doi: 10.1002/art.41146]
27. **Petri M,** Elkhalfi M, Li J, Magder LS, Goldman DW. Reply to Letter to Editor: Do Hydroxychloroquine Blood Levels and Dosage Identify the Same or Different Populations at Risk for Retinopathy?. *Arthritis Rheum* 72:2166, 2020. [Epub August 2, 2020; doi: 10.1002/art.41462]

Michelle Petri, M.D., M.P.H.

28. **Petri M**, Elkhalfi M, Li J, Magder LS, Goldman DW. Reply to Letter to Editor: Early onset hydroxychloroquine retinopathy and a possible relationship to blood levels. *Arthritis Rheum* 73:359, 2021. [Epub December 24, 2020; doi: 10.1002/art.41521]
29. **Petri M**, Magder LS. Reply to Letter to Editor: More steps forward to optimize the dosing of hydroxychloroquine: comment on the article by Petri et al. *Arthritis Rheum*, 2021. [Epub May 27, 2021; doi: 10.1002/art.41880]
30. **Petri M**, Joyce D, Haag K, Fava A, Goldman DW, Zhong D, Shao S, Milstone AM, Magder LS. Reply to Systemic Lupus, Immunosuppressives, COVID Vaccination and Antibody Response. *Arthritis Care Res* 75: 2225, 2023. [Epub March 2, 2023; DOI: 10.1002/acr.25109]
31. Toro-Domínguez D, Martorell-Marugán J, Martínez-Bueno M, López-Domínguez R, Carnero-Montoro E, Barturen G, Goldman D, **Petri M**, Carmona-Sáez P, Alarcón-Riquelme ME. Response to the letter “Testing the Effectiveness of MyPROSLE in Classifying Patients with Lupus Nephritis”. *Briefings Biochem*, submitted 2023.
32. Schreiber K, Giles I, Costedoat-Chalumeau N, Nelson-Piercy C, Dolhain RJEM, Mosca M, Förger F, Fischer-Betz R, Molto A, Tincani A, Pasquier E, Marin B, Elefant E, Salmon J, Bermas BL, Sammaritano L, Clowse MEB, Chambers C, Buyon J, Abe Inoue S, Agmon-Levin N, Aguilera S, Al Emadi S, Andersen J, Andrade D, Antovic A, Arnaud L, Ashouri Christiansen A, Avcin T, Badreh-Wirström S, Bertsias G, Bini I, Bobirca A, Branch W, Brucato A, Bultink I, Capela S, Cecchi I, Cervera R, Chighizola C, Cobilinschi C, Cuadrado MJ, Dey D, Etomi O, Espinosa G, Flint J, Fonseca JE, Fritsch-Stork R, Gerosa M, Grintborg B, Gøtestam Skorpen C, Goulden B, Graversgaard C, Gunnarsson I, Gupta L, Hetland M, Hodson K, Hunt BJ, Isenberg D, Jacobsen S, Khamashta M, Levy R, Linde L, Lykke J, Meissner Y, Moore L, Morand E, Navarra S, Opris-Belinski D, Østensen M, Ozawa H, Perez-Garcia LF, Petri M, Pons-Estel GJ, Radin M, Raio L, Rottenstreich A, Ruiz-Irastorza G, Rumpl Tunjić S, Rygg M, Sciascia S, Strangfeld A, Svenungsson E, Tektonidou M, Troldborg A, Vinet E, Vojinovic J, Voss A, Wallenius M, Andreoli L. Global comment on the use of hydroxychloroquine during the periconception period and pregnancy in women with autoimmune diseases. *The Lancet Rheumatology*, Sept 2023. DOI: [https://doi.org/10.1016/S2665-9913\(23\)00215-1](https://doi.org/10.1016/S2665-9913(23)00215-1).
33. Petri M, Joyce D, Haag K, Fava A, Goldman DW, Zhong D, Xiao S, Milstone A, Magder LS. Reply to: Systemic lupus, immunosuppressives, COVID-19 vaccination, and antibody response: comment on the article by Petri et al. *Arthritis Care Res* 75:2223-2225, 2023. [doi: 10.1002/acr.25109]

Educational Publications

Petri M. Measuring disease activity and severity in clinical trials and the clinic: same or different? Presentation at the “Treatment of SLE: Bridging the Gap from Clinical Trials to Practice: symposium Annual Congress of the American College of Rheumatology on November 2 2012.

Petri M. *Systemic Lupus Erythematosus Curbside Consults: Tackling Challenging Cases* series. Vindico Medical Education. March 15, 2022.

- A patient with SLE experiencing adverse effects of corticosteroid therapy <https://cme.healio.com/rheumatology/20220315/1-a-patient-with-sle-experiencing-adverse-effects-of-corticosteroid-therapy>
- A teenaged patient with SLE and renal involvement. <https://cme.healio.com/rheumatology/20220315/2-a-teenaged-patient-with-sle-and-renal-involvement>
- A patient with SLE with cutaneous manifestations. <https://cme.healio.com/rheumatology/20220315/3-a-patient-with-sle-with-cutaneous-manifestations>
- Improving patient provider communication and shared decision making in SLE. <https://cme.healio.com/rheumatology/20220315/4-improving-patient-provider-communication-and-shared-decision-making-in-sle>

Peer-reviewed original educational publications

1. **Petri M.** Health Issues: Women with Lupus '98. *Newletter Bay Area Lupus Foundation* 21(2):5-6 Summer 1998.
2. **Petri M.** Antiphospholipid syndrome and lupus. *SLE in Clinical Practice* 1(2):1-2 1998.
3. **Petri M.** Ask the Doctor. *Lupus Update (Issue 102)* June 1999.

FUNDING

EXTRAMURAL FUNDING
Research Extramural Funding

Current

09/28/2023-09/27/2024	A Registry-Based Observational Study of Cutaneous Lupus Erythematosus Biogen \$109,114 PI: M. Petri
03/21/2022-12/31/2026	Lupus Omics Cutaneous Kidney Investigative Team (LOCKIT) NYU \$629,591 PI: M. Petri
12/2020-6/2024	Relationship between remission, Lupus low disease activity State Janssen \$202,604.00 PI: M. Petri
03/2019-02/2024	Monitoring Disease in Lupus University of Houston \$214,461 PI: M. Petri
11/1/2012-10/31/2025	Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking Database and Repository APS ACTION \$17,227 PI: M. Petri
09/28/2023-09/27/2024	A Registry-Based Observational Study of Cutaneous Lupus Erythematosus Biogen \$109,114 PI: M. Petri

Pending

04/2027-03/2029	Liquid Biopsy for Intra-renal Molecular Events in Lupus Nephritis University of Houston \$131,000 PI: M. Petri
07/2023-06/2028	Urinary Biomarkers of Lupus Nephritis University of Houston \$200,000 PI: M. Petri
03/2023-02/2026	Rapid and Quantitative Point of Care Urine Assay for the Diagnosis and Monitoring of Lupus Nephritis University of Houston \$81,875.01 PI: M. Petri
01/2024-12/2024	Renal Risk Calculator GSK \$279,990.71 PI: M. Petri

Michelle Petri, M.D., M.P.H.

09/2024-09/2028	Telemonitoring of Lupus University of Houston \$425,752.00 PI: M. Petri
-----------------	--

Previous

12/1/2016 – 2/14/2021	Exagen: prospective analysis of complement on red blood cells Exagen Diagnostics \$140,661 PI: M. Petri
12/1/2016 – 2/14/2021	HealthTell: Analysis of Immuno-signatures in Hopkins Lupus Cohort Healthtell \$75,075 PI: M. Petri
9/15/2012 – 12/31/2020	Lily – Disease Progression, Treatment Patterns and Outcomes of a SLE US Cohort Eli Lilly \$226,158 PI: M. Petri
11/1/2012 – 10/30/2020	Immunarray: validation of new biomarkers in lupus Immunarray \$71,890 PI: M. Petri
5/1/2019 – 2/1/2022	Urinary proteomics as a marker GSK \$312,1120 PI: M. Petri
12/20/2019 – 9/30/2020	AMP Proteomics supplement Foundation of the National Institutes of Health \$531,300 PI: M. Petri
9/15/2019 – 9/14/2022	Transcription factor analysis of SLE Childrens Hospital of Philadelphia/DoD \$91,678 PI: M. Petri
9/10/2016 – 7/31/2023	The Hopkins Lupus Cohort RO1 5R01AR069572 NIH - NIAMS \$2,729,180 PI: M. Petri
9/04/2014 – 5/30/2020	Accelerating Medicines Partnership in RA and Lupus: Network Research Sites (UH2/UH3) UH2AR067679 NIH - NIAMS \$1,472,490 PI: M. Petri
12/01/2017-10/31/2022	Systemic Lupus Erythematosus (SLE) Prospective Observational Cohort Study (SPOCS) AstraZeneca \$140,661 PI: M. Petri
09/01/2018 -08/30/2023	Characterization of the lupus nephritis microRNAome University of Alabama at Birmingham \$192,735 PI: M. Petri

Michelle Petri, M.D., M.P.H.

7/1/2014-6/30/2016	GAP R01AR043727 NIH - NIAMS \$?? PI: M. Petri ??%
05/01/08-03/31/14	The Hopkins Lupus Cohort RO1 AR043727 NIH - NIAMS \$356130 PI: M. Petri 28%
09/01/08-08/31/13	Predictors of Pregnancy Outcome in SLE and APS RO1 AR0497 NIH (Subcontract HSS) \$23718 PI: Salmon Co-PI 3%
09/18/09-08/31/14	Epigenomics of SLE NIH (CHOP Subcontract) R01 AR058547 \$61896 PI: Sullivan Co-PI 2%
12/10/12-09/09/14	GSK Pregnancy Retrospective GSK \$55490 PI: M. Petri 5%
11/10/10-11/09/13	MI CP212 Clinical Trial MedImmune MI CP212 \$95079 PI: M. Petri 2%
11/01/05-10/31/16	LBSL99 Human Genome Science Inc. \$63443 PI: M. Petri 1%
12/01/11-07/31/13	AN-SLE3322 Anthera \$32838 PI: M. Petri 2%
09/15/12-12/31/16	Eli Lilly Retrospective Eli Lilly \$67468 PI: M. Petri 5%
01/01/11-12/31/13	UCB SL0009 UCB \$58275 PI: M. Petri 1%
11/01/12-01/31/14	ImmunoArray ImmunoArray \$31647 PI: M. Petri 1%

Michelle Petri, M.D., M.P.H.

10/01/12-06/30/13	Kypha Kypha \$5003 PI: M. Petri 1%
09/01/12-12/30/14	MedImmune prospective IFN MedImmune \$37252 PI: M. Petri 4%
01/01/12-06/30/13	CXCR5 biomarkers in SLE Sanofi-aventis \$45716 PI: M. Petri 1%
11/01/12-10/31/14	Sanofi longitudinal ASY12263 Sanofi-aventis \$747399 PI: M. Petri 5%
04/23/12-04/22/15	Pfizer Butterfly Pfizer \$33060 PI: M. Petri 1%
12/01/11-06/30/14	Evaluation of Bio-Rad anti-dsDNA in SLE Bio-Rad \$80830 PI: M. Petri 2.5%
12/01/11-06/30/14	Evaluation of Bio-Rad anti-dsDNA in SLE Bio-Rad \$80830 PI: M. Petri 2.5%
04/14/06-03/31/13	Cognitive Function in SLE 126549/126345 NIH (Subcontract Texas) \$81874 (under NCE) PI: R. Brey Co-PI
05/01/08-03/31/13	Program Project in the Genetics of SLE NIH (UAB Subcontract) P01-AR-49084 \$56475 PI: G. Alarcon Co-PI 6%
07/01/09-06/30/12	Biogen Lupus Registry Study Biogen Idec \$205863 PI: M. Petri 10%
01/01/10-06/30/12	MI Lupus Registry MedImmune \$105824 PI: M. Petri
01/01/11-12/31/12	AN-SLE3321 Anthera \$32838 PI: M. Petri 2%

Michelle Petri, M.D., M.P.H.

04/01/11-03/31/13	MedImmune CP1067 MedImmune \$100217 PI: M. Petri 2%	
06/24/11-06/23/13	Teva LA Teva \$33834 PI: M. Petri 2%	
07/06/11-07/05/13	Teva LN Teva \$44650 PI: M. Petri 2%	
04/01/10-08/31/12	Natural History of SLE GlaxoSmithKline \$75581 PI: M. Petri	
11/01/11-05/31/12	Steroids GlaxoSmithKline \$75581 PI: M. Petri 5%	
10/01/10-09/30/11	LFA-Neuropsychiatric Lupus Lupus Foundation of America \$75000 PI: Pomper	Co-PI
09/01/09-02/29/12	Autoimmunity Center of Excellence-Rochester NIH (Rochester Subcontract) 3 U19 AI056390-06S1 \$128537 PI: Sanz Co-PI 5%	
10/01/09-09/30/10	LFA-AROSE Lupus Foundation of America \$85000 PI: M. Petri 5%	
09/28/04 – 06/30/10	Revision of ACR Reclassification of SLE Criteria NIH 5U01AR051871 \$150000 PI: M. Petri 6%	
09/26/02 – 08/31/10	Brain CONECTIONS NIH RO1 AR 49125 \$336819 PI: M. Petri 9%	
11/08/08 – 10/31/10	MI CP179 Clinical Trial MedImmune MI CP179 \$41548 PI: M. Petri 1%	

Michelle Petri, M.D., M.P.H.

08/01/07 – 08/31/10	HGS BLISS-76 Clinical Trial Human Genome Sciences Inc BLISS-76 \$19963 PI: M. Petri 1%
12/14/05 – 12/31/10	Aspreva WX17801 Clinical Trial Aspreva Pharmaceuticals Corporation WX17801 \$74658 PI: M. Petri 1%
03/15/07 – 03/14/10	UCB SL0006 Clinical Trial UCB SL0006 \$59484 PI: M. Petri 1%
09/01/04-08/31/09	Predictors of Pregnancy Outcome in SLE and APS RO1 AR0497 NIH (Subcontract HSS) \$309765 PI: Salmon Co-PI 6%
04/01/04-03/31/09	Inflammation and Cardiovascular Disease in Rheumatoid Arthritis R01 AR50026 NIH – NIAMS \$427337 PI: J Bathon Co-PI 3%
04/01/03-03/31/08	Immune Complex Stimulation of TNF Alpha R01-AI51323 NIH (Children’s Hospital Subcontract) \$29301 PI: K. Sullivan Co-PI 2%
10/01/05-09/30/07	Further Studies of Atherosclerosis in the Lupus Atherosclerosis Prevention Study Lupus Research Institute \$200000 PI: A. Kiani Co-PI: M Petri 1%
09/24/02-08/31/07	Program Project in the Genetics of SLE NIH (UAB Subcontract) P01-AR-49084 \$50184 PI: G. Alarcon Co-PI 5%
09/26/02-08/31/07	Brain Connections RO1 AR49125-01 NIH – NIAMS \$347 817 PI: M Petri 9%
09/01/04-08/31/07	Kirkland Scholar Award Kirkland Scholar Award Hospital For Special Surgery PI: M. Petri 0%

Michelle Petri, M.D., M.P.H.

09/28/04-06/30/07	ACR Reclassification of SLE Criteria R01 AR04005 NIH – NIAMS \$150000 PI: M Petri 6%
09/01/02-03/31/07	Prospective Lupus Cohort Study of Disease Activity and Predictors of Morbidity (Damage) and Health Status (Includes Registry for Malignancy in SLE and the Atherosclerosis & Neuropsychiatric Registry. RO1 AR043727 NIH – NIAMS \$244 677 PI: M Petri 22.5%
09/30/01-09/29/06	Biomarkers in SLE Contract NO AR12256 NIH-NIAMS \$102803 PI: Gregerson Co-PI 9%
07/01/05-06/30/06	Further Studies of Atherosclerosis in the Lupus Atherosclerosis Prevention Study RFA 005-1 Lupus Foundation of America \$125000 PI: M Petri 10%
04/01/02-02/28/06	2002 AF Target in Lupus Identification Grant Lupus Atherosclerosis Prevention Study (LAPS) National Arthritis Foundation \$231481 PI: M Petri 10.5%
10/01/04-01/31/06	ACR Reclassification of SLE Criteria Lupus Foundation of America RFA 004-2 \$100000 PI: M Petri 2%
09/30/99 –0 8/31/05	Randomized Clinical Trial of High Dose Immunoblative Therapy in Patients with SLE NIH-NIAMS NIH N01-AR-92243 \$146317 PI: M Petri 5%
09/30/00-09/29/05	Antiphospholipid Syndrome Collaborative Registry (APSCORE) NIH (UNC Subcontract) NIH N01-AR-02248 \$30328 PI: Robert Roubey Co-PI 5%
07/01/05- 06/30/06	A Phase Iib Multi-Center Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept vs. Placebo on a Background of Oral Glucocorticosteroids in the Treatment of Subjects with Systemic Lupus Erythematosus and the Prevention of Subsequent Lupus Flares Bryistol Myers Sqibb \$45868 PI: M Petri 1%

Michelle Petri, M.D., M.P.H.

06/01/05-05/31/06	A Phase III Randomized Double-Blind Placebo-Controlled Multi-Center Clinical Trial of Epratuzumab in Patients with Acute Severe SLE Flares Excluding the Renal or Neurologic Systems Immunomedics \$123967
06/01/05-05/31/06	A Phase Iii Randomized Double-Blind Placebo-Controlled Multi-Center Clinical Trial of Epratuzumab in Patients with Active Systemic Lupus Erythematosus Immunomedics \$123967 PI: M Petri 1%
05/01/05-04/30/06	Memantine in Systemic Lupus Erythematosus Forest Laboratories \$102480 PI: M Petri 1%
04/01/05-07/31/07	A Randomized Double-Blind Placebo-Controlled Multicenter Phase II/III Study to Evaluate the Efficacy and Safety of Rituximab in Subjects with Moderate to Severe Systemic Lupus Erythematosus Genentech Inc. \$195875 PI: M Petri 1%
09/30/99-08/31/04	Safety of Estrogens in Lupus Erythematosus: National Assessment. U01 AR42540 NIH (HJD Subcontract 3634) \$335618 PI: J Buyon Co-PI 10%

Educational Extramural Funding – None

Clinical Extramural Funding – None

System Innovation or Quality Improvement Extramural Funding – None

Other Extramural Funding – None

INTRAMURAL FUNDING

Research Intramural Funding

Current

07/01/19-06/30/20	Cupid Award – Marisa Mizus \$25,000 PI: M Petri 1%
-------------------	---

Pending - None

Previous - None

Educational Intramural Funding – None

Clinical Intramural Funding – None

System Innovation or Quality Improvement Intramural Funding – None

Michelle Petri, M.D., M.P.H.

Other Intramural Funding – None

Other Previous Grants

Clinician Scientist Award 1991 – 1993
 Maryland Lupus Foundation Lupus Pregnancy Center 1989 – 1993
 Maryland Lupus Foundation Hopkins Lupus Cohort 1991 – 1993
 Maryland Arthritis Foundation Quality of Life 1993
 Lupus Foundation of America Hopkins Lupus Cohort 1991 – 1993
 Arthritis Foundation Homocysteine & Vit B Therapy in SLE 1995 – 1998
 Maryland Chapter Arthritis Foundation 1996
 National Institutes of Health (FIRST) 1991 – 1996
 American Heart Association 1993 – 1996
 American Heart Association 1996 – 1999
 Arthritis Foundation Maryland Chapter 1998 – 2001
 NIH SCOR (UVA Subcontract 55-2480)1998-2002

CLINICAL ACTIVITIES:

Clinical Focus

I am co-director of the Hopkins Lupus Clinic and of the Hopkins Lupus Pregnancy Center. I see and treat approximately 2,000 lupus patients per year.

Certification

Medical, other state/government licensure

1986 - present Maryland Board of Physicians (D0033659), exp 9/30/2021

Boards, other specialty certification

1983 Board Certified, Internal Medicine
 1985 Board Certified, Allergy and Immunology
 1986 Board Certified, Rheumatology

Clinical (Service) Responsibilities

Dates	Specialty	Role	Time Commitment
	Rheumatology	Attending Consult Service	1 months/year
	Rheumatology	Faculty Practice	300 new patients and 3000 ret patients yearly
	Rheumatology	In-patient Consultation Service	yearly (January)
	Rheumatology	Lupus Center	2 full days weekly

Clinical Productivity

2010-present My targeted clinical effort assignment is (___%). My clinical effort variance is (___Y %) indicating that I am exceeding the target by (___%); in 2014-2015, I treated (___#) of patients; performed, etc.

Clinical Draw

2010-present 260/799 patients came from other states such as DC, WV, PA, NY, DE, NJ, NC, SC, GA, FL
100/799 patients came from Saudi Arabia, Kuwait, Dubai

Membership in or examiner for specialty board - None

Clinical Program Building / Leadership - None

Clinical Demonstration Activities - None

Michelle Petri, M.D., M.P.H.

Development of nationally/internationally recognized clinical standard of care

The Hopkins Lupus Center, with its multi-disciplinary approach to the management of systemic lupus erythematosus is internationally recognized as establishing the standard of care for this population. I was the founding Director of the Center and – based on this clinical experience and associated scholarship – am recognized as one of the country’s leading experts in the evaluation and treatment of SLE.

EDUCATIONAL ACTIVITIES:

Educational Focus

I have served as a mentor for hundreds of students, residents, fellows and faculty over the last 30 years, and continue to be actively engaged in mentoring activities. I have years of experience and great expertise in both clinical and translational research in SLE, and advise mentees in both of these areas. Of note, these skill sets are also highly relevant in advising mentees whose interests are outside of lupus. Consistent with this, my mentoring activities extend to trainees working across the spectrum of autoimmune rheumatic diseases.

Teaching

Classroom instruction

1996 1997	Epidemiology Section Leader
yearly	Clinical Skills Rheumatology
6 times yearly	Case Resident Lecture Systemic Lupus Erythematosus
1998	Rheumatology Pathophysiology Course Antiphospholipid Antibody Syndrome
1998	Pathophysiology Lupus Nephritis Section
yearly	Grand Rounds: Dermatology OB-Gyn Hematology Pathology Radiology

Clinical instruction

2 half-days weekly	CASE Resident Rotation in Rheumatology
	Clinical Instruction of Rheumatology Fellows
yearly	Attending: Rheumatology Consult Service
one semester yearly	Undergraduate Clinical Preceptorship
January 2000	Master Clinician Program: preceptorship of undergraduates (Director Ronald Fishbein).
1999-2000	MKSAP – Author of Connective Tissue Disease Section
	PIER – American Board of Internal Medicine Website on Rheumatology – Author of SLE Section.

CME instruction

1998-2009	Rheumatology Board Review Courses University of California San Francisco Instructor
1998-2009	Rheumatology Board Review Courses Hospital for Special Surgery New York Instructor
1999	Rheumatology Board Review Courses University of Alabama Birmingham Instructor

Workshops / seminars

Mentoring

Pre-doctoral Advisees / Mentees

Post-doctoral Advisees / Mentees

Name: Susanna Perez-Guttham MD MPH *Dates:* *Degree:*
Present Position:

Awards/Grants/Degrees: Coronary Artery Disease in Systemic Lupus Erythematosus

Name: Niharika Kiri MD MPH *Dates:* *Degree:*
Present Position:

Awards/Grants/Degrees: Osteoporosis in Systemic Lupus Erythematosus

Name: Berthold Rzany MD MPH *Dates:* *Degree:*
Present Position: Academic Faculty Department of Dermatology University of Heidelberg

Awards/Grants/Degrees: Renal Insufficiency in Systemic Lupus Erythematosus

Michelle Petri, M.D., M.P.H.

Name: Heena Solanki *Dates:* *Degree:* MS
Present Position: United States Army Aberdeen Proving Ground
Awards/Grants/Degrees:

Name: Somchai Akkasilpa MD (Thailand) *Dates:* 1997 *Degree:*
Present Position: Assistant Professor of Medicine Chulalongkorn University
Awards/Grants/Degrees: Sabbatical Appointment

Name: Audrey Ho MD MPH *Dates:* 1998-2000 *Degree:*
Present Position: Physician Chesapeake Rheumatology Associates
Awards/Grants/Degrees: Clinical Scholar Lupus Flares

Name: Abraham Zonana-Nacach MD MPH *Dates:* 1997-1998 *Degree:*
Present Position: Epidemiology Graduate Student University of Arizona
Awards/Grants/Degrees: Damage in SLE

Name: Susan Barr MD MSc FRCPC *Dates:* 1998-2000 *Degree:*
Present Position: Sabbatical Appointment JHU
Awards/Grants/Degrees: Patterns of Disease Activity

Name: Emily (Papadopoulos) Somers Sc.M. *Dates:* 1998-1999 *Degree:* Sc.M.
Present Position: Epidemiologist University of Michigan Division of Rheumatology
Awards/Grants/Degrees: Thrombosis in SLE

Faculty Mentees:

Zsuzsanna H. McMahan MD, 2017-2018
Andrea Fava MD, July 2022-present

Fellows: Lupus Fellowship

Muznay Khawali MD, July 2017-2018
Andrea Fava MD, July 2018-2019
Romy Kallas MD, September 2018-2020
Hakan Babaoglu MD, January 2019-June 2019
Selcan Demir MD, July 2019-December 2019
Marisa Mizus MD, July 2019-2020
Emma Weeding, July 2021-2022

Undergraduates: 3 month Clinical Research Elective (alphabetical)

Anna Abraham; Sona Aggarwal; Kelly Baek; Janet Baker; Valerie Bazelais; Elena Caffentzis; Connie Choi; Michelle Conroy; Rooshin Dalal; Dawn Edmond; Ed Fajardo; Debbie Ferman; David Finn; Mona Foad; Shuvo Ghosh; Shiela Haffar; Audrey Ho; Tracy Hourigan; Denise Howard; Richard Huang; Virginia Huang; Allison Huffman; James King; Jordana Kron; Christiana Lakatta; Charmaine Leung-Shea; Gloria Lim; Joy Masseaux; Melissa Minor; Fred Nucifora; Suzan Pae; Andrea Sachs; Sara Schuler; Denise Spence; Jessica Steckroth; Marcia Suzuki; Ilene Timko; Sylva Toussounian; Tien Vu; Jacquelyn Weber; Sean Whelton; Tina Wu; Nalini Yadla; Maria Yialamas; Seung-Schik Yoo;

Medical Students: Clinical Research Elective (1-3 months) with current position

Allan Gelber MD MPH Asst. Professor Johns Hopkins University
Elizabeth Karlson MD MPH Instructor Harvard University
Craig Longenecker MD Formerly Director Housestaff Training Abington Hospital;
Currently Hopkins School of Hygiene and Public Health
Mark Genovese MD Chief Division of Rheumatology Stanford University
Jill Albritton MD Instructor Dermatology
Melissa Turner MD MPH Resident John Hopkins Hospital
Linda Gorgos MD Resident Massachusetts General hospital
Audrey Ho MD Physician Chesapeake Rheumatology Associates
Fran Reis Jensen MD Resident Johns Hopkins Univ. School of Medicine
Jan Price MD Resident
See-Wai Chan MPH Medical Student New York University
Akiki Omura Medical Student Downstate SUNY
Maria Yialamas Resident Brigham and Women's Hospital

Michelle Petri, M.D., M.P.H.

Jordana Kron	Medical Student Johns Hopkins University
Dominique Foulkes	Intern Johns Hopkins University
Emily Thompson	Medical Student Thomas Jefferson University
Brooke Willows	Medical Student Johns Hopkins University

Student Awards

Jordana Kron	ACR 2000 Medical Student Research Preceptorship
Emily Thompson	ACR 2000 Medical Student Research Preceptorship
Jordana Kron	Denison Award Johns Hopkins University
Kristen Johnson	ACR 2006 Medical Student Research Preceptorship

Physicians: Clinical Research Elective (1-3 months)

Kathy Brown MD	Bayview Hospital
Sudha Pai MD	Harbor Hospital
Monica Stewart MD	Rheumatology Fellow Washington Hospital Center
Berthold Rzany MD MPH	Germany Academic Faculty Klinik Mannheim University

Thesis committees

Name: Susanna Perez-Guttham MD MPH

Title:

Dates:

Role::

Name: Niharika Kiri MD MPH

Title:

Dates:

Role::

Name: Berthold Rzany MD MPH

Title:

Dates:

Role::

Name: Heena Solanki MS

Title:

Dates:

Role::

Name: Audrey Ho MD MPH

Title:

Dates:

Role::

Name: Emily Papadopoulos Sc.M.

Title: A Prospective Study of Antiphospholipid Antibodies and Incident Thrombotic Events in Systemic Lupus Erythematosus

Dates: 1999

Role:

Name: Tammy Utset MD MPH

Title:

Dates:

Role::

Training Grant Participation

[Add Names]

Educational Program Building / Leadership

Educational Demonstration Activities to external audience

RESEARCH ACTIVITIES

My major role over the last 33 years at Johns Hopkins has been as the Principal Investigator of the Hopkins Lupus Cohort of over 2,600 patients. The cohort is unique as each patient is seen by protocol, both in terms of timing of visits and routine laboratory assessments. The cohort continues to emphasize the aims of prediction of disease activity/flare, prevention of organ damage, and improvement of quality of life in SLE, but also supports multiple NIH subcontracts and industry projects

Michelle Petri, M.D., M.P.H.

related to SLE. The application of proteomics to the prediction of and biomarkers for lupus nephritis is currently a major focus.

Research Program Building / Leadership

7/86 - present Principal Investigator and Director of the Hopkins Lupus Cohort in rheumatology, Johns Hopkins University School of Medicine. I am responsible for research into risk factors, biomarkers and prevention of organ damage in lupus.

Research Demonstration Activities - None

Inventions Patents Copyrights - None

Technology Transfer Activities - None

SYSTEM INNOVATION AND QUALITY IMPROVEMENT ACTIVITIES - NONE

ORGANIZATIONAL ACTIVITIES:

Institutional Administrative Appointments

5 years Medical Student Interview Committees
GRCC Committee
1996 – present General Clinical Research Center: Advisory Committee.
1994 - present Outpatient Clinical Research Center Protocol Review Committee.
1997 Department of Medicine Finance Council
1998 “Osler Way” Department of Medicine

Editorial Activities

Editorial Board appointments

Arthritis and Rheumatism (1996-1998)
Journal of Rheumatology
Journal of Clinical Rheumatology
Arthritis Care and Research
Lupus
The American Journal of Medicine
VersusMed: Rheumatology Update
Rheumatology and Immunology Research (12/2019 – present)

Journal Peer review activities

Annals of Internal Medicine
American Journal of Medicine
Medicine
Lancet
JAMA
Southern Medical Journal
Fertility and Sterility
Scandinavian Journal of Rheumatology
Rheumatology

Other peer review activities [*non medico-legal*] - None

Advisory Committees / Review Groups / Study Sections

FDA Arthritis Advisory Committee 1994 to 1999; Chairman 1997 to 1999
NIH Oversight Committee of the Scleroderma Registry 1995 to present
NIH Oversight Committee of the Lupus Registry 1995 to 1999

Michelle Petri, M.D., M.P.H.

Ad Hoc Review Committee member 2003 Abbott Scholar Award in Rheumatology Research Program 2003
International Scientific Advisory Board member 12th APLAR Congress Kuala Lumpur Malaysia 2006.
APS ACTION Executive Committee, 2020 to Present.

Professional Societies

American College of Rheumatology Fellow 1986 to present
Council on Research Diagnostic & Therapeutic Criteria Committee Sub-committee on Disease Activity in SLE 1991 to 1997
Abstract Selection Committee 1991 1992 1994 1997 1998
Medical Student Recruitment Sub-committee 1992 to 1995
Committee on Research Sub-committee for Clinical Trials 1993 to 1995
Committee on Research 1994 to 1997
Communications and Marketing 1994 to 1995
Southeastern Regional Council 1995 to 1997
Ad hoc Committee to Develop Response Criteria for SLE 2000-2001
Lupus Foundation of America
Education Committee Medical Advisory Board 1997 to present
Systemic Lupus International Cooperating Clinics (Formerly NATO Working Group on Lupus Activity Indices and Lupus Damage Index) 1990 to present
Arthritis Foundation Medical and Scientific Committee 1997 to 2000
European Group for Blood and Marrow Transplantation Working Party Autoimmune Diseases SLE/vasculitis subgroup 1999 to present.
Immune Tolerance Network
RA/SLE subcommittee of the Autoimmunity Subgroup 2001 to present.

Conference Organizer - None

Session Chair

“Optimizing the use of old drugs”, 12th European Lupus Meeting, March 25-27, 2020. Bruges, Belgium

Consultantships

Maryland Lupus Foundation Board of Directors 1988 to 1992.
Medical Advisory Board Lupus Letter.
Medical Advisory Board Lupus News Newsletter of the Lupus Foundation of America Inc.
American Autoimmune Related Diseases Association Inc. National Scientific Advisory Board 1995 to present.
Scientific Advisory Board Center for Osteonecrosis Research and Education 1996 to present.
Scientific Advisory Board National Osteonecrosis Foundation 1996 to present.
Medical Advisory Board American Autoimmune Related Diseases Association 1997 to present
Women's Health Guide Expert Reviewer 1998
Scientific Advisory Board Sally Nyborg Foundation
Academic Advisory Board The 2000 Pfizer Visiting Professorship Program in Rheumatology 1999-2000.
Academic Advisory Board The 2001 Pfizer Visiting Professorship Program in Rheumatology 2000-2001.
Lupus Research Institute Physicians Leadership Council 2001 to present.
Genelabs: protocol review
IDEC: protocol review
Biogen: protocol review
Hoechst Marion Roussel: protocol review
Searle: Speaker's Bureau
Educational Initiative for SLE Outcomes Faculty Dannemiller Memorial Educational Foundation and Helix Medical Communications LLC 2005-6
Lupus Now Advisory Board Lupus Foundation of America
Medical/Scientific Advisory Council Lupus Foundation of America 2006-2011.
External Advisory Committee Silver MCRC P60 Grant 2007.

RECOGNITION

Michelle Petri, M.D., M.P.H.

Awards Honors

NIH Clinical Associate Physician Award Dec. 1988 to 1991

Hopkins Clinician Scientist 1991-1992

Edmund L. Dubois Award American College of Rheumatology Southeast Region 1993

Listed in "America's Top Doctors" Castle Connolly Medical Ltd. 2003-2008

Listed in "Guide to America's Top Physicians" Consumers' Research Council of America 2004-2005 edition.

Listed in "Best Doctors in America" 2005-2008.

Listed in "Who's Who in America" 2009 edition.

Outstanding Speaker Award, 34th Annual Congress of Clinical Rheumatology, May 17-19, 2018.

2018 Evelyn V Hess Award, Lupus Foundation of America. October 22, 2018.

Clarivate Analytics Highly Cited Researchers 2018.

ACR Master, November 2019

Roger Demers Award, 52nd Laurentian Conference of Rheumatology 2022, May 6, 2022.

RWCS Kahuna Teaching Award 2024, Rheumatology Winter Clinical Symposium 2024, February 16, 2024, Maui, Hawaii.

Invited Talks

Speaker of the Royal College of Physicians and Surgeons of Canada Region 3 Advisory Committee May 14-15 1993.

Janice M. Wiles Memorial Lecture on SLE, Univ. of Massachusetts Medical Center, October 6, 1994.

Invited Speaker La Sociedad Mexicana de Reumatologia July 25 1995.

The 29th Annual Knowles Lecture Arthritis Foundation Northern California Chapter May 5 1995

Joan Sutton Memorial Lecture Maryland Society of Rheumatic Diseases February 6 1997

Irwin R. Callen Memorial Lectureship Miami Heart Institute April 8 1997

Marion Ropes Memorial Lecture American College of Rheumatology November 1997

Metro Ogryzlo Memorial Lecture October 6 1999 Winnipeg Canada.

Invited Speaker NIH-FDA Conference Biomarkers and Surrogate Endpoints: Clinical Research and Applications April 15-16 1999 Bethesda MD.

Invited Speaker NIAMS/NIH meeting Nervous System Involvement in SLE May 24-25 1999 Bethesda MD.

The X and the Y: Current Issues in Gender Specific Biomedicine Press Seminar May 20-21 1999 Boston MA.

Glenn Clark Memorial Lecture University of Tennessee May 18 1999 Memphis Tennessee.

Invited Speaker NIEHS/NIH meeting Decreasing the Gap: Developing a research agenda on socioeconomic status environmental exposures and health disparities July 7-9 1999 Chicago IL.

Invited Speaker NIH meeting Accelerated atherosclerosis in systemic lupus erythematosus September 8-9 1999 Chevy Chase MD.

Keynote Speaker The Stephen R. Koller Address October 21 1999 Lupus Foundation of America Central Virginia Chapter Richmond VA.

William K. Ishmael Lectureship February 18 2000 Arthritis Foundation Oklahoma Chapter Oklahoma City OK.

M. Paul Strottmann Lecture April 5 2002 Iowa Rheumatology Symposium Iowa City Iowa.

Evans Memorial Lecture October 8 2004 The Center for Rheumatic Disease and the Center for Allergy and Immunology Kansas City MO.

Invited Speaker Lupus Foundation of Greater Washington 10th Annual Symposium October 1 2005 Washington DC.

Karen Gilhooly Memorial Lecture Munson Medical Center February 24 2006 Traverse City MI.

Sommer Memorial Lectures Oregon Health & Science University May 11-12 2006 Portland OR.

Stewart E. First MD Lectureship Lankenau Hospital October 26 2006 Wynnewood PA.

31st Annual Michael Einbender Distinguished Lectureship University of Missouri November 15 2007 Columbia MO.

The Askari Lecture University Hospitals Case Medical Center October 13 2009 Cleveland OH.

Feng Pao Hsii Lecture Singapore, August 21, 2010.

The Ray A. and Robert L. Kroc Lecture University of Texas Southwestern Medical Center February 14 2011 Dallas TX.

Donald Mitchell Lectureship Royal University Hospital, Saskatoon, Canada, May 6, 2015.

Rochester General Hospital Association Fellow, November 14-15, 2017, Rochester, NY.

Galens Memorial Lecture, Beaumont Royal Oak Hospital, May 2, 2018, Beaumont, MI.

G. Gill Richards MD Endowed Lecture, University of Utah, February 21, 2019, Salt Lake City, UT.

Ira Goldstein Honoree, New York University Langone Health, March 15, 2019, New York City, NY.

Invited Speaker, Education Program, 61ST American Society of Hematology, Annual Meeting and Exposition, Orlando, Florida, December 7-10, 2019.

Invited Speaker, Best of ACR 2020, Dubai, United Arabs Emirates, 7-8 February 2020.

Invited Speaker, Emirates Society for Rheumatology Annual Meeting 2020, Dubai, United Arabs Emirates, 20-22 February

Michelle Petri, M.D., M.P.H.

2020.

Roger Demers Award Speaker, 52nd Laurentian Conference of Rheumatology 2022, May 6, 2022.

72nd Annual Pemberton Lecture, Philadelphia Rheumatism Society, October 11, 2022.

Finger Lecture, Department of Medicine Grand Rounds, Baylor College of Medicine Sept 21st 2023.

Stuart S. Kassan MD Endowed Lecture in Rheumatology, George Washington University, September 19, 2024.

Visiting Professorships

Bohan Visiting Professorship, University of Kansas Medical, October 25, 2017, Kansas City, Kansas.